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Abstract
In v2-herpesviruses the balance between lytic infection and reactivation from 
latency depends entirely on expression of an immediate-early viral gene {ORF50) 
encoding the Replication and Transcriptional Activator (Rta) protein. Although 
studies have elucidated how Rta can activate viral genome leading to a cascade of 
events necessary for the viral lytic infection, much less is understood about the 
regulation of Rta expression itself. Nonetheless, extensive work has produced a 
body of evidence describing several interactions between cellular factors signaling 
pathways and physiological stimuli, which are able to induce or repress Rta gene 
expression and hence influence lytic infection cycle as well as reactivation from 
latency. In this study, the murine model, MHV-68, was used to characterize 
transcription activity of different domains within the Rta promoter sequence. Initial 
observations demonstrated that Rta promoter activity is both cell-type dependent 
and domain-specific. Overall, Rta promoter had a greater basal activity in 
immunocompetent cells than cells which were unable to respond to type I IFN 
signaling. Specifically, the transcription activity of a region between 1019 and 391 
bp upstream of ORF50 ORF was down regulated when cells are pre-treated with 
IFN-ot/p. Detailed bioinformatics analysis of this domain revealed a series of 
putative binding sites most closely associated with IFN response elements, including 
interferon regulatory factors 3 and 7 (IRF3 and IRF7). Site-specific mutation of these 
viral sequences within the Rta promoter resulted in cell type dependent modulation 
of Rta promoter. Interestingly, data obtained from different cell types strongly
XV
suggested that endogenous IRF7 was involved in upregulation of the promoter in 
murine B lymphocytes which was different from non-B cells. Paradoxically, 
exogenous expression of IRF7 reduced activation of the Rta promoter in fibroblasts 
with an abrogated type I IFN pathway and in a promoter sequence-specific manner. 
Although, physical interaction between IRF7 and Rta promoter using EMSA could 
not be demonstrated further work is required to show how IRF7 may affect Rta 
promoter and under different cell conditions. Taken together, these findings show 
for the first time the domain- and cell-type-specific activities of the Rta promoter 
and the complexities of Rta promoter regulation by type I IFN mediated responses. 
These findings also give credence to previous work which demonstrated that y- 
herpesviruses have evolved strategies alongside type I IFN-dependent cellular 
pathways which modulate their lytic as well as latent (persistent) stages of 
infection.
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Chapter 1
Introduction
Chapter 1 
Introduction
1.1 Herpesviruses
Herpesviruses (family Herpesviridae) are double-stranded DNA viruses with 
genomes ranging from 100 to 230 Kbp and coding from 70 up to 200 genes. They 
are highly disseminated in nature, being isolated from a wide array of organisms. 
Herpesviruses are categorized into three main evolutionary groups: those isolated 
from amniotes; those isolated from amphibians and bony fish and a single 
invertebrate isolate (identified in oysters) (Davison and Stow, 2005). Extensive 
research has been done predominately in those isolated from amniotes, thus 
concerning mammals, birds and reptiles (Wang et al., 2007).
Fig 1.1 Herpesvirus particles. Electron 
microscope image of the murine y- 
herpesvirus-68 showing typical spheroid 
morphology with inner electron dense 
DNA genome. Magnification X 100,000.
To date, approximately 130 herpesviruses have been described in this group, 
including eight human pathogens: herpes simplex virus 1 and 2 (HSV-1 and 2, or 
human herpesviruses - HHV - 1 and 2); varicella-zoster virus (VZV or HHV-3); 
Epstein-Barr virus (EBV or HHV-4); human cytomegalovirus (HCMV or HHV-5);
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human herpesviruses 6 and 7 (HHV-6 and 7) and Kaposi's sarcoma associated 
herpesvirus (KSHV or HHV-8) (Damania, 2004).
1.1.1 Virus structure
Membership in the family Herpesviridae has been based historically in its 
characteristic virion architecture composed of several distinct components 
(McGeoch et alv 2006). A typical herpes virion is comprised of a core - the viral 
genomic DNA in the form of a torus (doughnut-shaped), an icosahedral capsid, the 
tegument (also referred to as matrix) and an envelope (fig 1.2). Arrangement of the 
particle is described as follows: the genomic DNA is densely packed within an 
icosahedral capsid, with 115-130 nm diameter and 162 capsomeres (150 hexamers 
and 12 pentamers)(David M. Knipe, 2007). Although presenting limited sequence 
similarity, the capsid protein composition seems to be conserved, nonetheless, in 
terms of the number of major constituents and their molecular weights: four capsid 
proteins have been described so far; major capsid protein, triplex-a, triplex-(3 and 
the small capsid protein, making up the basic matrix of the capsid (Trus et al., 2001). 
Enclosing the capsid is the tegument (or matrix). Unique to herpesviruses, the 
tegument is composed of several different protein species with important roles in 
the assembly and egress from infected cells (Guo et al., 2010). Furthermore the 
proteins associated with the tegument are also associated either with assembly of 
the tegument structure itself or modulation of the host cellular environment at the 
very initial stage of infection e.g. in shutting down host protein synthesis, inhibition 
of infection-triggered cell defences and stimulating viral expression (David M. Knipe, 
2007). The tegument itself is bound within the outermost element of the
3
herpesvirus virion particle, the envelope. The envelope is a lipid bilayer embedded 
(taken from the host cell) with viral glycoproteins and numerous host proteins and 
constituents (the lipid bilayer is cell derived) (Liu and Hong Zhou, 2007).
Glycoprotein spikes
Envelope
Tegument• • • •
i :•••
Capsid
Genome
Fig 1.2 Herpesvirus virion structure. Different structures that comprise the viral 
particle: the viral genome, capsid, tegument or matrix and the envelope.
1.1.2 Herpesviruses life cycle
Despite the different tropisms associated with different herpesviruses, all share a 
key survival strategy; herpesviruses replicate and package their viral genome inside 
the nucleus of infected cells. Production of new virion particles and successful 
propagation and transmission requires the efficient entry into host cells, transport 
of capsids to the nucleus, replication of the viral genome, assembly of the viral 
particle and egress from the infected cell (Connolly et al., 2011).
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1.1.2.1 Entry and traffic to the nucleus
The entry of herpesviruses can be divided in two different steps and involves a 
functional core of conserved glycoproteins (glycoproteins B; H and L) mediating 
fusion with the cell membrane. Around this conserved core machinery, a variety of 
receptor binding glycoproteins interacts with the cell membrane and tethers the 
virus to the cell surface (table 1.1).
First, the virus binds the host cell through specific receptors and brings the viral 
fusion apparatus in close proximity to the cell membrane. Second, the viral 
membrane fuses with either the cell plasma membrane or the endocytic vesicle 
membrane (as reviewed in (Connolly et al., 2011; Stefan Pohlmann, 2007)). Once 
the virus particle has effectively fused with the cell plasma membrane it still needs 
to be actively trafficked through the cytoplasm to the nuclear pore complex, where 
the viral DNA is released into the nucleus. The efficient transport of the capsid to 
the nucleus is achieved by engaging and remodelling the host cytoskeleton, moving 
complex viral structures within the cell (Lyman and Enquist, 2009).
Microtubules are stiff cylinders, comprising a- and p-tubulin heterodimers which 
provide tracks for long distance transport of endocytic and exocytic vesicles, 
organelles and chromosomes within the cell. These structures have a distinct 
polarity, with a dynamic "plus" end capable of rapid growth and shrinking 
(described as dynamic instability) and a relatively stable "minus" end, tethered to 
the microtubule-organizing centre (often located juxtaposed to the nucleus). The 
directional movement of cell structures along microtubules is governed by two 
classes of molecular motors, plus-end and minus-end directed motors involved in 
the transport to or from the cell periphery, respectively. Both types of transport are
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Table 1.1 Interactions between viral glycoproteins and cellular receptors
Herpesviruses Glycoprotein Cellular receptors Function
HSV-1 gC HSPG Attachment
gB HSPG Fusion
gD HVEM/Nectin-l/3-OS-HS Attachment/fusion
gH/gl Integrins Fusion
HSV-2 gC HSPG Attachment
gB HSPG Fusion
gD HVEM/Nectin-1 Attachment/fusion
VZV gC HSPG Attachment
gB HSPG Fusion
CMV gB HSPG/TLR/EGFR/Integrins Attachment/fusion
gO/gH/gl Integrins Fusion
HHV-6 gH/gl/gQl/gQ2 CD46 Attachment/fusion (?)
HHV-7 gB HSPG Attachment/fusion
EBV gp350/220 CD21 Attachment
gH/gL CD21 Attachment/fusion
gp42 MHC-II Attachment/fusion
BMRF2 Integrins Attachment
KSHV K8.1 HSPG Attachment
gB HSPG/Integrins Fusion
HSPG - Heparan sulphate
HVEM - Herpesvirus entry mediator
3-OS-HS - 3-O-sulfated heparan sulphate
TLR - Toll like receptor
EGFR - Epidermal growth factor receptor
MHC-II - Major histocompatibility complex II
(Information compiled from (Connolly et al., 2011; Stefan Pdhlmann, 2007))
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mediated by motor proteins, powered by the hydrolysis of ATP. Plus-end transport 
is mediated by kinesin, while movement towards the minus-end is mediated by 
dynein {Lyman and Enquist, 2009).
Several studies have shown that, upon entry of the host ceil, herpesviruses interact 
with the microtubule network, effectively highjacking the associated dynein motor 
(where tegument proteins most likely have a preponderant role) and promoting the 
traffic of the viral capsid towards the nuclear pores (David M. Knipe, 2007; Lyman 
and Enquist, 2009).
1.1.2.2 Lytic replication and latency
Once the capsid is transported to the nuclear pores it releases the viral genome into 
the nucleus, where it undergoes viral transcription and replication. However, in 
specific cell types, herpesviruses are able to enter a quiescent phase termed latent 
phase, a non cytophatic infection in which there is limited viral gene expression and 
no detectable virion production (not to be confused with chronic infection, where 
infectious progeny may be present) allowing the virus to evade effectively the host 
immune system. This distinct feature is shared between all herpesviruses and is 
crucial for definition of membership within this viral family. During latency, viral 
DNA, harboured in the cell's nucleus, takes the form of a covalently closed episome, 
generally without integrating into the host genome (nonetheless, evidence exists to 
support site-specific integration of viral genome with HHV-6), while the small subset 
of genes expressed is involved in genome copy number maintenance and immune 
evasion. Importantly, the latent viral genome retains the capacity to undergo 
reactivation in response to specific signals (an example being, as it was shown more
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recently, the stimulation of the Toll-like receptor pathway in cells latently infected 
with gammaherpesviruses), triggering the expression of lytic replication-associated 
genes. Production of progeny virus follows the trigger of the lytic gene expression 
cascade, which if not controlled may culminate in different clinical manifestations 
characteristic of each herpesvirus (Barton et al., 2011; Damania, 2004; David M. 
Knipe, 2007; Gargano et al., 2009; Gregory et al., 2009; Guo et al., 2010).
1.1.2.3 Nuclear and cellular egress
Viral replication of herpesviruses is translated into production and assembly of all 
the necessary components into a viable, infectious viral particle (or virion). This 
process takes place initially in the nucleus, where nascent capsid proteins are 
assembled onto a temporary scaffold and packed with viral genomic DNA. As the 
viral genome is replicated through a rolling circle mechanism, it produces long 
head-to-tail concatemers of viral DNA, which are cleaved (at conserved sequences 
that define the genomic termini) into monomeric molecules during packaging into 
the capsid (encapsidation) (David M. Knipe, 2007).
These steps are then followed by initial interactions with tegument proteins, 
primary envelopment during transit through the inner nuclear membrane and 
deenvelopment at the outer nuclear compartments (fig 1.3). Alternatively, another 
model states that perinuclear virions undergo full tegumentation and already 
contain envelope proteins characteristic of mature extracellular virions. In this 
model, originally proposed for HSV-1, the perinuclear virions retain their integrity 
and leave the cell through the secretory pathway (Guo et al., 2010; Mettenieiter, 
2002). A third process of nuclear egress under investigation relates to the transport
8
of non-enveloped virion particles into the cytoplasm, through enlarged nuclear 
pores, sequentially enveloped and modified into their mature form in the Golgi or in 
early endosomes (David M. Knipe, 2007).
Nucleus membrane luclear pore
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Outer
nuclear
membrane
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Plasma membrane
Fig 1.3 Herpesvirus egress pathways. Alternative pathways for herpesvirus egress 
from the infected cell (Boehme and Compton, 2004).
1.1.3 Classification of herpesviruses
Initial classification of herpesviruses, based on biological properties, has been more 
recently revised through the use of molecular phylogenetic studies. Interestingly, 
these analyses have supported the early classifications. Thus, three herpesvirus 
lineages have been identified to this date. Two represent herpesviruses isolated 
from bivalves (OsHV-1) or described in fish and amphibians (CCV, SalHV-1 and -2 
and RaHV-1 and -2) (Davison, 2002). The third lineage, representative of 
herpesviruses endemic in reptiles, birds and mammals can be divided into three 
subfamilies; the Alpha-, Beta- and Gamma-herpesvirinae (fig 1.4) (David M. Knipe,
9
2007; Davison, 2002; McGeoch et al., 2006; Wang et alv 2007). With the advent of 
accessible sequencing, more than 50 herpesviruses genomes have now been 
examined, allowing for further categorization into genera based on sequence 
similarity and genome sequence arrangement (David M. Knipe, 2007; Wang et al., 
2007).
Alphaherpesvirinae: Alphaherpesviruses have a variable host range and a relative 
short productive cycle. They spread rapidly in culture and cause an efficient 
destruction of the infected cell. Latency is established primarily in sensory ganglia, 
although not exclusively (David M. Knipe, 2007). This subfamily includes the genera 
Simplexvirus (HSV-1), Varicellovirus (VZV), Mardivirus (GaHV-2) and lltovirus (GaHV- 
1) (McGeoch et al., 2006). The first two genera are mammalian viruses, while the 
latter two have avian hosts. Also included in this subfamily are the reptilian viruses. 
However, they have not been currently attributed to any genera (David M. Knipe, 
2007).
Betaherpesvirinae: This subfamily contains the genera Cytomegalovirus (HCMV), 
Muromegalovirus (MCMV), Roseolovirus (HHV-6) and Proboscivirus (EIHV-1) 
(McGeoch et al., 2006). The productive cycle is long and the infection progresses 
slowly in culture. The infected cells frequently display cytomegalia (become 
enlarged). Latency is maintained in secretory glands, iymphoreticular cells, kidneys 
and other tissues (David M. Knipe, 2007).
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Gammaherpesvirinae Gammaherpesviruses have a narrow natural host range. In 
vitro all members can replicate in lymphoblastoid cells, although lytic infection has 
been also demonstrated in epithelioid and fibroblastoid cells (David M. Knipe, 2007; 
Nash et al., 2001; Suarez and van Dyk, 2008). However, gammaherpesviruses show 
specificity fori and B lymphocytes and latency has been demonstrated in lymphoid 
tissues (Barton et al., 2011). The genera included within this subfamily are the 
Lymphocriptovirus (EBV), Rhadinovirus (HHV-8), Macavirus (EHV-2) and Percavirus 
(AHV-1) (McGeoch et al., 2006).
— GaHVI 
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HHV3 (VZV) 
EHV1
GaHV3
------------------GaHV2
---------------MeHVI
CeHVI
HHV1 (HSV-1)
BHV1
SuHVI
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CCMV
- HHV5 (HCMV)
HHV6
HHV7
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EHV2
BHV4
MHV4
AtHV3 
SaHV2 
CeHVI7
■ HHV8 (KSHV)
CalHVS
CeHVI5
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Fig 1.4 Phylogenetic tree representing the herpesvirus family, as described for the 
amniotes lineage. The herpesvirus family can be divided into three subfamilies; a-, 
p- and y-herpesviruses. In the figure some known human herpesviruses are 
highlighted within each subfamily: HSV-1 and VZV are alphaherpesviruses, HCMV 
belongs to the betaherpesvirus subfamily, while EBV and KSHV have been assigned 
into the gammaherpesvirus subfamily (Wang et al., 2007).
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The shared features, biological properties and phylogenetic evidence obtained from 
studies done on herpesviruses, have allowed classification within the family and 
subfamily and provided the opportunity to investigate herpesviruses evolution 
history and mechanisms. This focus in herpesvirus evolution has also produced 
evidence of co-evolution between herpesviruses and their natural host with, in 
many instances, viral speciation occurring at approximately the same time as host 
speciation (McGeoch et al., 1995). It shows an intimate shared evolutionary history 
between the virus and its natural host, which includes the acquisition of genes and 
genetic functions of host origin. This evolutionary strategy has resulted in a 
delicately regulated interaction with the natural host, with the virus being able to 
highjack or interact with cellular signals over the course of the long-term relation 
with the infected individual (David M. Knipe, 2007). Such evolution has equipped 
the virus to attain a delicate equilibrium between its own replication (and 
persistence in the infected individual) and the overall survival of its natural host, 
allowing for an efficient transmission through the population (David M. Knipe, 
2007). Nonetheless, infection of a heterologous host can lead to fatal outcome in 
some cases, as with malignant catarrhal fever caused by AIHV-1 and ovHV-2 (Russell 
et al., 2009). Furthermore, infections in immunocompromised individuals have been 
associated with several malignancies, specifically in gammaherpesviruses where 
evidence exists that strongly correlates infection with the development of 
lymphoproliferative diseases, lymphomas and other nonlymphoid cancers (Barton 
et al., 2011).
12
1.2 Gammaherpesviruses
Gammaherpesviruses are lymphotropic viruses. Latency is predominantly 
established in lymphoid cells, but lytic replication has also been demonstrated in 
epithelial and dendritic cells, fibroblastoid cells and macrophages (Edelman, 2005; 
Nash et al., 2001; Suarez and van Dyk, 2008). This subfamily has been primarily 
divided into the genera, Lymphocryptovirus (yl-herpesviruses), typified by Epstein- 
Barr virus (HHV-4) of humans and related viruses of old world primates, and 
Rhadinovirus (y2-herpesviruses), that includes Kapsosi's sarcoma associated 
herpesvirus (endemic in humans). More recently, some authors have further 
divided this subfamily to include two other genera (artiodactyls, perissodactil and 
carnivore viruses); the Macavirus and Percavirus, whose internal structure 
resembles the lymhocriptovirus clade (McGeoch et al., 2006). In a similar fashion to 
what was observed earlier in virus classification into the Herpesviridae family, 
assignment of viruses into the Gammaherpesvirinae subfamily was initially 
established on the basis of biological properties (David M. Knipe, 2007). These 
included episome persistence in dividing cells, establishment of latency in 
lymphocytes (although elements from the Betaherpesvirinae also latently infect 
lymphocytes) as well as oncogenic properties. Recently, extensive work has been 
done in genome characterization, providing a more definite approach to 
segregation into this subfamily based on nucleotide/protein sequence and genomic 
collinearity (David M. Knipe, 2007). These studies have revealed a strong 
conservation of specific blocks of genes, generally coding for factors involved in 
replication related functions or structural components of the virion particle (fig 1.5). 
These are separated by genes that appear to be virus-specific, generally implicated
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in the establishment of latency and/or transformation of infected cells (Virgin et al.,
1997).
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Fig 1.5 Comparison of genome organization among gammaherpesviruses. ORF
numbers are attributed based on position within HVS genome and related to the 
remaining genomes based on collinear and nucleotide/functional homology. The 
four conserved blocks of genes between gammaherpesviruses are shown in shaded 
boxes. Virus-specific genes are indicated above each block in white boxes. (Virgin et 
al., 1997).
An interesting observation is that although these genes seem to be virus-specific, 
they have been somewhat linked to oncogenic mechanisms, a central feature that is 
shared by and characterizes gammaherpesviruses. More importantly, the 
description of oncogenesis as a distinct aspect of gammaherpesviruses 
pathogenesis has stem originally from a clear correlation between EBV infection and
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Burkitt's lymphoma (Epstein et al., 1964). More recent data have also associated 
EBV with Hodgkin's lymphoma, nasopharyngeal carcinoma and lymphomas in 
immunocompromised hosts (David M. Knipe, 2007; Gulley et al., 1993; Weiss et al., 
1987; zur Hausen et al., 1970). KSHV, on the other hand, after been discovered 
initially in Kaposi's sarcoma tissues (Chang et al., 1994) and being described as 
related to lymphotropic gammaherpesviruses (Neipel et al., 1998), suggested links 
to lymphoproliferative diseases that resulted in the association of this virus with 
primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD), 
reinforcing the clinical importance of these viruses (Cesarman et al., 1995; David M. 
Knipe, 2007; Soulier et al., 1995).It has prompted a keen interest in the study of 
gammaherpesvirus biology and the necessity to understand better their molecular 
biology, pathogenesis and oncogenic mechanisms. However, both EBV and KSHV 
are characterized by a narrow host range and the development of an accurate 
pathogenesis animal model system in which to investigate infection has proved 
difficult (Simas and Efstathiou, 1998). Infection of nonhuman primates with EBV and 
KSHV does not accurately recapitulate human disease (Blasdell et al., 2003), other 
option being the study of viral simian homologues in their respective natural hosts 
(Blaskovic et al., 1980; Bruce et al., 2006; Gulley et al., 1993; O'Connor and Kedes, 
2007; zur Hausen et al., 1970). Nonetheless, although highlighting the importance 
of infection in the context of a natural host when developing an accurate model of 
gammaherpesviruses pathogenesis, primate studies are not always feasible (Barton 
et al., 2011). Alternatively murid herpesvirus type 4, or murine gammaherpesvirus 
68 (MHV-68), has been employed as a small tractable animal model to aid our 
understanding of gammaherpesviruses pathogenesis (Barton et al., 2011; Blaskovic
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et ai., 1980; Nash et al., 2001; Simas and Efstathiou, 1998; Sunil-Chandra et aL, 
1994; Virgin et al., 1997; Weiss et al., 1987).
1.2.1 MHV-68 as a model of gammaherpesviruses pathogenesis
Murine gammaherpesvirus 68 was initially isolated from bank voles {Myodes 
glareolus) and yellow-necked field mice [Apodemus flavicollis) captured in Slovakia 
(Blaskovic et al., 1980) with a later survey in the United Kingdom presenting 
evidence that MHV-68 was endemic in wood mice. The same study failed to provide 
confirmation of infection in bank voles, suggesting that wood mice are a major 
reservoir for MHV-68 (Blasdell et al., 2003). Like KSHV, MHV-68 belongs to the 
Rhadinovirus genera (y2-gammaherpesvirus). However, rodent and primate y2- 
gammaherpesvirus are estimated to have diverged around 60 million years ago, and 
they are distantly related. The viral genome has been sequenced (Virgin et al 1997). 
As discussed previously, sequencing of the viral genome showed several genes 
unique to MHV-68 absent from the KSHV genome and vice-versa. Yet, while some 
specific aspects of viral pathogenesis could be distinct between distantly related 
gammaherpesviruses due to this, core pathogenic strategies are very likely to be 
conserved, and as such this mouse model has much to offer (Barton et al., 2011). 
Furthermore, MHV-68 virus readily infects laboratory mice [Mas musculu) and it is 
relatively easy to manipulate and construct virus deletion mutants. Combined with 
the existence of several gene knockout mouse strains, this virus offers a system to 
understand better viral pathogenesis and develop and evaluate chemotherapeutic 
and vaccination strategies (Simas and Efstathiou, 1998).
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Taking advantage of the possibilities provided by MHV-68, Sunil-Chandra et al first 
described the infection by MHV-68 in vivo in BALB/c mice (fig 1.6). In this study, 
MHV-68 was introduced into five to six-week-old inbred mice intranasally, as 
comparison with other gammaherpesviruses and insights from a survey of bank 
voles and wood mice, in the UK, suggested the respiratory tract was a primary route 
of entry (Nash et al., 2001; Sunil-Chandra et al., 1992). This resulted in a productive 
infection of alveolar epithelial cells, with high titres of infectious virus detected 
between days 1 to 7 post-infection. Clearance of the virus in lung tissue was 
observed at day 10 post-infection (Sunil-Chandra et al., 1992), concomitant with 
viral spread to the mediastinal lymph node (MDL), where dendritic cells, 
macrophages and B cells were infected (Nash et al., 2001). According to the same 
study, infected dendritic cells may be responsible for transporting virus to the 
draining lymph node, where MHV-68 undergoes reactivation and infection of other 
cell types occurs. Upon infection in the MDL, B cells undergo a rapid expansion, 
accompanied by an increase in latently infected B cells. Viral trafficking from MDL to 
the spleen and other lymphoid compartments was also observed (carried through 
infected B cells) followed by a rapid expansion of latently infected B cells in the 
spleen (week two post-infection), mirroring infection in the MDL (Nash et al., 2001). 
The number of latently infected cells increases up to 1 in 104 splenocytes in the 
space of a few days, but by week three the number of infected ceils falls to 1 per 
106 (Nash et al., 2001). It is a common rationale that, from this point onwards, the 
virus establishes a lifelong persistence in the host, and that, similar to EBV, the B 
lymphoid compartment will function as a major site of MHV-68 latency (Stewart et 
al., 1998). The progress of infection as described above and the observed lytic
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reactivation of the virus upon specific signalling, reiterates the importance of the 
balance between latent and lytic infection. In fact, this balance is a central paradigm 
in herpes virus pathogenesis, as it not only allows the dissemination of the virus 
within the host but also enables the infection of potential new hosts (Pavlova et al., 
2003; Stewart et al., 1998; Wu et al., 2000).
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Fig 1.6 MVH-68 infection in BALB/c mice. After primary lytic infection in the lungs, 
the virus traffics to the lymphoid tissues including the spleen where establishes 
latency mainly in B cells (Nash et al., 2001; Stewart et al., 1998; Sunil-Chandra et al., 
1992).
1.3 The replication and transcription activator - Rta: the key molecular switch for 
virus lytic infection cycle and reactivation
Gammaherpesviruses pathogenesis is dependent on ability of the virus cause lytic 
infection and to undergo lytic reactivation in latently infected cells. (Nash et al.,
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2001; Pavlova et al., 2003; Stewart et al., 1998). Although the molecular 
mechanisms triggering reactivation in vivo are not entirely clear, the consensus is 
that of an ordered cascade of viral gene expression. Immediate-early genes are first 
transcribed, stimulated by an environmental trigger (like hypoxia), the introduction 
of chemical compounds (aiding the study of reactivation in in vitro systems), such as 
phorbol esters and sodium butyrate, or factors associated with signal transduction 
pathways - which may indicate they play a role in pathogenesis and infection 
(Cesarman et al., 1995; Davis et al., 2001; Deng et al., 2000; Gargano et al., 2009; 
Gregory et al., 2009; Lu et al., 2005; Miller et al., 1996; Wilson et al., 2007). The 
transcribed immediate-early genes usually encode transcription activating proteins 
which will then be responsible for initiating the viral lytic cascade, activating the 
genetic expression of delayed early (DE) proteins - involved in viral DNA replication 
and metabolism. Late genes are expressed last, encoding structural proteins which 
are necessary for virion assembly, maturation and egress (Boyne and Whitehouse, 
2006; Damania et al., 2004; Deng et al., 2007; Pavlova et al., 2003).
Studies on gammaherpesvirus reactivation have described a viral immediate-early 
transactivator protein, Rta (replication and transcription activator) to be a key 
molecular switch in the initiation of the viral gene cascade. Rta is encoded by open 
reading frame 50 (ORF50) and its genomic location and function is well conserved 
amongst gammaherpesviruses (Pavlova et al., 2005; Virgin et al., 1997). However, 
the manner by which reactivation is dependent on Rta differs somewhat between 
yl- and y2-herpesviruses. yl-herpesvirus reactivation, as described in EBV, is the 
result of cooperation between two viral immediate-early proteins, Rta and Zta. Both 
are viral transactivators and able to activate a particular subset of lytic promoters,
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both viral transactivators are able to disrupt latency on their own (in latently 
infected cell lines), and a deletion mutant of either Zta or Rta abrogates viral 
reactivation (Chevallier-Greco et alv 1986; Cox et al., 1990; Feederle et al., 2000; 
Staudt and Dittmer, 2007; Wu et al., 2001). In y2-herpesviruses, Rta functions as the 
only lytic switch, sufficient to drive viral lytic replication (Lukac et al., 1999). Rta is 
expressed very early in the lytic cycle, before several other genes implicated as 
candidate regulatory genes in related viruses, and its expression can upregulate 
other viral promoters in transient assays (Chen et al., 2000; Lukac et al., 1999; 
Lukac et al., 1998; Song et al., 2003; Song et al., 2002; Zhang et al., 1998). 
Furthermore, expression of Rta alone in latently infected cell lines with MHV-68 
disrupts latency and drive viral lytic replication to completion (Wu et al., 2000). 
Similar observations have been made with Rta in KSHV and HVS infected cells. 
Studies done using Bacterial Artificial Chromosome technology (BAC) have also 
shown that knockout mutations within the ORF50, inhibit Rta expression and render 
the virus defective for lytic reactivation, incapable of DNA replication and virion 
production (Xu et al., 2005). Finally, Rta is responsible for promoter activation and 
gene transcription for a number of viral genes in KSHV involved in lytic reactivation 
from latency, including K-bZIP (ORFK8) (Lukac et al., 1999), Mta (ORF57) (Lukac et 
al., 1999), Nut-1 (Song et al., 2002) and vlL-6 (ORFK2) (Deng et al., 2002).
1.3.1 Rta transcript architecture
Analysis of Rta transcription following promoter activation (an overview of which is 
provided in section 1.4), describes multiple mRNA species, the products of splicing 
events (fig 1.7). Although Rta protein is mainly encoded within ORF50 a splicing
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event occurs upstream this locus and introduces a new methionine initiation codon
and adds an additional coding region.
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Fig 1.7 Rta mRNA splicing events. Rta mRNA splicing events have been described 
across gammaherpesviruses. The figure depicts the Rta mRNA splicing for A) MHV- 
68, B) KSHV and C) HVS. Adapted from (Lukac et al., 1998; Whitehouse et al., 1997; 
Wu et al., 2000).
This is observed and characterized throughout the gammaherpesviruses studied for 
Rta expression and transcription, which include EBV, KSHV, HVS and MHV-68. (Deng 
et al., 2007; Liu et al., 2000; Lukac et al., 1998; Manet et al., 1989; Whitehouse et 
al., 1997). This suggests that splicing events in Rta mRNA processing occur in all 
gammaherpesviruses. However, most herpesvirus lytic genes, in contrast to Rta,
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lack introns (Boyne and Whitehouse, 2006). Host processing of mRNA transcripts, 
which gammaherpesviruses rely upon, is linked and dependent on splicing. The 
virus overcomes this issue by encoding a protein (ORF57, also known as Mta) 
responsible for viral intronless mRNA nuclear transport to the cytoplasm (Boyne 
and Whitehouse, 2006; Goodwin et al., 1999). This protein is an IE gene, and, as Rta, 
undergoes splicing events upon transcription (Whitehouse et al., 1998b).
The suggested cause behind Rta (and ORF57) splicing events (as opposed to the 
other intronless lytic transcripts) relays this information to the temporal activation 
of lytic gene cascade. Rta expression is activated concomitant or before ORF57 and, 
as such, its transcripts need to be spliced for an efficient processing of its mRNA by 
the host cellular machinery (A. Whitehouse, SGM 2010, Edinborough).
1.3.2 Rta protein
The Rta polypeptide is comprised of two domains, one responsible for DNA binding 
and dimerization, located in the N-terminal, and a transactivation domain on the C- 
terminal rich in acidic amino acids (fig 1.8) (Wu et al., 2001). Presumably, Rta 
functions like other acidic activators e.g. yeast activator GAL4 and GCN4 or the VP16 
protein from the herpes simplex virus, interacting directly with TFIIB (Transcription 
Factor B for RNA Polymerase II) and enhancing transcription for the target gene. In 
vitro studies have shown the presence of the GAL4 or VP16 acidic activators to 
stimulate the binding of the TFIIB to an initiation complex at an adenovirus 
promoter (Lewin, 2004). Deletion of the acidic binding domain at the C-terminal of 
the protein, results not only in the removal of the transactivation function but 
creates a negative dominant mutant. This transactivation inhibition was observed
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even in mixed multimers with wild type Rta - also suggesting that Rta must form 
homomultimers to function as the lytic switch protein (Bu et al.7 2007; Wu et al., 
2001). Studies using hybrid Rta proteins from EBV, KSHV and MHV-68 have also 
shown that this transcription activator performs in a two-step process; first binding 
to DNA and then starting the transcription activation (Damania et al., 2004). It has 
been proposed that the specificity for reactivation lies not just in the activation 
domain, but also in the DNA binding domain (Rickabaugh et al., 2005). 
Paradoxically, it has been also shown that Rta is able to activate promoter 
transcription indirectly (Adamson et al., 2000; Chang et al., 2005; Chen et al., 2005; 
Liu et al., 1996; Ragoczy and Miller, 2001), suggesting different mechanisms of 
transactivation.
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Fig 1.8 Rta different domains. The N-terminal domain of the protein is responsible 
for Rta's DNA binding function. The transactivation domain is located on the C- 
terminal of the same protein. The dimerization domain is situated between these 
domains (Wu et al., 2001).
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1.3.3 Mechanisms of Rta transactivation:
Two different mechanisms through which Rta activates viral promoters have been 
described in EBV and KSHV. In both viruses research has shown that viral genes are 
activated by Rta by two distinct general modes of action (Chang et al., 2005; Chen 
et al., 2005).
A subset of promoters is transactivated through direct binding of Rta to specific 
DNA sequences (found within these promoters), known as Rta response elements 
(RRE) (table 1.1). In KSHV, Rta can transactivate ORF57 and K-bZIP by direct binding 
to a 12 bp DNA sequence 5' - AACAATAATGTT - 3', found within these promoters. A 
different RRE was also described within PAN/Nut-1 and K12 viral promoters 5' - 
AAATGGGTGGCTAACCCCTACATAA - 3' (Chang et al., 2005). Interestingly, while both 
RRE DNA sequences show no significant homology, a second study has reported 
that KSHV Rta forms oligomers that makes multiple contacts with a tandem array of 
phased A/T triplets in the configuration of (A/T)3(G/C)7 repeats, a pattern that can 
be discerned in these response elements (Liao et a!., 2003). Similarly, direct binding 
and transactivation of viral promoters by Rta, including BHRF1, BMLFl, BaRFl, 
BHLF1 and BLRF2 has also been observed in EBV (Chen et al., 2005). The consensus 
sequence in EBV is defined as GNCCNgGGNG (Gruffat et al., 1990). The DNA binding 
domain binds to this sequence possibly by recognizing the two major adjacent 
grooves in the DNA helix (West and Wood, 2003). RREs in other 
gammaherpesviruses have also been described. In HVS, the mechanism described 
so far involves direct DNA binding to a specific sequence motif CCN9GG, named 
ORF50 Response Element (Whitehouse et al., 1997; Whitehouse et al., 1998a). This
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sequence is analogous to the EBV RRE consensus sequence GNCCNgGGNG. With
regards to MHV-68, RREs have been found within the MHV-68 ORF57 promoter (5'- 
AATGIGAGGCm-B'), and it appears to be strongly activated by Rta. Moreover MK3 
(latency/lytic associated viral factor involved in the downregulation of the major 
histocompatibily complex (MHC) class I gene expression) promoter was reported to 
contain an MHV-68 RRE (Coleman et al., 2003; Pavlova et al., 2005; Staudt and 
Dittmer, 2007; Stevenson et al., 2000). These potential MHV-68 RREs bear 
significant homology to published KSHV RREs (table 1.1), but only a small number of 
MHV-68 promoters have been investigated in detail so far (Staudt and Dittmer, 
2007). The second subset of promoters was shown to be activated by an indirect 
mechanism of Rta. EBV Rta transactivates the BZLF1 promoter by activating 
mitogen-activated protein kinases (MAP kinase) and phosphoinositol kinases.
Table 1.2 Rta viral responsive elements (RREs).
Gammaherpesvirus Consensus sequence
EBV 5'-GNCCN9GGNG-3'
HVS 5'-CCN9GG-3'
KSHV
5' - AAATGGGTGGCTAACCCCTACATAA - 3'
5' - AAC A AT A AT GTT - 3'
MHV-68
5' - AATGTGAGGCTTT - 3'
5' - TTTTTNNNTGTTT- 3'
These kinases in turn lead to activation/phosphorylation of ATF2 which will bind to 
and activate transcription of BZLF1 promoter (Adamson et al., 2000). EBV Rta also 
activates viral DNA polymerase (BALF5) gene via USF and E2F binding sites and auto 
stimulates its own promoter by manipulation of Spl/Sp3 ratio which leads to Spl-
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mediated gene activation (Liu et al., 1996; Ragoczy and Miller, 2001) A parallel 
result was also observed in KSHV, where an Rta DNA binding defective mutant was 
still able to induce expression (albeit at reduced levels) of ORF57, vMIP-1 and 
ORF50 (Chang et al., 2005). In this study, the authors emphasized the fact that this 
indirect transactivation still required protein-protein interactions with cellular 
factors. It has been suggested that RBP-Jk, CBP and Oct-1 may partake in this 
process (Chang et al., 2005; Sakakibara et al., 2001; Swenson et al., 2001).
1.3.4 Rta as an E3 ubiquitfn ligase
In addition to its role as a crucial modulator of the balance between latency and 
lytic replication in gammaherpesviruses, some authors have also shown Rta is able 
to act as a non-canonical ubiquitin E3 ligase and target important cell factors for 
proteosome degradation. Proteosome degradation enables the cells to both 
dispose of misfolded or damaged proteins and fine tune the concentration of 
essential proteins within the cell. This specific and rapid degradation process can be 
achieved by the addition of one or several ubiquitin (Ub) molecules to a selected 
protein, targeting it for proteolysis - ubiquitination. Ubiquitination involves the 
sequential action a set of enzymes (El, E2 and E3) which engage in the necessary 
post-translational modification of the target protein, each one playing a specific role 
within this mechanism. Ubiquitin is first activated by Ub-activating enzyme El in an 
ATP dependent reaction, before being transferred to the Ub-conjugating enzyme E2 
before being attached to the substrate protein. This last step requires the Ub ligase 
E3, which recognizes binds the substrate protein and labels it with the Ub molecule. 
This process can be repeated until a polyubiquitin chain is formed targeting the
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substrate protein for degradation by the 26S proteosome complex. Ubiquitination 
plays a vital role in regulating many different pathways, not including only in protein 
degradation by also protein trafficking, cell-cycle control and cell signalling. This 
versatility of Ub as a modifier of cellular proteins and its use in the modulation of 
the cellular machinery and milieu characterized the mechanism as an attractive 
target for viral manipulation (Thompson et al., 2011).
Indeed, viral manipulation of this system by several viruses has been studied in the 
last years. The data obtained describes different strategies employed by viruses to 
highjack components participating in this mechanism and further subversion of this 
process for their own benefit. These include the expression of viral Ub, viral E3 
ligases with their specific cellular targets, viral adaptors able to recruit cellular E3 
ligases and redirect ubiquitination and the ability to target cellular targets for 
destruction endoplasmic-reticulum associated protein degradation (ERAD) through 
polyubiquitination (Boehme et al., 2006; Gaudreault et al., 2007; Gerlier and Lyles, 
2011; Kurt-Jones et al., 2004; Paludan et al., 2011; Schattgen and Fitzgerald, 2011; 
Takaoka et al., 2007; Yanai et al., 2009).
In 2005, Yu et al. demonstrated KSHV Rta was able to inhibit interferon-regulatory 
factor 7 (IRF7) induction of interferon (IFN) -a and -|3 expression (Yu et al., 2005). 
The same study showed Rta binds IRF7 and targets this protein for proteosome 
degradation and the mechanism is mediated by Ub E3 ligase activity, encoded 
within Rta N-terminus. Although the specific proteosome mechanism controlling 
the endogenous activity and turnover of IRF7 has not of yet been addressed, the 
authors speculated KSHV exploited this pathway to block IRF7 function. 
Furthermore, the same study suggested KSHV Rta had an enzymatic domain with
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functional parallels with the predicted E3 Ub ligase for IRF7. Interestingly, the E3 
ligase activity of Rta was located to three key residues, Cysm, Cysi41 and His^s a 
domain with no significant similarity to the previously described E3 ligase families, 
HECT (homologous to E6AP carboxy terminus), RING (really interesting new gene) 
and U-box (Thompson et al., 2011; Yu et al., 2005). Rta also possesses a central 
domain located between residues 273-544, responsible for IRF7 binding and 
presumably bringing it to the adjacent Rta catalytic region (Yu et al., 2005). 
Posterior work confirmed KSHV Rta E3 ligase activity and further demonstrated 
targeting of other cellular (including Heyl and K-RBP, or KSHV-Rta binding protein) 
and viral factors (LANA) (Krug et al., 2004; Wang et al., 2005b). More importantly, a 
recent study demonstrated the E3 ligase activity was also observed in MHV-68 Rta, 
strongly suggesting it is conserved throughout gammaherpesviruses (Sorensen et 
al., 2008). The evidence produced showed MHV-68 Rta targeted RelA (a subunit of 
NF-kB) for proteosome degradation, abolishing NF-kB activation and subsequent 
cytokine expression. Sequence alignment also revealed that KSHV Rta and MHV-68 
Rta share the conserved Ub cysteine-rich domain and that the Ub E3 ligase activity 
of MHV-68 is similarly dependent on two highly conserved cysteine residues (Cysi4i 
and Cysm). Not surprisingly, Rta E3 Ub ligase activity is associated with lytic 
reactivation/replication of KSHV and MHV-68. Targeting IRF7 and RelA for 
proteasome degradation enables viral evasion of innate immunity responses by 
blocking IFN induction and production of cellular cytokines, respectively. On the 
other hand, Heyl and LANA are known repressors of Rta expression while K-RBP is 
involved in downregulation of Rta-mediated transactivation function. Labelling 
these proteins for proteasome degradation by Rta may be one important step in the
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mechanism regulating the lytic/latency cycle (Sorensen et al., 2008; Wang et al., 
2005b; Yang et al., 2009; Yu et al., 2005).
1.4 Regulation of Rta gene expression
Rta is solely responsible for triggering the lytic gene cascade and subsequent virion 
production. Given that role, the mechanisms modulating Rta promoter activation 
and gene expression have been the subject of much attention. The combined 
output produced by several groups over the last decade, has therefore allowed for 
the characterization not only of the Rta promoter region for each 
gammaherpesvirus studied, but also interactions between specific signals (both 
cellular and viral) and Rta promoter. These interactions have revealed a complex 
system of gene regulation by these viruses to maintain control of both lytic and 
latent phase, necessary for an efficient viral infection. Not surprisingly, these studies 
provide evidence that the balance between lytic replication and latency depend not 
only on the stage of the viral infection, but also on cellular environment.
1.4.1 Effect of chromatin architecture on Rta gene expression
In eukaryotic cells, the genome is presented in a complex DNA/protein form termed 
chromatin in the nucleus. The positively charged histones bind tightly to the 
phosphate backbone of DNA, forming nucleosomal structures. These structures are 
the basic unit of cellular chromatin. Cellular chromatin forms a dynamic structure 
that maintains the stability and accessibility of DNA genome. Acetylation of lysines 
on histone tails by histone acetyltransferases (HATs) leads to the unravelling of 
chromatin and transcriptional activity, while deacetylation by histone deacetylases
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(HDACs) leads to chromatin condensation, and silencing transcription. Therefore,
chromatin regulation plays an important role in viral cycles and viruses have 
coevolved to manipulate these mechanisms (Lieberman, 2006).
During latency, gammaherpesviruses genomes are assembled into nucleosomal 
structures, similar to cellular nuclear chromatin. A number of studies (KSHV, EBV 
and MHV-68) have shown that at this stage viral reactivation can be induced by 
HDACs inhibitors, such as NaB. Furthermore, it has been shown that in KSHV 
latently infected cells, Rta promoter is associated with multiple HDACs (HDAC 1, 5 
and 7) and is repressed by a nucleosome positioned over a Spl/Sp3 binding site. In 
addition CBP, a cellular histone acetyltransferase is able to stimulate Rta 
transcription (Lu et al., 2003). Also, Rta promoter in MHV-68 latently infected cells is 
associated with HDAC 3, but not HDAC 1, 5 and 7, suggesting a relation between 
chromatin regulation and inhibition of Rta gene expression. Moreover, methylation 
of Rta promoter has been correlated with latency, by in vitro studies in KSHV and 
MHV-68 (Yang et al., 2009). Taken together, these observations indicate that 
methylation, chromatin remodelling and histone acetylation/deacetylation at the 
Rta promoter region is a critical step in modulation of its activation.
1.4.2 Regulation of Rta gene transcription by gammaherpesviruses proteins
The modulation of Rta promoter transcription by gammaherpesviruses proteins was 
initially observed in the context of EBV reactivation from latency. Over expression of 
Zta in latently infected cell lines stimulated the transcription of several lytic viral 
genes, including BRLF1 (Ragoczy et al., 1998). This was followed by experimental 
work done in KSHV, HVS, EBV and MHV-68 showing that Rta is able to auto-activate
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its own promoter (Damania et al., 2004; Deng et al., 2000; Wakenshaw et al., 2005).
More recently, transfection studies have described up-regulation of Rta promoter 
by ORF49 in the context of MHV-68 infection (Lee et al., 2007). ORF49 is the 
positional homologue of the BRRF1 gene in EBV, whose expression is activated in 
the early stages of infection following reactivation and it has been suggested ORF49 
has a role in KSHV lytic reactivation (Gonzalez et al., 2006; Hong et al., 2004). The 
data obtained from these studies suggests there is a feedback loop in 
gammaherpesvirus reactivation. Expression of immediate-early proteins initiates 
not only the viral gene cascade, but further stimulates the expression of Rta, a 
major player in the modulation viral lytic gene transcription, thus potentiating lytic 
replication. Conversely, proteins associated with the establishment of latency are 
able to interact with Rta promoter and downregulate its transcription. ORF73, a 
multifunctional protein essential for the latency establishment, suppresses lytic 
reactivation by associating with Rta (in vivo and in vitro) and inhibiting transcription 
activation of its own promoter, which leads to repression of basal levels of Rta 
expression (DeWire and Damania, 2005; Lan et al., 2004; Schafer et al., 2003). The 
control of Rta expression in latency is of paramount importance and repression of 
its activation by ORF73 allows the establishment of latency in infected cells. 
Interestingly, Rta has been shown to downregulate its own transactivation indirectly 
by inducing the expression of ORF73, providing a negative feedback loop and 
keeping viral replication in check (Deng et al., 2007). A similar mechanism is 
observed involving Rta and the cellular transcription repressor Hey-1. Rta was 
shown to induce Hey-1 transcription in vitro, and in turn, Hey-1 repressed activation
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of Rta promoter, possibly as part of a complex because direct binding of Hey-1 with
the promoter could not be demonstrated (Yada et al., 2006).
ORF49 BZLF1
ORF50 promoter
Rta
Fig 1.9 An overview of Rta promoter modulation by viral transcription factors.
ORF49, BZLF1 and Rta activate the Rta promoter and induce lytic replication. 
Latency associated protein ORF73inhibits the Rta promoter and drives the viral 
cycle into latency. Rta participates in this mechanism either by inducing ORF73 
expression or a cellular transcription repressor Heyl.
1.4.3 Cellular signalling that controls Rta expression
Addressing the role of cellular signalling in lytic infection or establishment of latency 
in gammaherpesviruses is a critical question. Understanding which host signals 
interact with Rta promoter and how they modulate its activation gives an insight on 
how the cellular environment influences the balance between lytic replication and 
latency and which events trigger viral reactivation. A common strategy employed to 
study gammaherpesvirus reactivation from latency in vitro involves triggering the 
viral gene cascade with 12-0-tetradecanoyl-phorbol-13-acetate (TPA). Experimental 
work with KSHV has shown that induction of the AP-1 pathway by TPA is followed 
by Rta promoter activation by c-Jun and c-Fos (Wang et al., 2004). Furthermore, a
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comprehensive study examining cellular induction of KSHV Rta gene expression in
vitro (in an indirect manner) demonstrated a several cellular factors were involved 
in upregulation of Rta promoter activation - table 1.3 (Yu et al., 2007). Ets-1 
activation of Rta promoter has shown that this is mediated by the Ras/Raf/MEK/ERK 
pathway. Ets-l is involved in cell proliferation, angiogenesis and immune response, 
while the Ras/Raf/MEK/ERK pathway is vital to cell survival, differentiation and 
proliferation (Kolch, 2000). The authors hypothesized this pathway is essential for 
the virus to sense important environment cues at different stages of infection (Yu et 
al., 2007). There also some evidence that unfolded protein response (UPR) pathway 
(a physiological response mechanism) plays a role in activation of KSHV Rta 
promoter and virus reactivation in PEL cells (Wilson et al., 2007). Chemical induction 
of endoplasmatic reticulum stress activates the UPR, which will in turn lead to the 
expression of the active form of the transcription factor X box binding protein 1 
(XBP-1). Endogenous XBP-1 reactivates KSHV from latency and its over expression 
transactivates Rta promoter. Considering XBP-1 plays an important role in terminal 
differentiation of B cells into plasma cells (Reimold et al., 2001) it suggests the 
signalling associated with this event trigger viral reactivation by transactivating Rta 
promoter. Moreover, plasma cell differentiation is also associated with reactivation 
of EBV and MHV-68, and MHV-68 viral protein M2 can manipulate and drive plasma 
cell differentiation (Laichalk and Thorley-Lawson, 2005; Liang et al., 2009). 
Differentiation of latently infected B lymphocytes in a B cell compartment 
(unidentified) in the oral mucosa activates Rta promoter is believed to lead to viral 
reactivation and the subsequent shed of virion particles into saliva (Thorley-Lawson 
and Gross, 2004; Wilson et al., 2007). Examination of other physiological stimuli
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Table 1.3 Activation of KSHV by cellular genes (Yu et al., 2007)
Symbol Annotation Luciferase 
activity - 
induction
Fold
LOC51508 Hypothetical protein 5.6
XBP1 X-box binding protein 1 7.7
Etvl ets variant gene 1 42.7
Zfp64 Similar to zinc finger protein 64 46.4
Prkaca Protein kinase, cAMP dependent, catalytic, 
alpha
164.6
KRAS2 Similar to v-Ki-ras2 Kirsten rat sarcoma 2 viral 
oncogene homolog
148.1
NR4A1 Homo sapiens nuclear receptor subfamily 4, 
group A, member 1
23.9
Cdknlb Similar to cyclin-dependent kinase inhibitor 
IB (P27)
13.9
Rifl Similar to RAS-like protein expressed in many 
tissues
39.2
Nfib Mus musculus, nuclear factor l/B, clone 
MGC:13959
17.4
Pitxl Similar to paired-like homeo-domain
transcription factor 1
21
Etsl Mus musculus, E26 avian leukemia oncogene 
1, clone MGC:18571
18
Gadd45a Similar to growth arrest and DNA damage- 
inducible 45 alpha
29.5
230058j06Rik Mus musculus mRNA for transcriptional 
coactivator (Taz gene)
57.2
Usf2 Mus musculus upstream transcription factor 2 6.1
LOC213541 Mus musculus, clone MGC:36628 7.8
3100004p22Rik RIKEN cDNA 3100004P22 gene 5.8
8430401F14Rik RIKEN cDNA 8430401F14 gene 15.1
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demonstrated that hypoxia inducible factor-1 alpha (HIF-la) is also a cellular stress
factor able to active Rta promoter in KSHV in vitro (Dalton-Griffin et al., 2009). How 
significant this is in vivo and potential roles in the context of gammaherpesviruses 
infection is yet to be demonstrated. Cellular signals are also able to inhibit Rta 
promoter activity. For example, NF-kB participates in establishment of 
gammaherpesvirus latency in B cells by inhibiting Rta gene expression (Brown et al., 
2003). In addition, over expression of NF-kB in epithelial or fibroblast cells inhibits 
MHV-68 replication (Deng et al., 2007). NF-kB translocation to the nucleus in most 
cell types is inhibited through interaction with another cellular protein 1-kB. 
However in B cells, expression of 1-kB is a downregulated and NF-kB transits freely 
to the nuclear compartment inhibiting activation of Rta promoter and hence playing 
a direct role in the establishment of gammaherpesviruses latency, (Hayden and 
Ghosh, 2008). Therefore, the cellular environment in different cell types might have 
a specific impact in the modulation of Rta expression, being selectively up or 
downregulated. Moreover, it has been shown that NF-kB expression is also induced 
in vitro by a KSHV viral transcription factor (vFLIP) associated with latency (Ye et al., 
2008). This results in inhibition of Rta promoter activation. Other cellular 
transcription factors also play a role in the inhibition of gammaherpesvirus Rta 
promoter activation. YY1 appears to downregulate EBV Rta expression (Zalani et al., 
1997) in the context of latency establishment in epithelial cells. An in vitro study 
with MHV-68 has also described inhibition of Rta promoter by Statl (Goodwin et al., 
2010). Statl is an important component of the interferon (1FN) signalling pathway 
which induces an antiviral state in infected cells. Interestingly, previous work had 
already described a link in the balance between lytic and latency reactivation in
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gammaherpesviruses and signalling associated with the IFN pathways. The results 
produced from these studies are somewhat conflicting in nature (Barton et al., 
2005; Gargano et al., 2009; Gregory et al., 2009; Monini et al., 1999; Steed et al., 
2006; Wang et al., 2005a; Zhang et al., 2005).
1.5 Gammaherpesviruses and the innate immune host responses
1.5.1 Toll-like Receptors and Interferons: Linking Innate and adaptative immunity
The immune system, as defined in vertebrates, is a complex array of defensive 
measures developed to protect the host from invading microorganisms (and other 
threats to the organism, like cancer). Likewise, immunity can be characterized as 
the state of protection from infectious disease (Richard A. Goldsby, 1999). A 
classical approach, employed to understand how this system works, entails the 
division of immune responses into two distinctly compartmentalized components, 
non-specific (defined as innate immunity), and specific (defined as adaptative 
immunity). Innate immunity is a set of broader mechanisms, not specific to a 
particular pathogen. In contrast, adaptative immunity is able to recognize the 
infectious agent and not only mount an effective response specifically against the 
pathogen in question, but also retains immunological memory. This allows a more 
efficient and rapid response on subsequent infections with the same pathogen. In 
this context, innate immunity is considered to provide the first line of defence after 
initial exposure to a pathogen as it is constitutively present while adaptative 
immunity responses require some time to be assembled. If the pathogen evades 
innate mechanisms or is not cleared effectively by them, the specific branch of the
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immune system is triggered (Hoebe et alv 2004; Richard A. Goldsby, 1999). This 
classical examination of the interaction between innate and adaptative immunity 
has been revised recently, showing that both are not independent but interact 
closely. The intricate relation between innate and adaptative immunity is not fully 
understand, but the interface between the both is suggested to occur through Toll­
like Receptor (TLRs) and Interferon (IFN) signalling. Following the discovery of TLRs 
and the description of these as sensors of pathogen-associated molecular patterns 
(PAMPs), it was shown that they are associated not only with innate immunity but 
also that polarization of the adaptative immune response is TLR-mediated. 
Stimulation of TLRs in dendritic cells (DCs) induces cytokines which influence T and 
B cell activation/differentiation (Hoebe et al., 2004; Iwasaki and Medzhitov, 2004). 
Similarly, interferons (IFNs), cytokines closely associated with antiviral cellular 
environment and induced by TLR signalling, have been shown to participate in the 
establishment of an adaptative immune response (Iwasaki and Medzhitov, 2004). 
IFN-a/p have also been shown to play a role in adaptive immunity as type I IFN 
signalling enables B cells to undergo isotype switching and differentiation into 
plasma cells (through activation of DCs) and promote the proliferation of memory T 
ceils (Le Bon et al., 2001; Tough et al., 1999).
1.5.2 Type I interferon signalling pathway
IFNs are a group of cytokines (cell-signalling proteins), described initially as involved 
in the inhibition of viral replication. Upon induction they establish an antiviral state 
not only within the infected ceil but also (as they are secreted into circulation) in 
neighbouring uninfected cells, capable of controlling most virus infections in the
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absence of adaptative immunity. It is worth noting that, however, viruses have 
developed several strategies to circumvent IFN response and can still replicate and 
cause disease in vivo (Randall and Goodbourn, 2008; Sen, 2001).
Interferons are grouped into three classes, type I, II and HI IFNs according to amino 
acid homology. Type I IFNs superfamily is comprised of several proteins, classified 
into IFNs-a, -(3, -6, -a), -e and -k. IFN-a includes 14 to 20 members, depending on 
species (13 in man) and IFN-p one to three in mammals (one in man). Both have 
been studied extensively and have been shown to be induced directly in response 
to viral infection. The remaining proteins have a less defined role, and generally are 
not considered when describing type I IFNs (Randall and Goodbourn, 2008). Type El 
has a single member (IFN-y) involved in the regulation of practically all stages of 
immune and inflammatory responses, including the activation and differentiation of 
T cells, B cells, NK cells and macrophages (Gattoni et al., 2006). Type III IFNs are 
constituted by three proteins, IFN-Xl, - A2 and A3. They appear to use the same 
pathway as IFN-ct/p and elicit antiviral response equivalent to type I IFNs (Onoguchi 
et al., 2007). However data suggests limited tissue distribution and there is little 
evidence supporting an essential role in response to infection by type III IFNs 
(Randall and Goodbourn, 2008).
Following gene expression, induced by viral infection of the cell, type I IFNs bind to 
a common cell-surface receptor, composed of two distinct subunits, IFNAR1 and 
IFNAR2 (Novick et al., 1994), constitutively associated with members of the Janus- 
activated kinase (JAK) family. Interaction of IFN with the receptor initiates a series 
of phosphorylation events that culminate in phosphorylation of signal transducers 
and activators of transcription (Stats) proteins (Statl and Stat2). Phosphorylation of
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these proteins activates Stats, enabling the formation of both homodimers and 
heterodimers. These transcription complexes include the IFN-stimulated gene 
factor 3 (ISGF3), comprising Stat 1, Stat2 and a DNA binding protein of the IFN 
regulatory factor (IRF), IRF9 and a Statl:Statl homodimer (also produced in the 
context of IFIM-y signalling). The produced protein complexes translocate to the 
nucleus and bind to specific DNA sequences within IFN responsive promoters. ISGF3 
binds to IFN-stimulated response elements (ISRE) while the Statl homodimer binds 
to a response element described as the IFN-y-activated site, or GAS. The JAK-Stat 
pathway (fig 1.10), is responsible for the transcription of IFN-stimulated genes 
(ISGs), which are necessary for promoting the specific IFN-mediated biological 
response (Platanias, 2005). IFN signalling, ultimately, induces the expression of set 
genes (Der et al., 1998). It is the combination of the expression of these genes that 
promotes, in turn, the antiviral state (Randall and Goodbourn, 2008). Several of 
these genes have been extensively studied in order to understand how IFN 
signalling influences the cellular milieu and induces an antiviral state - table 1.4 
(Der et al., 1998). In summary, the type I IFN signalling cascade results ultimately in 
the inhibition of protein transcription within the infected cell, the subsequent arrest 
of cell growth and proliferation and lead to cell apoptosis in a concerted effort to 
stall viral replication.
1.5.3 Viral recognition by host cells in the context of innate immunity
Induction of type I IFNs expression has to be tightly correlated with cellular 
mechanisms that recognize a viral infection is taking place and signal to the host the 
presence of said infection.
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Fig 1.10 An overview of activation of the JAK-Stat pathway by type I IFNs. IFN-a/P 
binds to the extracellular domain of the type I IFN receptor. The subunits of the 
receptor, IFNAR1 and IFNArR2 are associated, respectively, with the Janus activated 
kinases (JAKs) tyrosine kinase 2 (TYK2) and JAK1. Activation of these kinases leads to 
phosphorylation of Statl and Stat2, and formation of transcription complexes 
(ISGF3 and Stats homodimer) able to translocate to the nucleus. Once in the 
nucleus, ISGF3 and the Stats homodimers bind to specific sequences and activated 
expression of sensitive genes who mediate IFN-dependent biologic responses 
(Brierley and Fish, 2002; Platanias, 2005).
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Table 1.4 Type IIFN induced genes and their role in the context of IFN signalling
Induced protein Function
Protein Kinase R (PKR) PKR phosphorylates selected cellular proteins, including the a 
subunit of the eukaryotic translational initiation factor 2 (elF2). 
Phosphorylation of elF2 by PKR prevents its recycling inhibiting 
proteins synthesis. Furthermore, phosphorylation of elF2 can 
activate autophagy (degradation of the cell own components), 
and appears to be involved in apoptosis.
2'5/-oligoadenylate 
synthetase (OAS)
OAS participates in the activation of RNase L, which degrades 
cellular and viral RNAs. In addition the OAS/RNase system is also 
associated with apoptosis.
MX proteins Mx encodes for a GTPase, related to dynamin and involved in 
endocytosis and vesicle transport. Mx shows antiviral activity; 
the protein recognizes nucleocapsid related structures and 
controls their localization within the cell, restricting virus
ISG56
replication.
ISG56 (or P56) belongs to a clustered ISG family, all structurally 
related. ISG56 inhibit translation by interacting with the 
translation initiation factor elF3 complex and has a negative 
effect on cell growth.
Interferon regulatory
factors (IRFs)
The IRF family encodes for transcription factors that affect both 
IFN synthesis and IFN-mediated gene induction. They have also 
been implicated in B cell differentiation and macrophage 
maturation.
P200 family Members of the P200 family are strongly induced by type 1 IFNs. 
One of its members (P202) attenuates cell growth and inhibits 
cell proliferation by inhibiting sequence specific binding of other 
cellular factors. Another protein of this family, P204, inhibits 
ribosomal RNA transcription by binding to UBF-1, a transcription 
factor required for nuclear transcription of rRNA.
(Information compiled from (Brierley and Fish, 2002; Randall and Goodbourn, 
2008; Sen, 2001))
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Several recognition strategies have evolved to provide such mechanisms, based on 
the detection of a limited set of conserved molecular patterns unique to the 
microbial/viral world and invariant throughout the pathogen population (Iwasaki 
and Medzhitov, 2004). It is proposed that the innate immunity senses 
microbial/viral infections through receptors expressed in cells, referred to as 
pattern recognition receptors (PRRs), which are able to recognize pathogen- 
associated molecular patterns - PAMPs (Janeway, 1989). Four classes of PRRs have 
been described so far; Toll-like receptors, RIG-l-like receptors, cytosolic-DNA 
sensors and NOD-like receptors. Of these, the first three classes have been showed 
to be relevant in the study of the interaction between the innate immune system 
and gammaherpesviruses.
1.5.3.1 Toll-like Receptors
The best studied and characterized PRRs are Toll-like receptors (TLRs). TLRs are type 
I transmembrane receptors composed of an extracellular domain (containing 
leucine-rich-repeat motifs, responsible for recognition of respective PAMPs), a 
transmembrane domain and a conserved cytoplasmatic domain ~ the toll/IL-lR 
(TIR) domain, required for downstream signalling pathways. The mammalian TLR 
family is composed of, at least, 13 proteins. TLRs 1 through 9 are conserved in mice 
and humans, allowing for identification of each respective ligand, based on studies 
done in knockout mice (table 1.5). TLR 10 is not functional in mice while TLR11, 
TLR12 and TLR13 are lost in human genome. TLR proteins can be further subdivided 
according to their cellular localization. TLR1, TLR2, TLR4, TLRS and TLR6 are
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expressed exclusively on the cell surface, while TLR3, TLR7, TLR8 and TLR9 are
localized in intracellular vesicles (endolysosomes).
Table 1.5 Members of the TLR family, the respective ligands (PAMPs) and 
pathogens associated with recognition by each receptor (Kawai and Akira, 2009).
Toll-like receptor (TLR) PAMPs Pathogen associated
TLR1-TLR2 Triacyl lipopeptides Bacteria
TLR2-TLR6 Diacyl lipopetides Mycoplasma
Lipoteichoic acid Bacteria
Zymosan Fungus
TLR2 Peptidoglycan Bacteria
Lipoarabinomannan Mycobacteria
Porins Bacteria
tGPI-mucin Parasites
Hemagglutinin protein Virus
TLR3 dsRNA Virus
TLR4 Lipopolysaccharide Bacteria
Envelope proteins Virus
TLRS Flagelin Bacteria
TLR7 ssRNA RNA Virus
TLRS ssRNA RNA Virus
TLR9 CpG DNA Bacteria
DNA DNA virus
Malaria hemozoin Parasites
TLR expressed on the cell surface recognize microbial membrane components - 
lipids, lipoproteins and proteins while TLR3, TLR7, TLR8 and TLR9 sense nucleic acids 
(Fig 1.11). The recognition of nucleic acids as a strategy for pathogen infection is 
unexpected as DNA and RNA are not exclusively microbial. Indeed, TLRs can be 
activated by self nucleic acids and have been linked to autoimmune diseases 
(reviewed in depth in (Lanzavecchia and Sallusto, 2007). The answer to this 
dichotomy lies in the difficulties recognizing viral infection by innate immune 
receptors. As viruses highjack the host machinery to replicate, virions lack uniquely 
foreign features that would be easily distinguishable and most viral proteins are
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Triacyl
lipopeptide
Flagellin Diacyl 
lipopeptide
Peptidoglycan
Pro-inflammatory 
cytokines Pro-inflammatory cytokines
Type I IFNs
CpG DNA
Pro-inflammatory cytokines 
Type I IFNs
Fig 1.11 Cellular localization of TLR and the respective immune response mediated 
by each receptor, following interaction with the specific PAMPs (Kawai and Akira, 
2006).
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very much prone to mutation while retaining functionality (poor targets), viral 
recognition by this system relies on detection of viral nucleic acids (Barton, 
2007).These TLRs (and TLR4) are implicated in the detection of viral infection not 
only due to their ability to bind ligands of viral origin, but because their signal 
transduction induces both pro-inflammatory and type I IFN responses -TLR2, TLR6 
and TLRS only induce pro-inflammatory responses (Barton and Kagan, 2009).
Studies employing plasmacytoid dendritic cells (pDCs) have provided a picture as to 
how this system may work. These cells express TLR7 and TLR9 constitutively, but 
not TLR2, TLR3, TLR4 or TLRS. Consistent with this pattern, these cells do not 
respond to bacterial components and are useful to understand how viral 
recognition occurs and the corresponding signal transduction pathway takes place 
(McKenna et al., 2005). TLR7 has been shown to be responsive to single stranded 
RNA (ssRNA) molecules, either synthetic or derived from viruses such as human 
immunodeficiency virus (HiV), influenza virus. Moreover, pDCs derived from TLR7- 
deficient mice do not produce IFN-a upon infection with influenza virus and 
vesicular stomatitis virus (Diebold et al., 2004; Lund et al., 2004). A similar role has 
been proposed for TLRS (Diebold et al., 2004). TLR9 recognizes CpG DNA motifs 
present in viral DNA and was shown to stimulate an identical pathway to TLR7- 
mediated activation of type I IFNs (Honda et al., 2005a). In a parallel fashion to 
TLR7, abrogating TLR9 from pDCs results in an inhibition of IFN-a synthesis following 
infection with DNA viruses (reviewed in (Kawai and Akira, 2006)). Establishment of a 
role forTLRB was presented in 2001, when it was described it responded to double- 
stranded RNA (Alexopoulou et al., 2001), produced by many viruses during 
replication. Again, research with TLR3-deficient mice shows these to be susceptible
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to murine cytomegalovirus (MCMV) due to a reduced IFN production (Tabeta et al., 
2004).
As mentioned above, after recognition of PAMPs respective of each receptor, TLRs 
involved in viral detection trigger a signal transduction cascade that induces IFN- 
a/p. This signalling cascade differs between these TLRs, with respect to an 
intracellular TIR-containing adaptor protein that is recruited following PAMP 
recognition. TLR7, 8 and 9 recruit MyD88, which will, in turn, recruit and form a 
complex with members of the interleukin-l (IL-1) receptor-associated kinase (IRAK) 
family - IRAKI and IRAK4, and TRAF6. Interferon regulatory factor 7 (IRF7) is 
recruited by this complex, undergoes phosphorylation by IRAKI and ubiquitination 
by TRAF6 and translocates to the nucleus, where it activates type I IFN gene 
expression. TLRS acts in a MyD88-independent manner. TLRS recruits a different 
adaptor molecule, TRIF, which will recruits TANK-binding kinase 1 (TBK1) and IKKe. 
These kinases interact with IRF3, catalyzing its phosphorylation. Once IRF3 is active, 
it translocates to the nucleus and induces IFN-p expression. IFN-P expression 
initiates a positive feedback loop that upregulates IRF7 and type I IFN expression 
(Kawai and Akira, 2006; Randall and Goodbourn, 2008). Concomitant with IRF7 and 
IRF3 activation, TLR signaling also activate NF-kB and the heterodimer c-fun/ATF-2 
required for optimal induction of type I IFNs - described in fig 1.12 and fig 1.13 
(Kawai and Akira, 2006; Randall and Goodbourn, 2008). As expected, both factors 
are activated in MyD88-dependent or MyD88-independent manner, depending on 
the TLR responsible for the signalling transduction.
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Fig 1.12 MyD88-dependent signalling. MyD88 recruits the complex IRAK4, IRAKI 
and TRAF6 which activates IRF7, necessary for induction type I IFN gene expression. 
Parallel signalling cascades also involve activation of NF-kB and c-jun/ATF-2 factors. 
The complex TAK1/TAB1/TAB2/TAB3, recruited by TRAF6 activates IkB kinases, IKKa 
and IKKP, which phosphorylates members of the mitogen-activate protein kinase 
family (MAPKs) leading to the activation of c-jun/ATF-2. These factors also 
participate in the upregulation of IFN-a/p expression (Kawai and Akira, 2006; 
Randall and Goodbourn, 2008).
Fig 1.13 MyD88-independent signalling. Signalling through TLR3 occurs via the 
molecular adaptor TRIP. NF-kB and c-jun/ATF-2 activation occur in a similar fashion 
has depicted in fig.10. In the proposed model, IRF3 is activated first and upregulates 
IFN-p expression. Gene expression of IRF7 follows IFN signalling cascade, and this 
transcription factor, once activated by the TBKl/IKKe complex, induces both IFN- 
ct/3 (in positive feedback loop) (Kawai and Akira, 2006; Randall and Goodbourn, 
2008).
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1.5.3.2 RIG-1 like receptors
The RLRs class of receptors is comprised of three receptors, able to sense non-self 
RNA in the cytoplasm. RIG-1 (retinoic inducible gene-1), the prototypical member of 
this family contains tandem caspase recruitment domain (CARD) regions at its N- 
terminus, a central DExD/H helicase and a C-terminal repressor domain (RD) which 
binds to RNA. The two other members identified within this class include MAD5 
(melanoma differentiation-associated gene 5) also containing the tandem CARD 
regions and the central DExD/H domain but no repressor domain, and LPG2 
(laboratory of genetics and physiology) which possesses the central DExD/H and RD 
domains but not the tandem CARD regions (Kawai and Akira, 2009; Thompson et al., 
2011). Similarly to TLRs, the roles of these proteins have been elucidated through 
studies with mice deficient for each respective RLR. Both RIG-1 and MD5 have been 
implicated in the recognition and control of distinct RNA virus families, although 
recently it was also demonstrated these receptors play a role in recognition of DNA 
viruses, specifically HSV-1 and EBV (Gerlier and Lyles, 2011; Paiudan et al., 2011). 
Work with LPG2 has produced evidence suggesting it may act as a positive or 
negative regulator of RIG-1 and MADS responses, depending of the type of RNA 
viruses (Gerlier and Lyles, 2011). Upon binding to the RNA specific agonist, RLRs 
associate with stimulator-1 (IPS-1), also known as mitochondrial anti-viral signalling 
protein. IPS-1 contains an N-terminal CARD-like domain responsible for the 
interaction with RLRs and a transmembrane domain at the C-terminal end required 
for both mitochondrial targeting and induction of anti-viral responses. The 
interaction between CARD domains induces IPS-1 dimerization and recruitment of 
the factors TRAP, IKK and TBK1. This signalling cascade results in both the
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phosphorylation and activation of IRF3 and IRF7 and the phosphorylation of IkB 
which in turn leads to the activation of NF-i<B. The activation of these factors, 
coupled with the association of AP-1 with NF-kB culminates in the induction of type 
I IFNs expression. It is worth noting that some authors have reported an interaction 
between the stimulator of interferon genes (STING), (also known as mediator of 
1RF3 activation or MITA) and IPS-1 in the context of RIG-1 but not MDA5 signalling. 
Cells lacking STING showed lower levels of type I IFN induction following infection 
with VSV. STING is a membrane protein predominantly expressed in the 
endoplasmic reticulum, whose over-expression significantly activates the IFN-p 
promoter. MITA was found to be identical to STING and shown to be able to 
activate an IFN promoter. However, unlike STING, MITA is located at the outer 
membrane of the mitochondria, where it interacts with IPS-1 and recruits IRF3 
(Gerlier and Lyles, 2011; Kawai and Akira, 2009; Thompson et al., 2011).
1.5.3.3 Cytosolic DNA-sensors
In 2007 Takaoka et al. described a novel cytosolic DNA-sensor, termed DNA- 
dependent activator of IFN-regulatory factors (DAI) (Takaoka et al., 2007). This 
sensor is composed of three domains implicated in DNA binding, Za, zp and D3, 
while a fourth region (located in the C-terminus) is involved in downstream 
signalling and the triggering of innate immune responses. Activation of DAI, through 
binding to DNA present in the cytosol, results in its oligomerization and the 
recruitment of TBK1 and subsequent phosphorylation and activation of IRF3. In a 
similar fashion to what is observed in TLR transduction signalling, activation of IRF3 
allows its translocation to the nucleus and induction of type I IFNs. Recent data has
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shown that such signalling might be transmitted through the mitochondria as 
knockout studies demonstrated the IPS-1 have a role in transduction of this specific 
pathway. Furthermore, DAI mediated induction of type I IFNs was also shown to be 
impaired in the absence of STING/M 1TA. In light of these new observations, it is 
thought that DNA binding by DAI leads to the interaction of IPS-1, STING/MITA and 
TBK1 and activation of IRF3, similarly to what is observed in the context of RIG-1 
signalling. In addition to IRF3 activation, DAI binding to cytosolic DNA also triggers 
the activation of NF-kB and the subsequent induction of transcription of 
inflammatory cytokines (Yanai et al., 2009).
Upon identification of DAI other cytosolic-DNA sensors were described, including 
AIM2 and IFI16. Both belong to the same protein family, termed PYHINs. The N- 
terminus of PYHIN proteins contains a pyrin (PYD) domain, responsible for 
interactions with other PYD-containing protein and formation of complexes which 
have a role in inflammation, apoptosis and cell cycle. The C-terminus of these 
proteins contains a DNA-binding domain, HIN-200 responsible for recognition of 
cytosolic-DNA. AIIVI2 is able to bind cytosolic-DNA, undergo oligomerization and 
associate with the apoptosis-associated speck-like protein (ASC). ASC is a molecular 
adapter, consisting of a PYD and a caspase recruitment and activation (CARD) 
domains, able to mediate caspase-1 dependent pro-interleukin 1(3 (por-IL-l(3)/pro- 
11-18 cleavage and secretion of their bioactive forms (IL-1(3 and IL-18). These 
bioactive forms are then able to mediate inflammatory responses to infection. 
Cytosolic-DNA binding by IFI16, on the other hand, leads to activation of IFN-|3 
expression through a transduction pathway similar to what is currently described 
for DAI. Interestingly, it was also shown (in the context of KSHV infection) that in
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specific circumstances IFI16 is able to recognize viral DNA within the nucleus and 
induce a similar inflammatory response to AIM2 (Kerur et al., 2011; Schattgen and 
Fitzgerald, 2011).
More recently, two studies have independently shown that RNA polymerase ill is 
also implicated in indirect recognition of non-self DNA in the cytosol, induction of 
IFN-P expression and the responses associated with its pathway. RNA polymerase III 
is able to transcribed AT-rich DNA into 5'-ppp RNA, which in turn activates RIG-1 and 
has been reported to be involved in type I IFN induction following EBV and HVS-1 
infections (Thompson et al., 2011).
1.5.3.4 Recognition of herpesviruses by PRRs
Immunological control of herpesviruses is achieved by both arms of the immune 
system. While CD8+T cells play a crucial role in the adaptative immune response, 
type I IFNs and natural killer cells have important roles in containment of 
herpesviruses infections, in the context of innate immunity (Paludan et al., 2011). 
As described above, an essential step in the activation of the innate immune 
responses is the recognition of pathogen-associated molecular patterns (PAMPs). 
Recognition of PAMPs triggers a signalling cascade responsible for the activation of 
a response to the infection taking place. In the case of herpesviruses, and 
subsequently gammaherpesviruses, previous studies have shown that recognition 
of viral infection can occur either by TLRs, RLRs and cytosolic DNA sensors. Three 
classes of herpesviruses generated PAMPs are recognized by the innate immune 
receptors; viral proteins, DNA and RNA, depending on the PRR looked upon (table 
1.6). Detection of herpesviruses proteins by PRRs has been demonstrated through
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work done with TLR2. These studies have shown this specific receptor is specifically 
able to recognize glycoproteins gB and gH (HCMV) or dUTPases (EBV). Furthermore, 
the ablation or suppression of TLR2 expression in cells revealed this receptor plays a 
role in the induction of inflammatory responses to infection with HSV-1, and HSV-2 
and VZV, thus confirming its role in the recognition of herpesviruses (Boehme and 
Compton, 2004; Boehme et al., 2006; Gaudreault et al., 2007; Kurt-Jones et al., 
2004; Paludan et al., 2011; Sorensen et al., 2008; Wang et al., 2005b).
Table 1.6 PAMPs and PRRs involved in recognition of herpesviruses by the innate 
immune system (Adapted from (Paludan et al., 2011))
PRR Virus PAMPs
TLR2 HSV-1 Virion component
HSV-2 Virion component
VZV Virion component
HCMV gB and/or gH
EBV dUTPase
TLR3 HSV-1 dsRNA
MCMv dsRNA
EBV EBERs
TLR7 MCMV ssRNA
TLR9 HSV-1 Genomic DNA
HSV-2 Genomic DNA
MCMV Genomic DNA
HCMV Genomic DNA
EBV Genomic DNA
MHV-68 Genomic DNA
MADS HSV-1 Replication intermediate
RIG-I/Pol III HSV-1 Genomic DNA
EBV EBER DNA/RNA
DAI HSV-1 Genomic DNA
HCMV Genomic DNA
IFI16 HSV-1 Genomic DNA
KSHV Genomic DNA
AIM2 MCMV Genomic DNA
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Another RAMP considered in the study of recognition of herpesviruses by PRRs has 
been genomic DNA, regarded as their most potent immune-stimulating component. 
This has produced a clear body of evidence, spanning all three subfamilies of 
herpesviruses. The data obtained mostly relates to viral DIMA sensing by TLR9 in 
endosomes (Krug et alv 2004; Urn et al., 2007; Lund et al., 2003; Varani et al., 2007), 
although it was also shown herpesviruses genomic DNA is also recognized by DAI 
and A1M2 in the cytosol or by IFI16 within the nuclear compartment. Viral DNA 
sensing by an indirect mechanism was also reported, through studies done with 
HSV-1 and EBV. These studies showed transcription of viral DNA by RNA pol III can 
elicit recognition by RIG-l and the associated response (Ablasser et al., 2009; Chiu et 
al., 2009; DeFilippis et al., 2010; Rathinam et al., 2010; Schattgen and Fitzgerald, 
2011; Thompson et al., 2011; Unterholzner et al., 2010). The third class of molecular 
patterns associated with herpesviruses infection, RNA has been shown to be 
detected TLR3, TLR7, MADS and RIG-1. TLR3 and TLR7 sense dsRNA and ssRNA in 
endosomes, respectively. In a similar fashion with TLR3, RIG-1 is able to detect EBV- 
encoded RNAs (EBERs) in the cytosol, while data suggests HSV-1 RNA structures are 
recognized by MADS receptor (Iwakiri et al., 2009; Tabeta et al., 2004; Zhang et al., 
2007; Zucchini et al., 2008).
1.5.4 IRF7 and IRF3: bridging innate immune recognition and type IFN signalling 
pathways
IRF7 and IRF3 belong to the interferon regulatory factor (IRFs) family, comprised of 
ten members in mammals and involved in host immune response, 
immunomodulation and haematopoietic differentiation. All members are
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characterized by a conserved helix-turn-helix DNA binding domain (DBD) of 120 
amino acids (N-terminal) and function as transcriptional activators or repressors - 
with some actually encompassing both functions (Honda et al., 2005c; Huang et al., 
2010). Among the members of this family, four proteins have been implicated in the 
regulation of type I IFN gene transcription - IRF1, IRF3, IRF5 and IRF7 (Au et al., 
1998; Au et al., 1995; Barnes et al., 2001; Miyamoto et al., 1988). However, in vitro 
infection of murine embryonic fibroblasts, derived from knockout mice, has 
demonstrated that both 1RF1 and IRF5 may not play an essential role in the 
induction of IFN-a/3 (Matsuyama et al., 1993; Takaoka et al., 2005). On the other 
hand, IRF7 and IRF3 do play a critical role in the activation of IFN-ct/p gene 
expression. Furthermore, recent studies in 1RF77‘ and IRF37' mice have revised not 
only the understanding of IFN-ot/p activation but also of both factors gene 
expression in different cell types (Honda et al., 2005b).
The IRF3 gene is expressed constitutively in all tissues and its transcription is not 
enhanced by viral infection or IFN treatment. IRF3 localizes in the cytoplasm in an 
inactive form, until phosphorylation events induce its activation and dimerization. 
The human 1RF3 is a 55-kDa protein with 427 amino acid (aa) residues and 
comprises 4 different domains; a DNA binding domain (BDB), a transactivation 
domain containing a nuclear export signal (NES), a proline-rich region and the IRF 
association domain (IAD), located between aa 134 and 390, and two autoinhibitory 
domains. The first autoinhibitory domain is located between aa 98 and 240 and the 
second autoinhibitory region between aa 380 and 427. The latter contains several 
phosphorylation sites, implicated in activation of its transcription activation 
function. Phosphorylation of these sites results relieves conformational constraints
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and allows dimer formation. Phosphomimetic mutations (substitution of serine and 
threonine residues by aspartic acid) within this region described potential 
phosphorylation sites (Ser396, 398, 402, 405 and Thr-404). Of these, Ser 396 and 
Ser398 were implicated as critical sites for virus-induced phosphorylation sites (fig 
1.14) (Lin et al., 1998; Lin et al., 1999). Once in the nucleus, IRF3 forms a complex 
with CBP and binds to a specific DNA sequence, consensus 5'- 
GAAAC/GC/GGAAANT/C-3', dubbed IFN-stimulated response element (ISRE) (Lin et 
al., 2000a).
DNA binding domain Transactivation domain
NES Pro IRF association domain
tt ttt
Fig 1.14 The modular domains of IRF3 protein. The dark arrows represent potential 
phosphorylation sites, implicated in activation of IRF3 (Lin et al., 1999).
IRF7 was first described in the context of EBV infection. IRF7 was shown to bind and 
repress the Qp promoter of EBNA1 (Zhang and Pagano, 1997). Unlike IRF3, IRF7 
gene expression is induced by type I IFNs following viral infection (Marie et al., 
1998). However, in a similar fashion to IRF3, IRF7 locates to the cytoplasm in 
uninfected cells and only traffics to the nucleus after phosphorylation (Au et al., 
1998). The human IRF7, of 503 aa (fig 1.15), comprises a DNA binding domain 
(DBD), a constitutive activated domain (CAD), a inhibitory domain (ID) and a signal
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response domain (SRD) analogous to the phosphorylation region in IRF3. The 
transactivation domain (denominated viral activated domain - VAD) is located 
between aa 247 and 305, as deletion of this region abrogates the activation 
function (Lin et al., 2000b). A parallel strategy to the one utilized with IRF3 
(phosphomimetic mutations) demonstrated that two serine positions (Ser477 and 
479) potentially function as phosphorylation sites for its activation.
DNA binding domain CAD VAD Inhibitory domain 503
EGVSSLDSSSLSLCLSSANSLYDD
ft
Fig 1.15 IRF7 and its modular domains. The black arrows shows the serine residues, 
potential phosphorylation sites necessary for activation and translocation to the 
nucleus (Lin et al., 2000b).
After translocation into the nucleus, IRF7 interacts with CBP and binds to an ISRE 
DNA sequence. The consensus sequence differs slightly from the one described for 
IRF3: 5'-GAAA/TNC/TGAAANT/C-3' (Lin et al., 2000a). Both IRF7 and IRF3, once in 
the nucleus, bind to c/s-regulatory domains within IFN-a/p promoters, the positive 
regulatory domains (PRD) I and III, which contain sequences similar to the 
consensus sequences described earlier.
Studies carried out with virus-infected fibroblasts suggested an initial model of IFN 
activation by IRF7 and IRF3, depicting differential induction kinetics of IFN-a/p
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promoters. In this model, type I IFNs were subdivided into two subgroups, 
immediate early (IFN-p and IFN~a4) and delayed type genes (other IFN-ot subtypes). 
Upon virus infection IRF3, NF-kB and c-jun/ATF2 were post-translationally activated 
by phosphorylation, translocate into the nucleus, and induce IFN-P and IFN-a4 gene 
expression. The secreted IFNs would in turn initiate the JAK-Stat pathway already 
and upregulate expression of IRF7. Continuous viral infection would then induce 
phosphorylation of IRF7, and together with IRF3, enhance expression of IFN, both 
immediate early and delayed type subgroups, potentiating the host innate response 
(Lin et al., 2000b). This model was supported by initial lines of evidence 
demonstrating IRF3 activated IFN-p and IFN-a4, but not the IFN-a subtypes (Lin et 
al., 2000a; Schafer et al., 1998). In addition, work with murine fibroblasts (MEFs) led 
to the notion that IFN-a/p induction occurred sequentially (Honda et al., 2005c) and 
that IRF7 was only expressed in some cell types (Lin et al., 2000b).
With the recent availability of IRF77‘ knockout mice, this classical view has changed. 
In this model, it was demonstrated that IRF7'/' MEFs were significantly impaired in 
the induction of IFN-a/p following infection with VSV and HSV-1 more so than 
infection in 1RF37’ MEFs Furthermore, type I interferons were induced by IRF7 in 
the absence of IRF3 (Honda et al., 2005b). This work described IRF7 as the master 
regulator of type I IFN dependent responses thatlRF7 must be present at very low 
levels in unstimulated cells (by constitutive IFN signalling) and suggested 1RF3 needs 
to interact with IRF7 to activate IFN-a/p expression. At this point both models 
merge. IFN signalling enhances IRF7 gene expression, in a positive feedback loop. 
Continued viral infection induces IRF7 activation which leads to the induction of 
type I IFN transcription, providing a robust antiviral response.
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1.5.5 Modulation of gammaherpesviruses lytic infection by signalling from innate
immune responses
Considering the roie played by the pathways described above, it comes as no 
surprise that modulation of gammaherpesviruses infection (and reactivation from 
latency) by type I IFNs, TLR signalling and interferon regulatory factors. The data 
generated do give some insight into the mechanisms involved in the interface 
between virus and innate immune responses and consequences to the lytic/latency 
balance.
1.5.5.1 Type I IFNs inhibit reactivation of KSHV and MHV-68 in latently infected 
celts
Modulation of gammaherpesvirus reactivation by type I IFNs has been carried out in 
a number of studies. The In vitro PEL derived cell lines (BCBL-1 and BC-1 cells), 
latently infected with KSHV, were treated with IFN-a following lytic induction with 
TPA. The evidence produced showed that IFN-a inhibited amplification of KSHV DNA 
in BCBL-1 in a dose-dependent manner and the inhibition of reactivation could be 
reversed with the addition of antibodies against IFN-a or the type I IFN receptor. In 
addition, a similar outcome was observed in peripheral blood mononuclear cells 
(PBMCs) from KSHV-infected individuals. These observations suggested that IFN-a 
reduced KSHV load and/or inhibited viral reactivation (Monini et al., 1999). These 
results were further corroborated with similar observations in MHV-68 infected IFN- 
a/f* FT/' mice. Reactivation of latent virus in peritoneal cells and splenocytes derived 
from these mice was enhanced when compared with wild type cells. Depletion of 
IFN-a/p in wild type mice (during viral latency) also lead to a significantly increased
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viral reactivation (Barton et al., 2005). Associated with both studies was the notion 
that IFN-a/p induced pathways regulated viral gene expression and played a critical 
role in inhibition of reactivation. Barton et al., demonstrated that M2 (a latency 
associated protein) was upregulated in IFN-a/p FT/’ mice, and proposed type 1 IFNs 
inhibited expression of this viral protein. A recent study demonstrated that MFIV-68 
latency-associated protein M2, could promote plasma cell differentiation which also 
correlated with MHV-68 reactivation (Liang et al., 2009). In this study, the authors 
suggested the viral protein represented a new class of herpesvirus gene products, 
which facilitated virus reactivation by manipulating the cellular environment and 
providing a permissive background for reactivation. Further work is necessary to 
pursue this line of evidence.
Therefore a picture is emerging whereby IFN-ct/P inhibits reactivation by triggering 
activation of downstream signals that downregulate Rta (expression or 
transactivation functions) while at the same time reduces the ability of the virus to 
manipulate the cellular milieu into an environment that would promoter viral 
replication.
1.5.5.2 TLR modulation of viral reactivation
The focus of research on the interface between gammaherpesviruses and the TLR 
signalling system stems from studies demonstrating that human 
gammaherpesviruses undergo reactivation from latency upon secondary infections 
(Gregory et al., 2009). FIIV-1 and CMV were shown to induce in vitro reactivation of 
EBV (CMV) and KSFIV (HIV-1 and CMV) in latently infected cells (Arcenas and Widen, 
2002; Merat et al., 2002; Varthakavi et al., 2002; Vieira et al., 2001). Considering the
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role TLRs have in recognition of viral infections, two similar studies have showed 
that reactivation of gammaherpesviruses might potentially be mediated by TLR7, 
TLRS and TLR9. Screening of PEL cell lines (BCBL-1, BCP-1, VG-1 and BC-3) with 
specific agonists for different TLRs resulted in KSHV reactivation by TLR7/8, but not 
TLR9. These results were further confirmed with superinfection of BCBL-1 cells with 
VSV virus (known for activating TLR7 and 8). Moreover, the authors showed TLR7/8 
signalling enhanced activation of a reporter construct harbouring Rta promoter, 
revealing KSHV reactivation in this context was dependent on inducing Rta gene 
expression. In addition, transfection of an IRF7 dominant- negative construct after 
stimulation of TLR7 reduced reactivation markedly (Gregory et al., 2009). The data 
does suggest Rta is activated following TLR7/8 activation, and that this activation is 
mediated by IRF7.interestingly, analysis of KSHV Rta promoter does not reveal a 
specific binding site for IRF7. Considering this, the authors suggested that IRF7 must 
activate Rta expression through an indirect mechanism, possibly via interaction with 
another as yet unknown factor. A second study, investigating TLR-mediated 
reactivation of MHV-68 in vivo, in vitro and ex vivo, also demonstrated similar 
results. B cells (A20-HE) latently infected with MHV-68 were treated with 
antagonists for different TLRs. Treatment of ligands specific for TLR3-4 and TLR9 led 
to reactivation of the virus. These results were further confirmed in splenocytes 
derived from MHV-68-infected mice, where stimulation of the same subset of TLRs 
led to virus reactivation. In the same study, in vivo stimulation of TLR4 and TLR9 
followed by harvest of splenocytes (24 hours post stimulation) showed a three-fold 
increase in MHV-68 reactivation (Gargano et al., 2009).
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KSHV MHV-68
Fig 1.16 Stimulation of TLR7/9 results in reactivation of gammaherpesviruses.
However, the molecular mechanisms linking stimulation of TLR with reactivation 
still need to be further elucidated (Gargano et al., 2009; Gregory et al., 2009).
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TLR-mediated reactivation of MHV-68 was also suggested to be associated with
reactivation of gammaherpesviruses following secondary infection. Yet, no 
mechanism related to Rta activation of the viral lytic gene cascade was presented. 
Another intriguing detail concerning both studies is the fact that KSHV was 
reactivated by stimulation of TLR7 and not TLR9, while the opposite occurred with 
MHV-68. Considering that both PRRs signal through the same pathway (MyD88- 
dependent signalling pathway), both PRRs should be able to reactivate these two 
viruses. Furthermore, following the rationale behind KSHV study, stimulation of 
TLR9, shown to recognize MCMV (Boehme and Compton, 2004), should reactivate 
the virus. Therefore, it is likely that is an unknown difference in the pathways 
triggered by TLR7 and TLR9, responsible for these outcomes. Alternatively, a simpler 
explanation for the different outcomes could be tied to a deficient stimulation of 
TLRs in both studies.
1.5.5.3 IRF7 modulation of lytic replication
The interaction between IRF7 and gammaherpesviruses has been best studied 
within the context of latent infection with EBV. EBV latent membrane protein 1 
(LMP1) induces expression of IRF7 and its subsequent activation. The activated IRF7 
regulates both cellular and EBV target genes involved in latency, transformation and 
immune regulation. In particular, IRF7 actively participates in the maintenance of 
EBV latency type III, by downregulating the Qp promoter (Zhang and Pagano, 1997, 
2001). In the perspective of lytic replication, the data obtained also confirmed an 
intimate coevolution process between IRF7/3 and gammaherpesviruses. KSHV in 
particular encodes viral homologous of cellular IRFs, which are associated with the
63
inhibition of transactivation by 1RF7 through protein-protein interactions (Joo et al., 
2007). Furthermore, Rta has been shown, in EBV and KSHV, to downregulate either 
transcription of IRF7/3 or induce proteosome-mediated degradation of 1RF7 (Bentz 
et al., 2010; Yu et al., 2005). In KSHV, the protein encoded within ORF45 inhibits 
phosphorylation of IRF7 and consequently blocks IFN-a/p induction by this viral 1RF 
(Zhu et al., 2002). Given IRF7 is a key regulator of type i IFN immune responses to 
viral infections, it is a likely target for viruses to counteract and block IFN-a/p 
mediated effects. Conversely, an interesting study has showed that transfection of 
KSHV latently infected cells with IRF7 (in vitro) blocks replication by competing with 
Rta for specific binding sites on ORF57 promoter, inhibiting the lytic gene cascade in 
the early stages (Wang et al., 2005a). This model, depicting IRF7 merely as an 
antagonist factor for lytic replication and, more specifically, Rta-mediated 
transactivation, is challenged by work mentioned above linking TLR signalling to 
KSHV replication (Gregory et al., 2009). It was demonstrated that 1RF7 is involved, at 
some stage, in the activation of Rta promoter and viral reactivation. The authors 
have suggested this occurs through interactions with an unknown factor but did not 
provide a plausible mechanism. This evidence does suggest that Rta modulation 
(either of its promoter or its transactivation function) are closely linked with host 
innate immune responses. Moreover, it does points to the notion that this link is 
complex one. More work studying the molecular mechanisms underlying lytic 
infection and reactivation from latency by type I IFN associated signalling (in 
particular concerning Rta, as this is a key molecular lytic switch in 
gammaherpesviruses), is needed.
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1.6 Aims
in v-2-herpes viruses which include the human herpesvirus Kaposi's sarcoma- 
associated herpes virus and murine v-2-herpesvirus-68 (MHV-68), the ORF50 gene 
encodes a key viral protein, Rta, whose expression has been shown to be essential 
in virus lytic infection cycle as well as establishment of latency. Expression of Rta is 
sufficient to initiate lytic replication, whereas inhibition of its transcription 
promotes viral latency. Thus, understanding how this key viral gene may be 
regulated, by studying its cognate promoter, will be of importance in understanding 
the molecular mechanisms involved in gammaherpesvirus lytic infection, latency 
and pathogenesis.
Using the murine model, MHV-68, the aim of this project was to understand how 
Rta promoter activity may be modulated in B and non-B cell types by in vitro assays. 
More specifically the aims were to:
1. Characterise and identify domains within the MHV-68 Rta promoter in 
response to Rta protein, provided in trans, and in different cells types; and
2. Characterise and identify domains within the Rta promoter which may be 
type I IFN-dependent.
65
Chapter 2
Material and Methods
Chapter 2
Material and methods
2.1 Plasmid vectors
pGL3-basic:
Luciferase reporter vector (Promega, UK, Cat No. E1751,), which lacks eukaryotic 
promoter and enhancer sequences was used in transient transfection assays 
Expression of luciferase activity depends on insertion and orientation of a functional 
promoter upstream of the luciferase coding region, and carries the AmpR gene (See 
Appendix for vector map).
pRL-CMV:
Renilla reporter vector (Promega, UK, Cat. No. E2231), whereby the renilla 
luciferase gene is driven by the immediate-early CMV promoter was used as to 
assess efficiency of transfection as an internal control reporter and carries the 
AmpR gene (see Appendix for vector map).
MHV-6S Rta promoter and related plasmids:
These constructed were generated by Louise Roaden (Ebrahimi lab).
-211pGL3: Reporter plasmid pGLB-basic and harbours the IVIHV-68 genomic 
sequence between positions 66549-66760 coordinates, upstream the firefly 
luciferase coding region.
391pGL3: Reporter plasmid pGLB-basic harbours the MHV-68 genomic sequence 
between positions 66369-66760 coordinates upstream the firefly luciferase coding 
region.
-1019pGL3: Reporter plasmid pGLB-basic harbours the IVIHV-68 genomic sequence 
between positions 65741-66760 coordinates, upstream the firefly luciferase coding 
region.
1230pGL3: Reporter plasmid pGLB-basic which harbours the MHV-68 genomic 
sequence between positions 65530-66760 coordinates, upstream the firefly 
luciferase coding region. This construct contains the full-length MHV-68 Rta 
sequence is referred to as the wild type Rta promoter.
Viral IRF3 and IRF7 site containing promoters and related plasmids:
WTpGL3: The reporter plasmid pGLB-basic harbouring the MHV-68 genomic 
sequence between positions 65741-66041, containing an IRF7 and IRF3 binding 
sites, upstream the firefly luciferase coding region. AmpR;
AlRF7pGL3: Reporter plasmid pGLB-basic harbouring the MHV-68 genomic 
sequence between positions 65741-66041, containing the mutated IRF7 and the 
wild type IRF3 binding sites, upstream the firefly luciferase coding region. AmpR;
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AIRF3pGL3: Reporter plasmid pGL3-basic harbouring the MHV-68 genomic 
sequence between positions 65741-66041 containing the wild type 1RF7 and 
mutated IRF3 binding sites, upstream the firefly iuciferase coding region. AmpR; 
AIRF7/IRF3pGL3: Reporter plasmid pGL3-basic harbouring the MHV-68 genomic 
sequence between positions 65741-66041, containing the mutated IRF7 and 1RF3 
binding sites, upstream the firefly Iuciferase coding region. AmpR.
IFNa6pGL3:
Reporter plasmid pGL3-basic harbouring the murine IFNa6 promoter sequence 
upstream the firefly coding region. AmpR.
pEGFP-IMl:
N-terminal enhanced fluorescent protein (EGFP) vector suitable for generation of 
GFP fusion proteins (Clontech, US, Cat No. 6085-1). The EGFP gene is driven by the 
CMV immediate-early promoter. KanR, NeoR.
pFLAG-CMV-2:
Expression Vector derivative of the pCMV5 transient expression vector for 
intracellular expression of proteins in mammalian cells (Sigma-Aldrich, UK, Cat No. 
E7033). Contains the CMV immediate early promoter upstream the multiple cloning 
site for constitutive expression of the protein of interest. AmpR.
Rta expression plasmids:
pFLAG-CMV2/Rta: Expression plasmid derived from pFLAG-CMV-2 transient 
expression vector, harbouring the MHV-68 Rta cDNA sequence (kindly provided by 
Professor Ren Sun). AmpR.
pDRIVE-mEFla:
Expression plasmid containing the murine elongation factor la upstream the 
multiple cloning site for ubiquitous expression in different mammalian ceil lines 
(Invivogen UK, Cat No. pdrive-mefl). ZeoR.
IRF7p expression plasmids:
pDRlVE-IRF7p: Expression plasmid derived from pDRIVE-mEFla, harbouring a gene 
encoding a murine phosphomimetic IRF7 mutant. The IRF7 mutant contains ser-asp 
substitutions at specific position within the C-terminal regulatory domain which 
mimic the phosphorylation state of the IRF7 activated form. ZeoR.
pBluescript/!RF7p: Cloning vector derived from pBluescript II SK(+) harbouring the 
murine phosphomimetic IRF7 mutant. AmpR.
pBluescript II SK (+):
Phagemid designed for cloning experiments (Agilent Technologies, UK, Cat No. 
212205). AmpR.
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2.2 Tissue culture
2.2.1 Murine cell lines
Table 2.1 Cell lines utilized in this project
Cell line Description
NIH3T3 Highly contact inhibited murine fibroblast cells developed 
from NIH Swiss embryo cultures, transformed with SV40 
(Jainchill et al., 1969) - ATCC: CRL 1658
MEF IFN-a/3 Rko Mouse embryonic fibroblasts derived from mice with a 
inactivated type 1 IFN receptor through homologous 
recombination (Muller et al., 1994)
A20 BALB/c B cell lymphoma line derived from a spontaneous 
reticulum cell neoplasm found in BALB/cAnN mouse (Kim et 
al., 1979)-ATCC: TIB-208
2.2.2 Growth and maintenance of cells lines
Murine fibroblasts cell lines were grown in Dulbecco's Modified Eagle's Medium 
(Sigma, UK, Cat No. D6546) supplemented with 10% (v/v) bovine serum (Invitrogen, 
UK, Cat No. 26170-026), 1% L-Glutamine 200Mm (Sigma, UK, Cat No. G7513), 1% of 
100 U/ml penicillin (Invitrogen, UK, Cat No. 15140-122) and 1% 100 pg/ml 
streptomycin (Invitrogen, UK, Cat No. 15140-122) and incubated at 37°C under 5% 
C02 atmosphere. Cells were passaged with 0.05% trypsin (Gibco, UK, Cat No. 
25300-054) along with the chelating agent, lx Versene-EDTA (Gibco, UK, Cat No. 
15040-033), and spun at lOOxg for 5 minutes before reconstitution in complete 
media.
Murine B cell line A20 was grown in RPMI 1640 (Invitrogen, UK, Cat No. R0883,) 
supplemented with 10% (v/v) foetal bovine serum (Invitrogen, UK, Cat No. 10082-
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139,), 1% L-Glutamine 200Mm (Sigma, UK, Cat No. G7513,), 1% of 100 U/mi 
penicillin (Invitrogen, UK, Cat No.15140-122) and 1% of 100 |ig/ml streptomycin 
(Invitrogen, UK, Cat N. 15140-122,) and incubated at 37 °C under 5% C02 
atmosphere. Passage was done by centrifugation at lOOxg for 5 minutes and 
reconstitution in complete media at a concentration of 3.0xl05 cells/ml.
2.3 Transient transfection assay
Cells were seeded in Nunc multidish six wells plates (Thermofisher Scientific, UK, 
Cat No: 140675), at 1.5x10s cells per well and incubated overnight at 37°C under 5% 
C02 atmosphere in complete growth media. Prior to transfection, complete growth 
medium was replaced with OptiMEM (Gibco, UK, Cat No: 51985-026), 
supplemented with 10% (V/V) calf serum. The plasmid mix (up to three micrograms 
of vector per well unless stated otherwise) was prepared for each two replicates in 
a 7 ml bijoux tubes and suspended in 800 pi of OptiMEM. Lipfectamine 2000 
(Invitrogen, UK, Cat No.11668,) was prepared in a separate bijou, in a ratio of 4 
microlitters per two micrograms of DNA, suspended in 856 pi OptiMEM and 
incubated at room temperature for five minutes. The plasmid mix was then 
transferred to the lipofectamine 2000 suspension, mixed by pipetting and kept at 
room temperature for 20 minutes. Five hundred microlitres of the transfection mix 
was added to each well and in replicates. The plates were incubated at 37°C, 5% 
C02 atmosphere for 6 hours, followed by wash with one ml of OptiMEM and media 
replacement with 3 ml of OptiMEM with 10% (v/v) of bovine serum. The plates 
were kept overnight at 37°C, 5% C02 atmosphere. On following day, the media were 
removed and replaced with complete medium plus antibiotics. In studies examining
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IFN effect on modulation of promoter activity, the media replacement also includes 
a 0.1% (v/v) murine type I IFN-ot/p (100,000 international units). Cells were then 
harvested at the set time points and analyzed for total protein concentration and 
reporter activity.
2.4 Electroporation
Three millilitres of complete growth medium was added to each well of a Nunc 
multidish six well plate and incubated at 37°C under 5% CO2 atmosphere. Cells were 
harvested in the exponential phase, centrifuged at 100 x g for 5 min and re­
suspended in media supplemented with 0.5% (v/v) bovine serum at a concentration 
of 2xl06 cells/ml. In an eppendorf, five micrograms of plasmid DNA were mixed in 
100 \i\ of medium). One ml of medium plus cells was added to the eppendorf 
described previously and mixed gently by pipetting. The cell suspension was 
transferred to a 4mm electroporation cuvette (GeneFlow, UK, Cat No. EP-104,) and 
placed in ice for 2 minutes. Cells were electroporated at 324 V, 1800 pF and infinite 
shunt resistance and immediately transferred into Nunc multidish six well plates 
with fresh complete medium. The plate was kept overnight at 37°C and 5% C02 
atmosphere. At set time points cells were harvested and analyzed for total protein 
concentration and reporter activity. Transfection experiments were carried out in 
triplicates.
2.5 Cell lysis and luciferase assays
At predefined time points post transfection, media were removed and the 
monolayer washed with one ml of 1 x phosphate buffer saline (PBS) (Qbiogene, UK,
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Cat NO.PBS10X02) with a pipette. Five hundred microlitres 1 x passive lysis buffer
(PLB) (Promega, UK, Cat N. E1910) was added to each well, ceils harvested using a 
cell lifter. Samples were stored at a -80°C immediately. Electroporated cells in 
suspension were spun down at 100 x g for 5 min and resuspended in one ml of 1 x 
PBS. Samples were then transferred to eppendorf tubes and centrifuged at 13,000 
RPM for 1 minute in a bench microcentrifuge. Cells were then re-suspended in 500 
pi of 1 x PLB and stored directly at -80°C. Harvested cells were subjected to two 
cycles of thaw and freeze in dry ice and spun down at 13,000 RPM for 1 minute in a 
bench centrifuge. Twenty microlitres of each sample were transferred to each well 
of a 96 well plate, in triplicate, and assayed for luciferase and renilla activities with a 
luminometer plate reader (Berthold Technologies, UK, Cat No. LB941).
2.6 Protein concentration measurements
Total protein quantification of each sample was determined using the Bradford 
assay. Immunoglobulin G standards (serially diluted and ranging from 2 mg/ml to 
31.25 pg/ml) were prepared in 20 pi of O.lxPLB. Each sample was subjected to 2- 
fold 2 dilutions in 20 p! of O.lxPLB. Samples were vortexed and spun down in 
between dilutions. One millilitre of Bradford reagent (Bio Rad, UK, Cat No.500-0006) 
was added to test and standard solutions, briefly vortexed and incubated at room 
temperature for 5 minutes. Absorbance of samples was then measured at 595 nm 
and in triplicate. Following this, the average of each standard was determined and 
used to plot a calibration curve. Samples absorbance was averaged and total 
protein concentration calculated using the calibration curve.
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2.7 Electromobility shift assay (EMSA)
2.7.1 Probes and buffers utilized in EMSAs
____ Table 2.2 Probes utilized in gel retardation analysis
Probe S'-B' sequence
Probe IRF7 WT GCTGAAAAGGAAGTCATAG 
Probe IRF7 MT GCTGCCCAGGAAGTCATAG
Table 2.3 General buffers utilized in gel retardation analysis
Buffer Composition
Buffer A 10 mM HEPES, 1.5 mM MgCI2, 10 mM KCI, 0.5mM DTT, 
0.2 mM PMSF
Buffer C 20 mM HEPES, 25% glycerol (v/v), 420 mM NaCI, 1.5 mM 
MgCI2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF
Binding buffer (lOx) 40% (v/v) glycerol, 10 mM EDTA, 50 mM DTT, 0.1 M Tris- 
HCI (pH7.5), 1 M NaCI, 1 mg/ml BSA (nuclease free)
Loading buffer 0.25 M Tris-HCI, 1.9 m glycine, 0.01 M EDTA
TBE (lOx) 0.89 M Tris-borate, 0.89 Boric acid, 0.02 mM
2.7.2 Generation of radiolabelled probes for EMSA
Probe sequence were synthesised by MWG biotech (Germany). Oligonucleotides 
were then resuspended in a total volume of 100 pi of Millipore water, at a final 
concentration of 100 ng/pl, and incubated at 65°C for 10 minutes. Annealing was 
facilitated by leaving heated sample to reach room temperature for about an hour. 
Half a microlitre of annealed oligonucleotides (50 ng), 1 unit of T4 polynucleotide 
kinase (PNK) (Promega, UK Cat No m4101,), two microlitres of PNK buffer (lOx) and 
1 pi y[32P]-dATP in a final volume of 20 pi was incubated at 37°C for 15 minutes.
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2.7.3 Generation of nuclear extracts for EMSA
All centrifugations were carried out in a bench-top microcentrifuge. Transfected 
cells were resuspend in 1.5 ml of cold PBS and transferred to an eppendorf tube. 
Cells were centrifuged for 10 seconds at 6000 RPM and resuspended in 400 pi of 
cold buffer A. Cells were then incubated on ice for 10 minutes vortexed for 10 
seconds, centrifuged for 10 seconds at 13000 RPM. The supernatant was discarded 
and the pellet resuspended in 100 pi of cold buffer C and incubated on ice for 20 
minutes (high salt extraction). Cellular debris was removed by centrifugation for 2 
minutes, at 4°C, 13000 RPM. The supernatant fraction was transferred into an 
eppendorf and stored at -70°C.
2.7.4 Binding assay of cellular nuclear extract and labelled probe
Binding reaction mix was prepared by adding 5 pi nuclear extract, 1.5 pi binding 
buffer (lOx) and 2 pi herring sperm DNA (10 mg/ml) (Sigma-Aldrich, UK, Cat No. 
D7290) in a total volume of 14 pi. Reactions were incubated at room temperature 
for 15 minutes and then kept on ice prior to addition of probe. One microlitre of 
V[32P]-dATP-labelled probe was added to the reaction mix and incubated at room 
temperature for 15 minutes. Controls included no probe or cold probe. The 
resulting DNA-protein complexes were then separated by running a 4% (w/v) 
polyacrylamide get. Following electrophoresis, gels were blotted to 3MM filter 
papers, dried under vacuum for one hour using (Bio Rad, UK Cat No: 165-1745,). 
Dried gels were exposed to phosphor screens for up to ten days, followed by 
scanning using a Storm 860 Molecular Imager (GMI, UK Cat No. WS-STORM860,) 
and the ImageQuant software.
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2.8 Gel electrophoresis
2.8.1 Agarose gel electrophoresis
DNA was separated by electrophoresis in a 1% (w/v) agarose gel (Bioline, UK, Cat 
No. BIO-41025) in TAE buffer (40 mM Tris base, 20 mM Glacial Acetic acid, 1 mM 
EDTA), at a constant voltage of 100 V and 250 mA. The molecular weight marker 
used was GeneRuler DNA Ladder mix (Fermentas, UK, Cat No: SM0311). The gels 
were viewed under UV transillumination at a wavelength of 302 nm and images 
recorded using GeneSnap software (Syngene, U.K.).
2.8.2 Recovery of DNA from agarose gels
DNA samples were separated by electrophoresis in a 1% (w/v) agarose low-melting 
gel (Flowgen, UK, Cat No. AG25LM-SVE), at a constant 50 V for up to one hour. The 
molecular weight marker used was GeneRuler DNA Ladder mix (Fermentas, UK). 
DNA bands were visualized under UV light, at 365 nm and the band of interest 
excised from the agarose gel with a clean scalpel blade. DNA was purified from gel 
using the QIAquick Gel extraction Kit (Qiagen, UK, Cat No 28704,) and according to 
the manufacturer recommendations. The DNA was eluted with 50 pi of sterile- 
filtered water.
2.9 Restriction digestion
2.9.1 Restriction enzymes utilized in this project
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Table 2.4 Buffers utilized in gel electrophoresis
Enzyme Activity
EcoRI (Roche, UK, Cat No: 1175 084)
Acc65l (New England Biolabs, UK, cat no: R0599S) 
Bsu36l (New England Biolabs, UK, cat no: R0524S)
10 000 U/ml
10 000 U/ml
10 000 U/ml
2.9.2 Restriction digestion
Single restriction digests were performed in a total volume of 20 pi, using 1 pi of the 
appropriate enzyme (10U) and the recommended enzyme buffer. Samples were 
incubated at 37 °C for one hour and the products of the reaction separated by 
agarose gel electrophoresis. Double restriction digestions for isolation of inserts 
from plasmids were performed in a total volume of 50 pi with 1 pi of each enzyme 
and the recommended compatible buffers. Samples were incubated for six hours at 
37 °C, with a further microliter of each enzyme added during the incubation to 
ensure complete digestion. The products of digestion reactions were then analysed 
by agarose gel electrophoresis.
2.10 Plasmid growth and propagation
Bacteria cultures were routinely plated in Luria Bertani agar (LA) and Luria Bertani 
broth (LB), supplemented with the specific antibiotic. Agar plates were prepared 
with 1% LB (w/v) (Sigma-Aldrich, UK, Cat No: L3022), 1.5% (w/v) (Sigma-Aldrich, UK, 
Cat No. 05040) and 0.5% NaCI (w/v) (Fisher Scientific, UK, Cat No. S/3160/65) in 
millipore water. LB media was prepared with 2% LB (w/v) (Sigma-Aldrich, UK, Cat 
No: L3022) and 0.5% NaCI (w/v) (Fisher Scientific, UK, Cat No. S/3160/65) in 
millipore water. LA and LB media were supplemented with either 0.1% (v/v)
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ampicillin 100 mg/ml (Sigma-Aidrich, UK, Cat No. A9518-5G), 0.1% (v/v) kanamycin 
50 mg/ml (Merck, UK, Cat No. K31035177) or 0.25% (v/v) zeocin (Invivogen, UK, Cat 
No. ant-zn-1,). Cultures plated in LA were incubated at 37 °C and grown overnight. 
Cultures inoculated in LB media were incubated at 37 °C and 220 RPM and grown 
overnight.
2.11 Plasmid purification
2.11.1 Endofree maxi preparations
Plasmid preparations were carried out using endofree maxi prep kit (Qiagen, UK, 
Cat No. 12362) to generate endotoxin-free plasmid reagents for use in transfection 
assays and according to the manufacturer recommendations with modifications. In 
brief, E. coli cultures transformed with the plasmid of interest were grown overnight 
in 100 ml of LB (2% LB (w/v) (Sigma-Aidrich, UK, Cat No: L3022) and 0.5% NaCI (w/v) 
(Fisher Scientific, UK, Cat No. S/3160/65) in millipore water) with appropriate 
antibiotic, at 37 °C and 220 RPM. Bacterial cells were pelleted at 6000xg, for 15 
minutes at 4 °C in a 250 ml centrifuge bottle. The pellet was then resuspended in 10 
ml of buffer PI and homogenised. Ten millilitres of buffer P2 was added to the 
pellet, tube inverted to mix and incubated at room temperature for 5 minutes 
followed by the addition of 10 ml of pre-chilled neutralization buffer P3 mix again. 
The lysate was transferred to a Qiafilter cartridge (provided with the kit), incubated 
at room temperature for 10 minutes and filtered, followed by addition of 2.5 ml of 
buffer ER, inverted to mix and incubated on ice for 30 minutes. This solution was 
then loaded into a Qiagen-tip and allowed to enter the resin by gravitational flow.
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The resin was washed with the buffer QC and the DNA eluted with 15 ml of buffer
QN into a 50 ml Falcon tube. DNA was precipitated with 10.5 ml of isopropanol, 
inverted to mix and centrifuged at 5000 x g for one hour at 4 °C. The supernatant 
was discarded and the pellet washed with 5 ml of 70% ethanol. The sample was 
further centrifuged at 5000 x g for one hour at 4 °C and the supernatant carefully 
decanted. Excess ethanol was removed and the pellet air dried. The final pellet was 
dissolve in 100 p] of sterile-filtered tissue culture water with minimal levels of 
endotoxins. The quality and quantity of purified plasmids was checked by measuring 
the absorbance using the ND-1000 spectrophotometer (NanoDrop) and by digestion 
with appropriate restriction enzymes followed by separation of restriction products 
by gel electrophoresis.
2.11.2 Plasmid mini preparations
All centrifugations were carried out in a bench top microcentrifuge. Plasmid 
preparations were carried out using the Qiagen mini kit (Qiagen, UK, Cat No. 27104) 
and according to the manufacturer recommendations. Briefly, £. coli cultures 
transformed with the plasmid of interest were grown overnight in 5 ml of LB with 
the respective antibiotic, at 37 °C and 220 RPM. The pellet was resuspended in 250 
pi buffer PI and transferred to a microcentrifuge tube. 250 pi buffer P2 was added 
to each sample inverted to mix and incubated at room temperature for no longer 
than 5 minutes. 350 pi Buffer N3 was then added to each sample, inverted to mix 
and centrifuged for 10 minutes, at 13000 RPM. The supernatant was then loaded 
onto miniprep columns and centrifuged for 60 seconds at 13000 RPM. The miniprep 
column was washed with 500 pi buffer PB and 750 pi buffer PE. Columns were spun
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for a further minute to remove residual traces of ethanol. DNA was finally eluted
with 50 \x\ of sterile-filtered water. The quality and quantity of purified plasmids was 
checked by measuring the absorbance using the l\ID-1000 spectrophotometer 
(NanoDrop) and by digestion with appropriate restriction enzymes followed by 
separation of restriction products by gel electrophoresis.
2.12 DNA Ligation reactions
Molar ratios of 1:3 and 1:6 of plasmid to insert were calculated based on molecular 
weights and used in ligation reactions with T4 DNA ligase in a and according to 
manufacturers recommendations a total volume of 20 pi (New England Biolabs, UK, 
Cat No. M0202).
2.13 Transformation of bacterial competent ceils
The XL-10 Gold supercompetent cells (Agilent Technologies, UK, Cat No. 200159) 
were used in transformation reactions. Competent ceils were kept on ice until 
thawed. One hundred microlitres of thawed competent cells were transferred to 
pre-chilled 50 ml falcon tubes and incubated on ice for 10 minutes. Fifty nanograms 
of plasmid DNA in a total volume of 10 pi were then added to competent cells, 
mixed gently and incubated on ice for a further 30 minutes. The cells were heat- 
shocked in a water bath set at 42 °C for 45 seconds followed by immediate 
incubation on ices for 2 minutes. Pre-warmed LB (900 pi) with no antibiotics was 
added to the cells followed by incubation at 37 °C, for one hour at 220 RPM. The 
mixture was then platted on LA, supplemented with the specific antibiotic. The 
plates were incubated overnight, at 37 °C.
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2.14 Sequencing
2.14.1 Primes utilized in sequencing
________ Table 2.5 Primers utilized in IRF7p sequencing
Primer___________ S'-S" sequence__________________
pDRIVE_Forl401 CGGGATCTGTACGACGATGACGATA 
pDRIVE_Revl661 GACAGTATCGGCCTCAGGAAGATCG 
pDRIVE IRF7p TCCAGCATGTGTCTCCCGGCCTTCA
2.14.2 DNA Sequencing
Plasmids of interest were sequenced by MWG biotech (Germany). Samples were 
prepared according to specifications provided, labelled with the respective code 
and sent together with respective forward and reverse primers to MWG. 
Sequencing output was presented online and compared by alignment against 
predicted sequences and by analysis of the nucleotide frequency in sequencing 
results.
2.15 Bioinformatic analysis of transcription factor binding sites (TFBSs)
Promoter sequences of interest were retrieved from the GenBank database 
(http://www.ncbi.nlm.nih.gov) and investigated for presence of possible binding 
sites using the Matlnspector from Genomatix (http://www.genomatix.de). Analysis 
output was presented online and exported into excel files.
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Chapter 3
Bioinformatics analysis of 
the MHV-68 Rta promoter
sequence
Chapter 3
Bioinformatics analysis of the MHV-68 Rta promoter sequence
3.1 Introduction
Transcription factors are proteins able to bind specific DNA sequences within the 
promoter of a specific gene, modulating its expression. Upon binding, these 
proteins may then mediate repression or upregulation of that gene. Thus, 
understanding events that modulate the transcription of a gene of interest includes 
the analysis of interactions between its promoter and specific transcription factors 
which. An important step in this analysis is the prediction of initially putative but 
potentially functional transcription factor binding sites (Cartharius et al., 2005). 
Unlike other DNA binding proteins such as restriction enzymes, site recognition by a 
transcription factor is flexible and two regulatory sites bound by the same factor, 
will often vary in nucleotide positions between them. However, and despite this 
promiscuity, if one compares regulatory sites, a common feature may arise with a 
frequent occurrence of specific nucleotides in specific positions. This common 
feature is described as an IUPAC consensus sequence and can be used to identify a 
sequence for possible transcription factor binding sites (Stormo, 2000). A more 
efficient alternative, and of widespread use nowadays, is the detection of binding 
sites by nucleotide or position weight matrices - NWM (Cartharius et al., 2005). The 
weight matrix for a binding site represents the complete nucleotide distribution for 
each single position. A nucleotide frequently observed (within a site) in a specific 
position will have a higher matrix value than a less frequent nucleotide at the same 
position (fig 3.1) (Stormo, 2000). The sum of the matrix values determines a score
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for any particular site. The consensus sequence has the highest score while any
sequence that differs from the consensus will have a lower score.
TACGAT 
TATA AT 
TATAAT 
GATACT 
TATGAT 
TATGTT
A -38 19 1 12 10 -48
C -15 -38 -8 -10 -3 -32
G -13 -48 -6 -7 -10 -48
T 17 -32 8 -9 -6 19
TATAAT---------- ► Consensus sequence
Fig 3.1 Nucleotide weight matrix description for a particular transcription factor 
binding site. The NWM represents all the possible combinations of nucleotides in 
each position. The matrix values for a nucleotide in a specific position are produced 
following alignment of functional binding sites presented on the left. Conserved 
nucleotides in a specific position in the context of the alignment will have higher 
matrix values than poorly conserved nucleotides. The NWM also allows the 
construction of a consensus sequence for the particular binding site. The score for a 
particular theoretical binding site is calculated as the sum of the correspondent 
matrix values (Stormo, 2000).
However, the decrease in score will depend on matrix value for different 
nucleotides in different positions. As some positions are more highly conserved 
than others (and more important for the site activity) this decrease will vary 
differently between a potentially functional binding site and one that is not. A pre­
determined threshold allowing for the difference in score between the consensus 
sequence and a functional binding site allows then the prediction of a potential 
TFBS within a particular promoter (Cartharius et al., 2005; Stormo, 2000).
3.2 Promoter analysis by the Matlnspector software
The MHV-68 Rta promoter is believed to span some 1.2 kb of DNA sequence 
upstream of ORF50 transcription initiation site (Rickabaugh et al., 2005). Analysis of
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this promoter region in this study was carried out by Mat Inspector, (licensed by 
Genomatix©), against a library of pre-determined weight matrices. This library is 
generated by the software called MatDefine (Cartharius et al., 2005). Input of 
sequences shown to have functional binding site by curation, and analysis of the 
alignment between binding sites allows MatDefine to construct a description of the 
consensus sequence. This description consists of a nucleotide distribution matrix 
and the conservation of each position within the matrix, represented by the 
consensus index vector (Q) (fig 3.2). Q vector is constructed by calculating the Q 
value for each position of the matrix and attributes weight to the respective 
position. It distinguishes between less or more conserved nucleotides within the 
consensus sequence. MatDefine also defines a core region, defined by the four 
consecutive nucleotides positions within the matrix which have the highest Q sum 
(Quandt et al., 1995). In fig 3.2, the core region is represented by the last four 
nucleotide positions. These three parameters are then evaluated for each potential 
binding site within the query sequence by Matlnspector. Matlnspector initially 
searches for the core region of each binding site, reducing the total number of 
matches and simultaneously enhancing the performance of the search. A core 
similarity is calculated for each position in the sequence, attributing the identified 
core region a value between 0 and 1. After comparison between the core regions, a 
matrix similarity is calculated between the consensus sequence and the putative 
binding site (fig 3.3). Multiplying each score by the Q allows for some tolerance of 
mismatches at less conserved positions (Quandt et al., 1995). The description (or 
not) of a potential binding site within the sequence is determined by a pre-defined 
matrix similarity threshold.
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Pos. l 2 3 4 5 6 7 8 9 10 11 12 13
A ■ 0 0 ■ 0 2 1 3 ■ 8 22 0 0
C 0 0 II 1 ■ 3 5 4 5 3 0 II 0
G 8 0 0 4 0 4 3 3 3 5 0 0 H
T 0 II 0 2 10 1 5 ■ 3 6 0 0 0
Q 59 100 100 42 57 31 19 26 24 17 100 100 100
Fig 3.2 NWM constructed by Matlnd for the ABF1 consensus sequence. The NWM
consists of the number of nucleotides observed at each position and the C, values 
for each position. Numbers shadowed in grey represent the most conserved 
nucleotides (Quandt et al., 1995).
Pos. 1 2 3 4 5 6 7 8 9 10 11 12 13
A 14- 0 0 H 0 2 1 3 m B* 22* 0 0
C 0 0 22* i ■* 3 5* 4 5* 3 0 22* 0
G 8 0 0 4 0 4 3 3* 3 5 0 0 22*
T 0 22* 0 2* 10 13* 5 P 3 6 0 0 0
Q 59 100 100 42 57 31 19 26 24 17 100 100 100
Seq. A T c T C T C G C A A c G
Score of the consensus sequence (■) = £ ((Qj) x maximum matrix value (/)) = 14426 
Score of the putative binding site sequence ( * ) = E ((CJ) x matrix value (bj)) = 
13426
Matrix similarity = 14426/14326 = 0.93
Fig 3.3 Determination of matrix similarity between the ABF1 consensus sequence 
and a putative binding site. Matrix similarity is calculated as the ratio between the 
score for a given binding site in the sequence of interest and the maximum score, 
obtained for the consensus sequence. The matrix similarity ranges from 0 < 1 and 
reaches only 1 if the candidate sequence corresponds to the most conserved 
nucleotide at each position of the sequence. The bottom row describes the putative 
binding site (Quandt et al., 1995).
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Genomatix has defined an optimized threshold (set as a default), particular to each 
individual matrix in order to minimize false positives and false negatives (Cartharius 
et al., 2005). It is important to note that the software allows for prediction of the 
site, it is the functionality which will then need to be tested experimentally.
3.3 Experimental design
The sequence between genomic positions 66760 to 65530 of the MHV-68 genome 
(Genbank accession number AF105037.1), representing the 1.2 Kbp promoter 
upstream of ORF50 start site, was used in promoter analysis to identify putative 
transcription factor binding sites. Analysis of this sequence was carried out using 
Matlnspector, and scanned for potential binding sites for transcription factors. Pre­
selection of matrices groups to compare against included three different subsets of 
regulatory sites: vertebrates, general core promoters and miscellaneous (which 
contains a description of EBV RRE). Initial inclusion of a theoretical binding site was 
dependent of a matrix similarity threshold, optimized for each matrix as 
recommended. However, and despite this parameter, further filtering was applied 
to select sites that showed a matrix similarity above 0.8. This cut-off value of 0.8 is 
described as a "good" match by the software developers. The output represented 
the family/individual matrix described in the sequence, the optimized threshold 
defined by the software for the individual matrix identified, the strand and position 
of the putative binding site within the sequence, the determined core and matrix 
similarity between the consensus and the identified site and the site DNA sequence, 
highlighting the core region.
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3.4 Results
3.4.1 Detailed bioinformatics analysis of the MHV-68 Rta promoter
Analysis of the 1.2 Kbp MHV-GS Rta promoter sequence produced 255 hits in total. 
Of these, 40 hits were excluded due to a matrix similarity less than 0.8 or because 
they were specific for factors associated with plants, C. elegans, bacteria and 
drosophila (included within the miscellaneous set of matrices). The remaining 215 
theoretical binding sites were examined for potential association and modulation of 
Rta promoter. Further selection included putative binding sites associated with 
cellular factors or signalling events previously shown to modulate either Rta gene 
expression or lytic replication in gammaherpesviruses (fig 3.4). The analysis output 
produced (tables 3.1 through 3.4) was used to divide the Rta promoter sequence 
into four promoter regions for further analysis. These promoter regions included 
the sequences between genomic positions 65530-65741, 65741-66369, 66369- 
66549 and 66549-66760 for better correlation with the results displayed in 
posterior chapters (chapters 4 and 5). The sum of the potential hits is better 
visualised in fig 3.5. The final output produced contained a total of 34 potential 
cellular binding sites. Additionally, the predicted binding sites seemed to form 
clusters in which two to five sites share close proximity with some overlap. 
Interestingly, of the 34 selected binding sites (again, due to previous description of 
some degree of interaction with Rta or reactivation), ten were associated with type 
I IFN or TLR transduction pathways and the establishment of an antiviral cellular 
environment. Sites associated with these pathways discriminated in the promoter 
analysis included multiple Stat IRF sites and AP-1 and NF-kB response elements.
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0CT1 Involved in modulation of cellular 
response to stress
API Involved in several cellular
processes including induction of 
inflammatory cytokines, including 
IFNs.
SRF Involved in cell growth, 
differentiation and muscle
development
STAT1 Involved in type I IFN downstream 
signalling following viral infection
IRF3 Induces IFN expression 
following viral infection
YY1 Involved in cell growth, 
differentiation, 
embryogenesis and
response to toxic stimuli
CBP Positive regulator of 
histone acetylation
RBP-Jk Associated with Notch 
signalling (pathway
involved in cell-cell 
communication)
IRF7 Induces (and is induced by) IFN 
expression in the context viral 
infection
HRE Hypoxia response element
XBP1 Transcription factor activated by 
UPR response
BLIMP1 Involved in B cell 
differentiation
IRF1 Involved in type I IFN 
downstream signalling
following viral infection
NF-kB Induces the expression of 
inflammatory cytokines,
including IFNs
HIFla Involved in cellular and systemic 
responses to hypoxia
MEF2 Associated with histone 
modification and involved 
in cell differentiation
Fig 3.4 Proposed roles for transcription factors discriminated in the analysis of the 
Rta promoter.
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Table 3.1 Potential binding sites described within the 65530-65741 region.
Matrix Position Core sim. Matrix sim. Evidence
OCT1 65535-65551 0.95 0.905 Recruited by Rta for auto­
activation in KSHV
(Sakakibara et alv 2001)
OCT1 65544-65560 0.75 0.844 Recruited by Rta for auto­
activation in KSHV
(Sakakibara et al., 2001)
API 65549-65559 0.886 0.961 API pathway is involved 
in activation of Rta 
promoter following
treatment with TPA
(Wang et al., 2004)
SRF 65664-65682 1 0.81 Associated with promoter 
activation by LANA-1 in 
KSHV (Roupelieva et al., 
2010)
STAT1 65677-65695 1 0.873 Represses MHV-68 Rta 
promoter (Goodwin et al., 
2010)
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Table 3.2 Potential binding sites described within the 65741-66369 region
Matrix Position Core sim. Matrix sim. Evidence
IRF7 65759-65779 1 0.873 Induces KSHV reactivation 
following TLR
signalling/inhibits KSHV
replication by competition 
with Rta for ORF57 (Gregory et 
al., 2009; Wang et al., 2005a).
HRE 65775-65791 1 0.932 Is associated with the 
induction of Rta expression in 
KSHV (Dalton-Griffin et al., 
2009)
XBP1 65787-65807 1 0.889 Induces Rta expression in KSHV 
(Wilson et al., 2007)
HIFlct 65790-65806 1 0.874 Induces Rta expression in KSHV 
(Davis et al., 2001)
IRF3 65951-65971 0.774 0.888 Induces type 1 IFN gene 
expression (Schafer et al., 
1998)
CBP 66032-66046 1 0.978 Induces Rta expression (Lu et 
al., 2003)
SRF 66033-66051 0.754 0.865 Associated with promoter 
activation by LANA-1 in KSHV 
(Roupelieva et al., 2010)
YY1 66032-66052 1 0.821 Represses EBV Rta promoter 
(Zalani et al., 1997)
OCT1 66041-66057 1 0.913 Recruited by Rta for
autoactivation in KSHV
(Sakakibara et al., 2001)
TATA
factor
66099-66115 1 0.945 Suggest the presence of a 
TATA box
TATA
factor
66119-66135 1 0.832 Suggest the presence of a 
TATA box
TATA
factor
66232-66248 1 0.904 Suggest the presence of a 
TATA box
RBP-Jk 66249-66261 1 0.942 Recruited by Rta for activation 
of downstream promoters in 
KSHV (Liang et al., 2002)
CBP 66256-66270 1 0.948 Induces Rta expression (Lu et 
al., 2003)
OCT1 66310-66326 0.846 0.805 Recruited by Rta for
autoactivation in KSHV
(Sakakibara et al., 2001)
BLIMP1 66309-66327 1 0.852 Involved in differentiation of B 
cells into plasma cells (Turner 
et al., 1994).
IRF3 66311-66331 1 0.948 Induces type 1 IFN gene 
expression (Schafer et al., 
1998)
SRF 66327-66345 1 0.868 Associated with promoter 
activation by LANA-1 in KSHV 
(Roupelieva et al., 2010)
YY1 66326-66346 1 0.965 Represses EBV Rta promoter 
(Zalani et al., 1997)
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Table 3.3 Potential binding sites described within the 66360-66549 region.
Matrix Position Core sim. Matrix sim. Evidence
STAT3/6 66386-66404 1 0.972 Represses MHV-68 Rta 
promoter (Goodwin et al., 
2010)
TATA
factor
66454-66468 1 0.828 Suggest the presence of a 
TATA box
OCT1 66512-66528 1 0.862 Recruited by Rta for 
autoactivation in KSHV 
(Sakakibara et al., 2001)
IRF1 66514-66534 1 0.871 IRF1 gene expression is 
induced by type 1 IFNs 
(Miyamoto et al., 1988)
Table 3.4 Potential binding sites described within the 66549-66760 region
Matrix Position Core sim. Matrix sim. Evidence
YY1 66559-66579 1 0.986 Represses EBV Rta
promoter (Zalani et al., 
1997)
TATA
factor
66618-66634 1 0.96 Suggest the presence of a 
TATA box
OCT1 66626-66642 1 0.887 Recruited by Rta for 
autoactivation in KSHV 
(Sakakibara et al., 2001)
API 66653-66663 1 0.997 API pathway is involved in 
activation of Rta promoter 
following treatment with 
TPA (Wang et al., 2004)
MEF2 66708-66730 1 0.879 Involved in chromatin 
remodelling of Zta
promoter in EBV (Gruffat et 
al., 2002)
Ikaros 1 66737-66749 1 0.925 Involved in TLR signalling- 
mediated phosphorylation 
of IRF7 (Kawai and Akira, 
2006)
NF-kB 66739-66751 1 0.901 Involved in the
establishment of latency by 
KSH V/M H V-68/EBV by
inhibition of Rta expression 
(Brown et al., 2003)
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Of particular importance are two sites within positions 66249 and 66270, 
encompassing sequences recognized by RBP-Jk and CBP. Both factors have been 
demonstrated to interact with Rta in transactivation of lytic promoters (Staudt and 
Dittmer, 2007). Furthermore, CBP is able to induce Rta gene expression in cells 
latently infected with KSHV (Lu et al., 2003), and close analysis of these sites also 
showed a similar sequence to a response element recognized by the RBP-JK/Rta 
complex involved in transactivation of viral promoters (fig 3.6) (Liang et al., 2002).
Response
element
RBP-Jk
GT GAGC
CA CTCC
"I
< V
3GGA A
3CCT T
: :tatgaaa
VATACTTT
CBP
TCTTCCGTCG
GTGGGAA CACCCTT *
Response element recognized by RBP-Jx/Rta 
in viral promoters (Liang et al., 2002)
Fig 3.6 Identification of a cis activating site responsive to transactivation by RBP- 
JK/Rta complex.
This description suggests a potential regulatory site responsive to transactivation by 
Rta. Furthermore, another feature includes a number of OCT-1 sites, present 
throughout the promoter sequence. As OCT-1 has been shown to participate in 
auto-activation of Rta promoter in KSHV, these sequences specific for OCT-1 suggest 
a number of possible regulatory sites responsive to Rta. Other factors that could 
potentially interact with this Rta promoter include HRE, HIF-la and XBP-1. All of the 
above have been shown experimentally to upregulate KSHV Rta promoter in 
response to hypoxia and the unfolding protein response. Several factors that have 
been shown to downregulate Rta expression in gammaherpesviruses were also
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identified in this study such as STAT, NF-kB and YY1. STAT and NF-kB were 
previously described within the MVH-68 Rta promoter (and in similar positions) and 
shown to inhibit Rta transactivation in vitro, thus validating the approach in this 
study, it was shown that YY1 can promote viral latency by inhibiting Rta and Zta in 
the context of EBV infection. However, downregulation of Rta by YY1 was observed 
through interaction with a site downstream of the start codon, as opposed to 
another site located within positions -206 to -227, sites upstream of Rta stop codon. 
It is known that transcription factor binding sites can occupy down- or up-steam 
locations of a given gene. BLIMP-l participates in B ceil differentiation to plasma 
cells, a process associated with KSHV reactivation (Wilson et al., 2007). IRF1, Ikaros 
1 and IRF3 are factors associated with innate immunity and the establishment of 
type I IFN responses, which inhibit reactivation of gammaherpesviruses. Finally, 
MEF2 (which participates in histone modification) induces Zta expression and a 
similar situation could be demonstrated with this promoter sequence.
3.5 Discussion
The expression of a give gene is dependent primarily on complement of 
transcription factors whose interactions will greatly influence the rate and levels of 
that gene being expressed. In this chapter, the Rta promoter sequence was 
analysed employing the software tool Matlnspector. The output of this analysis 
revealed 215 possible interactions between the promoter sequence and cellular 
factors, confirming previous observations that this promoter has a high degree of 
affinity for host proteins involved in transcription modulation (Yu et al., 2007). 
Further screening for hits previously reported in other studies identified 34 putative
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binding sites for 16 cellular transcription factors. The data obtained in this chapter 
shows a conserved degree of functional homology between the MHV-68 Rta 
promoter and the promoters of other gammaherpesviruses for example KSHV and 
EBV. This is of interest because it demonstrates the conservation of cellular 
pathways whose interactions with viral promoter sequences at the viral promoter 
level. It also gives an insight into the evolution of similar infections patterns these 
viruses. Additionally, binding sites potentially responsive to activation by protein 
complexes containing Rta and cellular factors were identified.
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Chapter 4
Characterization of the 
MHV-68 Rta promoter in 
immunocompetent murine
fibroblasts
Chapter 4
Characterization of the MHV-68 Rta promoter in immunocompetent 
murine fibroblasts
4.1 Introduction
Rta is a key viral protein which plays a pivotal role in gammaherpesviruses iytic 
infection cycle. Activation or inhibition of Rta transcription is directly linked to viral 
reactivation/lytic replication and production of virion progeny or the establishment 
of latency (Chevallier-Greco et al., 1986; Lukac et al., 1998; Wu et al., 2000). 
Therefore, the Rta promoter, not only in MHV-68 but also in other y-herpesviruses, 
has been a major focus of research to understand how modulation of this key viral 
promoter, by cellular and viral factors, may influence virus lytic and persistent 
phases of infection. Previous analysis of the MHV-68 Rta promoter sequence had 
identified several cellular putative binding sites, including several regulatory sites 
associated with type IIFN signalling (chapter 3). However, there has been a lack of a 
detailed study as to how different domains within the Rta promoter may respond to 
cellular environment in the absence of Rta. Due to the number of potential 
interactions within this promoter, and considering previous studies in 
gammaherpesviruses, it was of interest to understand how basal cellular 
modulation of Rta transactivation occurred and characterize potential regulatory 
regions within this promoter.
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4.2 Experimental design
The experimental approach undertaken in this chapter was aimed to identify 
potential regulatory regions within the MHV-68 Rta promoter using a luciferase 
based reporter assay transiently transfected into immunocompetent murine 
fibroblasts. A 1.2Kbp region upstream of Rta initiation start site was previously 
identified as the promoter for MHV-68 Rta (Rickabaugh et al., 2005). Therefore, this 
sequence was used to represent the full MHV-68 Rta promoter. The full 1.2 kb 
promoter sequence and four corresponding truncated versions were cloned 
upstream of a luciferase report gene and assayed for promoter activity in response 
to basal cellular activation, recombinant MHV-68 Rta protein and type I IFN 
treatment.
4.3 Results
4.3.1 Generation of MHV-68 Rta truncated promoter constructs
Four sequences originated from the full length promoter region were cloned 
separately upstream the luciferase gene in a pGL3-basic vector, generating four 
different reporter vectors (fig 4.1) (The four reporter constructs were cloned prior 
to the start of the PhD project in Dr Ebrahimi's lab). Each construct was transiently 
transfected into wild type NIH3T3. Samples were harvested at 6, 12, 24, 36 and 48 
hours post-transfection and processed for luciferase assays. The luciferase activity 
of cell lysates was measured normalized against renilla activity. In a second series of 
experiments, Rta, expressed from a different plasmid, was co-transfected with Rta
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promoter plasmid to assess the response of each Rta promoter region to Rta 
provided in trans. Samples were collected and treated as in the first experiment.
65530 65741 66369 66549 66760
i ------1 Rta promoter
tm -1230pGL3 
■1 -1019pGL3 
■■ -391pGL3 
■H -211pGL3 
■ pGL3-basic\
i
i
1--------------
i
i
1 ------------1
+,1
' ▼—i-----------------
1230 i !------------- 1------- —i-------
-1019
-391
-211 /
Luciferase gene
Fig 4.1 MHV-68 Rta promoter luciferase reporter constructs. Schematic 
representation of the four Rta construct cloned upstream of luciferase gene in the 
reporter plasmid pGL3-basic.
4.3.2 Characterization of basal Rta promoter activity in immunocompetent NIH 
3T3 cells
Activation property of different Rta promoter sequences was studied in murine 
NIH3T3 cells. Transfection and analysis of promoter activity throughout the 
experiment this cell line showed that basal activation of the four reporter 
constructs occurs differently across promoter sequences (fig 4.2). The -1019 and - 
211 bp sequences exhibited higher fold activation than the negative control, 
suggesting these sequences were activated by basal expression of cellular factors 
(fig 4.2 B). Of both sequences the -211 bp promoter exhibited higher levels of fold 
activation, between 9 to 17 fold activation depending on the time point observed. 
The -1019 bp promoter displayed lower transactivation levels, between 3 and 9 fold 
activation (again depending on the time point). Conversely, analysis of -1230 and - 
391 bp promoter transactivation demonstrated these sequences were not activated
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A)
Time (hours post transfection)
B)
Reporter
construct
Genome
coordinates
-1230pGL3 65530-66760
-1019pGL3 65741-66760
-391pGL3 66369-66760
-211pGL3 66549-66760
Relative activity
24h 36h 48h
Fig 4.2 Transcription activation of luciferase reporter gene by full length and 
truncated MHV-68 Rta promoter sequences. Basal transcription activation of each 
Rta promoter region was tested by transient transfection of luciferase reporter 
gene downstream of Rta promoter sequences. Murine NIH 3T3 cells were 
transfected with two micro grams of reporter plasmids using Lipofectamine 2000. 
Control samples included cells transfected with the empty vector (pGL3-basic). 
Total cell lysate was isolated and assayed for luciferase activity over the time course 
using Tristar LB 941 DLR reader (Berthold Technologies). B) Relative promoter 
activity of each region determined as fold change against empty vector activation. 
The sequences -1019 and -211 bp upstream the start codon exhibited an 
upregulation of their promoter activity compared to the negative control. The full 
length promoter and the region -391 bp upstream were either weakly 
transactivated or showed similar promoter activation to the negative control. C) 
Identification of positive and negative regulatory domains associated with basal 
transactivation along with the genomic coordinates of each promoter sequence. 
The arrows represent the promoter region. Red boxes characterize regions with 
regions exhibiting reduced activity (negative regulatory domains) while green boxes 
represent regions that showed significant upregulation, compare to the negative 
control (n=6 ± SD).
100
by basal cellular expression. Relative promoter activation of both sequences was 
lower than one (fig 4.2 B), indicating transactivation of -1230 and -391 bp 
promoters were transactivated at levels inferior to those observed for the empty 
plasmid pGL3-basic.
4.3.3 Characterization of Rta promoter transactivation by Rta
The above data clearly showed that the basal activity of Rta is highly dependent on 
different regions within the full length Rta promoter. It is known that Rta is able to 
auto-activate its own promoter and enhance gene expression (Damania et al., 2004; 
Deng et al., 2000; Wakenshaw et al., 2005).
The precise Rta response location within the Rta promoter is not well characterised. 
However, bioinformatics analysis of the Rta promoter sequence presented in 
chapter 3 identified putative sites associated with cellular factors which have been 
demonstrated to play a role in Rta-mediated transactivation of viral promoters. 
These include several Oct-1 response elements, shown to be critical in KSHV Rta 
auto-activation (Sakakibara et al., 2001), and a site involved in transactivation of 
KSHV lytic promoters by a functional Rta-RBP-Jx complex (Liang et al., 2002). 
Therefore, we were interested to understand if there was a specific region within 
the full length Rta promoter which would respond, either in a positive or a negative 
manner to Rta expressed in trans. Rta promoter constructs were co-transfected 
with an expression plasmid (pFLAG-CMV2/Rta) encoding MHV-68 Rta gene (kindly 
provided by Ren Sun). Promoter activity of each construct was measured and fold 
activation of each sequence determined by comparison against the negative control 
(empty pGL3-basic). Examination of relative promoter activities of the four
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promoter sequences (fig 4.3), demonstrated that both the -1019 and -211 bp 
sequences were highly transactivated in the presence of Rta, whereas the full 
length promoter and the -391 region exhibited weak activation. Comparison of 
relative promoter activities of -1019 and -211 regions in both studies (based on 
activation of the negative controls in both experiments), was analysed further. In 
the presence of Rta, both the -1019 bp and -211 sequences exhibited higher 
promoter activities when compared to basal activation in the absence of Rta, with 
fold changes higher than 100 between both experiments (fig 4.4). A similar analysis 
of both full length promoter and the -391 bp region activation demonstrated these 
sequences were not upregulated activated by Rta (fig 4.5). Furthermore, the 
relative promoter activities of both full length promoter and -391 bp promoter 
sequence were shown to be lower in the presence of Rta (compared against basal 
transcription).
4.4 Discussion
Modulation of Rta promoter by cellular factors has been the focused of several 
studies in order to understand how physiological and signalling transduction affect 
viral reactivation. These studies, per se, have traditionally set their attention on 
modulation of Rta gene expression by a specific cellular factor following description 
of binding sites within Rta promoter. However in the work described, we have 
looked at cellular basal transcription activation of MHV-68 Rta promoter sequences 
of different sizes. By examining promoter activity associated with these sequences, 
we expected to determine any possible regulatory domains within this promoter 
and relate the information with the putative binding sites previously identified (fig
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Time (hours post transfection)
Fig 4.3 Transactivation of promoter regions in the presence of Rta. Murine NIH 3T3 
cells were transiently transfected as stated above (see legend to Fig. 4.2). In 
addition to plasmid constructs carrying different regions of the Rta promoter 
sequence, cells were also co-transfected with 0.5 micrograms of pFLAG_CMV2/Rta 
which contains the MHV-68 Rta gene. Rta transcription activation of each promoter 
over a time course. Relative promoter activity, fold activation against the negative 
promoter (co-transfection of empty pGL3 basic with the Rta expressing plasmid), 
demonstrated the -211 bp and -1019 bp promoter sequences were upregulated, 
whereas the full length and -391 bp promoter sequences showed reduced activity 
(n=6±SD).
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10000 -1019 promoter region ■ Rta -
10000 -211 promoter region ■ Rta -
■ Rta +
6h 12h 24h 36h 48h
Time (hours post transfection)
Fig 4.4 Response of -1019 and -211 promoter regions to Rta. The relative promoter 
activity of each region determined as fold change against empty vector activation 
for each experiment. In both sequences the presence of Rta induces transcription to 
higher levels, compared to activation of the promoter on its own. Activation of the 
promoters by Rta was observed at all time points (n=6 ± SD).
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-1230 promoter region
■ Rta -
6h 12h 24h 36h 48h
Time (hours post transfection)
6h 12h 24h 36h 48h
Time (hours post transfection)
Fig 4.5 Response of the full length promoter and -391 region bp to Rta. The
relative promoter activity of each region was determined as fold change against 
empty vector activation for each experiment and compared to the basal 
transcription study. The relative promoter activities of both reporter constructs 
were lower when co-transfected with Rta (n=6 ± SD).
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3.5). Transfection of murine fibroblasts (NIH3T3 cell line) followed by promoter 
analysis showed, in the context of basal activity, two sets of regulatory domains 
within this promoter: two negative regulatory domains located between positions 
65530-65741 and 66369-66549 and two positive regulatory domains located within 
positions 65741-66369 and 66549-66760 (fig 4.2 B). The full length promoter, 
between positions 65530 and 66760 exhibited weak transactivation activity against 
the empty vector, used as a negative control. However, deletion of sequences from 
bp 65530 to 65741 resulted in upregulation of the promoter region, implying this 
region functions as a negative regulatory domain. Further deletion of the promoter 
sequence between positions 65741 and 66369 lead to a drastic downregulation of 
transactivation. The loss of activation associated with the deletion of this region 
suggests the sequence between both genomic positions was responsible for the 
promoter activity observed earlier, and could be described as a positive regulatory 
domain. A final deletion from bp 66369 to 66549 restored luciferase activity to the 
highest levels observed in the context of this experiment (fig 4.2 A). These results 
imply the 180 bp domain between 66369 and 66549 is a potent negative regulator 
as it repressed the transactivation observed for the -211 bp promoter (described in 
this study as a second positive regulatory domain).
In this study it was also shown transactivation of these promoter sequences by Rta 
occurs at different levels. Co-transfection of the four reporter constructs with an 
expression plasmid harbouring the ORF50 also showed Rta is able to auto activate 
its promoter, as described previously by several authors. Again, a similar analysis of 
the results obtained in this study suggests the existence of two different subsets of 
regulatory domains regarding Rta transactivation (fig 4.3). Two positive regulatory
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domains were described between positions 65741-66369 and 66549-66760 which 
are highly responsive to Rta (fig 4.4). Interestingly, these domains are coincident 
with the positive regulatory domains described in the context of basal activation. 
The second subset relates to two negative regulatory regions between positions 
65530-65741 and 66369-66549. Again, these domains were coincident with the 
negative regulatory domains associated with basal transcription (fig 4.6). However, 
the levels of exogenous Rta expression (through western blotting or q-PCR) in each 
sample were not assessed, rendering these results preliminary. Further work is 
necessary to effectively demonstrate the activation pattern observed is biologically 
significant. This could be achieved not only by demonstrating Rta was expressed in 
similar levels in each sample (through RNA extraction and q-PCR) but also by dose 
dependent studies. It was shown previously in KSHV that Rta is able to activate its 
own promoter in a dose dependent manner and similar results in this study would 
provide a clear picture on Rta activation of the different regions of its own promoter 
in MHV-68.
Initial examination of the promoter in search for Rta response elements revealed a 
similar sequence to the consensus TTTTTNNNTGTTT (described in table 1.1). 
Interestingly, this site was not found in the domains upregulated by Rta but within 
the region between positions 66369-66549, implying it is not a functional RRE. As 
described in chapter three, a putative site similar to a response element involved in 
transactivation of KSHV lytic promoters by an Rta-RBP-Jx protein complex has been 
identified at genomic positions 66249-66261 (fig 3.6). The putative site is located 
within the Rta auto activated domain 65741-66369 and is a likely candidate for 
further studies demonstrating functional interaction between Rta and its promoter.
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Although this site could be the subject of further studies, analysis of the results in 
fig. 4.3 and 4.4 for Rta auto activation suggests the RRE could be actually be located 
in the -211 bp promoter region. Promoter activation between the described 
positive regulatory regions {-1019 and -211 bp) differs only slightly. As the -1019 bp 
region includes the -211 bp minimal promoter, these results imply the RRE should 
be in the latter. RRE mapping can then be achieved by sequential deletions of 50 bp 
from this promoter region and further analysis of Rta auto activation of the 
produced constructs.
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Chapter 5
Characterization of the 
modulation of MHV-68 Rta 
promoter activity by type I
Interferons
Chapter 5
Characterization of the modulation of MHV-68 Rta promoter activity 
by type I IFNs
5.1 Introduction
Previous work with IFN-a/fJ FT/ mice showed that lack of type I IFN-receptor 
mediated signalling results in an uncontrolled systemic dissemination of MHV-68 
lytic infection (Dutia et al., 1999). Furthermore, IFN-a/P was shown to inhibit MHV- 
68 reactivation from latently infected cells (Barton et al., 2005). Similar results were 
observed in cells latently infected with KSHV (Monini et al., 1999). Therefore, type I 
IFN signalling pathways are closely involved in priming the cellular environmental 
creating an antiviral environment (Brierley and Fish, 2002). However, while no 
mechanism underlying the modulation of Rta promoter by IFN-a/P was described in 
these studies, analysis of MHV-68 Rta promoter (chapter three) identified several 
putative binding sites associated with either induction of IFN-a/P gene expression 
or correlated with downstream signalling following that induction. Therefore, the 
presence of such regulatory sites would suggest that the Rta promoter is more than 
likely a target for modulation by IFN-a/P receptor-mediated signalling.
5.2 Experimental design
The four MHV-68 Rta promoter constructs described previously (chapter 4 - section 
4.3.1) were transiently transfected into immunocompetent murine fibroblasts 
(NIH3T3 cell line) and murine fibroblasts from type I IFN receptor knockout cells 
(Muller et al., 1994). Modulation of Rta promoter by type I IFN was investigated by
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transient transfection of cells followed by IFN-ct/fJ treatment at 24 hours post­
transfection. The luciferase activity of cell lysates was measured, normalized against 
renilla activity and related to promoter activity. Similar studies were carried out in 
murine type I IFN receptor knockout cells to assess the role of type I IFN receptor- 
mediated signals on Rta promoter activity.
5.3 Results
5.3.1 Modulation of Rta promoter following IFN-a/3 treatment in 
immunocompetent murine NIH 3T3 cells
In view of the number of putative binding sites identified in Rta promoter sequence 
analysis (Chapter 3) and linked in type I IFN signalling (fig 3.5), the modulation of 
l\/IHV-68 transactivation by treatment with IFN-a/P was examined. 
Immunocompetent NIH3T3 cells were transfected with each of the four promoter 
constructs. The tissue culture medium was replaced media plus containing murine 
type I IFN (100,000 IU) at 24 hours post-transfection. Fold-activation of the four 
reporter constructs, following IFN-ot/fJ treatment, was determined against promoter 
activity of pGL3-basic (negative control). Comparison of the transactivation of the 
four promoter regions demonstrated that the -211 bp fragment upstream of the 
start site exhibited the highest activity. The remaining promoters (-1230, 1019 and 
391 bp sequences) displayed low activation levels similar to transactivation 
exhibited by the empty pGL3-basic. To confirm the reduced promoter activity of 
these promoters was in fact a result of IFN treatment, it was necessary to 
understand the difference between the treated and untreated samples.
Ill
Fig 5.1 Effect of IFN-a/3 on activation of Rta promoter in NIH3T cells. Cells were 
transfected with two micrograms of each reporter construct. Relative promoter 
activation of each reporter construct was determined over time following IFN-a/p 
treatment. The -211 bp promoter displayed the highest levels of transactivation in 
this study, while the remaining promoter sequences exhibited similar minimal 
promoter activities (n=6 ± SD).
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Fig 5.2 Modulation of Rta promoter by IFN-a/P in NIH3T3 cells. Relative promoter 
activity (against the negative control) of each reporter construct in the absence A) 
and presence of type I IFNs B). The -1019 bp region upstream the start codon was 
the only promoter region showing a significant difference between both studies, as 
its promoter activity exhibited a 4 fold decrease in activation (n=6 ± SD).
113
For this purpose, fold activation of all promoter sequences was compared against 
the promoter activity observed in the first study of basal transcription shown in 
chapter four (fig 5.2). Two time points were considered for comparison, at 36 and 
48 hour post-transfection (12 and 24 hour post IFN treatment). Of the four 
promoter constructs, only -1019 bp sequence showed a significant difference in 
activation. This promoter sequence exhibited a 4-fold decrease in promoter 
activation following treatment with type I IFNs (at both time points) to levels similar 
to the negative control. The remaining reporter constructs displayed similar 
promoter activities between both studies.
5.3.2 Modulation of Rta promoter activity following IFN-a/P treatment in type I 
IFN receptor knockout cells
In order to assess further the effect of type I IFN signaling on Rta promoter activity, 
additional studies were carried out in murine fibroblast that lack a functional type I 
IFN signaling pathway, derived from IFN-a/p receptor knockout mice. These cells do 
not express a functional IFNAR2 protein, a subunit of the IFN-a/p receptor and as 
such, the signalling transduction pathways that are activated following type I IFN 
expression are not induced in these cells (Muller et al., 1994). Basal transcription 
activation of the Rta promoter in this cell line was initially studied by transient 
transfection of the four reporter constructs previously described in chapter four (fig 
4.1). Relative activation of the four promoter constructs was determined as fold 
change against the empty control (pGL3-basic). Analysis of the promoter activity of 
all four sequences in the context of basal transactivation demonstrated that the Rta 
promoter was poorly activated in this cell line, when compared to basal promoter
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activity in immunocompenent NIH 3T3 cells (fig 5.3). The full length promoter plus 
the -1019 and -391 bp sequences exhibited relatively lower activities than the 
negative control (fold activation was lower than one). Of these three sequences, the 
-391 bp region showed the lowest promoter activation. Furthermore, the relative 
promoter activity of -211 bp promoter sequence, albeit slightly upregulated when 
compared to the empty vector, demonstrated that this sequence was poorly 
activated, especially when compared to the observed levels in NIH3T3 cells (chapter 
four). Transactivation of the different promoter regions following treatment with 
type I IFN was also examined in this cell line in a similar fashion to NIH3T3 cells. 
Cells were transfected with the four promoter sequences, treated with type I IFN at 
24 hours post-transfection and harvested at 12, 24, 36 and 48 hours post IFN 
treatment. Relative promoter activity for each promoter sequence was determined 
as fold change against negative control (pGL3-basic). The four sequences exhibited 
weak transactivation. The -211 bp sequence, although displaying the highest levels 
of promoter activity, was still poorly activated, only two fold higher than the 
negative control (empty pGL3-basic). The remaining promoter sequences exhibited 
even lower activities than the negative control, parallel to observations in cellular 
basal transactivation of Rta promoter in this cell line (fig 5.3). Additionally, the 
different promoter domains showed no significant difference in promoter activation 
in the presence and absence of type I IFNs (fig 5.4).
5.4 Discussion
Type I IFNs have been shown to inhibit gammaherpesviruses infection (Barton et ai., 
2005; Monini et al., 1999) but the mechanism by which viral replication is arrested
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Fig 5.3 Basal activation of Rta promoter region in IFN-a/P R"/" fibroblasts. . Basal 
transcription activation of each promoter against time (hours post-transfection). 
Cells were transfected with two micrograms of each reporter construct. Relative 
promoter activity of each promoter sequence was determined as fold activation 
against activation of empty plasmid. The promoter activities of all four promoter 
sequences demonstrated the Rta promoter was poorly transactivated in the context 
of cellular basal activation (n=6 ± SD).
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Fig 5.4 Effect of IFN-a/P treatment on activation of Rta promoter in IFN-a/P R / 
fibroblasts. Comparison of relative the promoter activities of each promoter region 
sequence, following treatment with IFN-a/p. Again, the four promoter sequences 
exhibited weak transcription activity. The -211 displayed the highest transactivation 
levels, while the remaining constructs were transactivated at lower levels than the 
negative control (n=6 ± SD).
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Fig 5.5 Modulation of Rta promoter by IFN-a/p in murine IFN-a/P R'/' fibroblasts.
Relative promoter activity (against the negative control) of each reporter construct 
in the absence A) and presence of type I IFNs B). Examination of promoter 
transactivation in this cell line demonstrated no significant change in activation was 
observed following IFN treatment (n=6 ± SD).
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has not been fully understood. Preliminary work analysing the effect of type I IFNs 
in the context of in vitro MHV-68 infection demonstrated several lytic genes 
transcription were inhibited by IFN-a/fS, including Rta (Bahram Ebrahimi, 
unpublished data). Moreover, the presence of putative binding sites within the 
promoter of Rta, closely linked to type IIF1M, clearly suggest a key role by type I IFN 
in Rta expression and subsequently in virus infection cycle.
Transfection of murine fibroblasts with the four Rta promoter reporter constructs, 
followed by type I IFN treatment, demonstrated that the promoter activity of the - 
1019 bp sequence upstream the start codon was significantly downregulated, when 
compared to activation in the absence of IFN-a/fS. The constructs representing the - 
1230, -391 and -211 bp upstream of the Rta initiation start site displayed no change 
in promoter activity in the presence or absence of type I IFN signalling. This 
evidence suggests that Rta transcription is downregulated by IFN-ot/3 in vitro, and 
this modulation is probably due to interactions between factors activated/induced 
in the context of type 1 IFN signalling pathway and the promoter region located 
between genomic positions 65741 and 66369 bp.
Previous analysis of the full promoter sequence had revealed several binding sites 
specific of cellular factors associated with type I IFN signalling pathway including 
1RF7 and IRF3. IRF3 is constitutively expressed in all cell types, undergoes activation 
upon viral infection and translocates to the nucleus where it induces lFN-(3 gene 
expression. However, its activation is dependent on induction of the TLR 
transduction pathway and its gene expression is independent of type I IFN signalling 
events. Conversely, IRF7 gene expression is induced by the transcription factor ISGF- 
3, activated following interaction between IFN-a/p and the respective IFNAR
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receptor. Activation of this transcription factor, like IRF3, is also dependent on TLR 
signalling. Independently of the degree of interaction with type I IFN signalling 
pathways, both IRF factors are possible candidates, responsible for the 
downreguiation observed and suitable targets for further work. In order to 
understand further understand modulation of Rta transcription by type I IFNs, 
activation of the different Rta promoter domains (previously described) was studied 
in murine fibroblasts cells without a functional IFN-a/P receptor. Transcription 
activation of Rta promoter in these cells was studied in the context of cellular basal 
activation and following cell treatment with IFIM-ot/p. Analysis of basal transcription 
activation demonstrated that Rta promoter was weakly transactivated in cells which 
do not respond to type I IFN. The low promoter activity levels observed in these 
cells did not allow a definite distinction in transcription activation of the different 
regulatory domains observed in cells which can respond to type I IFN described in 
chapter four (in the context of basal activation). Of the four promoter regions 
examined, only the -211 bp domain upstream Rta start codon exhibited a slight 
promoter activation compared to the negative control (pGL3-basic). The remaining 
three promoter regions showed reduced transcription activity at lower levels than 
the negative control. The activation pattern suggested type I IFN signalling actually 
might be involved in upregulation of Rta promoter transcription. These results 
suggest a more complex, dualistic, interaction between this promoter and type I IFN 
downstream signalling. An example is the KSHV reactivation by p38/MAPK pathway, 
which is activated by type I IFN signalling (Xie et al., 2008). Finally, treatment of 
these cells with type I IFN did not produce a significant effect in transactivation of 
the four promoter sequences. The lack of an effect in transactivation was to be
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expected, as functionality of the IFNAR2 subunit is abrogated in these cells 
abolishing type I IFN signalling. However, and in spite of the evidence presented by 
the work described here, further studies are still required to fully demonstrate that 
Rta transcription is indeed downregulated by type I IFNs. Such downregulation 
could be verified by examination of Rta transcript abundance in the context of in 
vitro MHV-68 infection following type I IFN treatment in both cell types.
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Chapter 6
Characterizing the role of IRF7 and IRF3 binding sites in Rta promoter 
activity
6.1 Introduction
1RF7 and IRF3 play a prominent role in the establishment of type I IFN responses to 
viral infections. Both IRF3 and IRF7 have been shown to upregulate IFN-a/p gene 
expression following recognition of viral infection of the cell by Toll-like receptors 
(as mentioned in chapter 1). IRF7, in particular, has been described more recently as 
a non-redundant factor in the induction of IFN-a/p transcription. Furthermore, IRF7 
gene expression is also induced downstream of type I IFN transduction pathway, in 
a positive feedback loop which potentiates the IFN-a/p response. Interestingly, IRF7 
was first described in the context of EBV latency with further work confirming 
intimate close interaction between gammaherpesviruses and IRF7/3 signalling. 
Gammaherpesviruses are able to downregulate transcription of IRF7/3 or induce 
proteosome-mediated degradation of IRF7 (Bentz et al., 2010; Yu et al., 2005). KSHV 
in particular encodes viral proteins homologous of IRFs, which are associated with 
the inhibition of transactivation by IRF7 through protein-protein interactions (Joo et 
al., 2007). Conversely, IRF7 has been shown to inhibit KSHV reactivation, in vitro, by 
competing with Rta for ORF57 promoter transactivation (Wang et al., 2005a). 
Moreover, it has also been demonstrated that 1RF7 plays a crucial role in TLR- 
mediated reactivation of KSHV (Gregory et al., 2009).
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6.2 Experimental design
The presence of putative IRF3 and IRF7 binding sites in MHV-68 Rta has not been 
investigated before. Consequently^ the experimental approach undertaken in this 
chapter was aimed at investigating the likelihood that these two putative binding 
sites may modulate Rta promoter activity which may also be cell-type dependent. 
Therefore, the presence of these binding sites was studied in two murine fibroblasts 
cell lines - wild type NIH3T3 and an IFN-a/p receptor knockout mouse fibroblast cell 
line - and a B cell line (wile type A20). Three hundred base pair constructs were 
derived from the MHV-68 Rta promoter sequence between genomic positions 
65741 and 66041 coordinates, which contains a putative site for IRF7 and IRF3 
respectively. Four reporter constructs were produced in order to investigate how 
both putative binding sites modulated activation of the promoter. Of these, one 
contained both binding sequences while two other included either the IRF7 or IRF3 
putative site. The last construct was produced without any of these putative sites. 
These reporter constructs were cloned upstream of the luciferase gene in the 
reporter plasmid pGL3-basic and assayed for promoter activity in murine fibroblasts 
and B cells in response to endogenously expressed IRF7/IRF3.
6.3 Results
6.3.1 Generation of wild type and mutants of IRF3 and IRF7 binding sites within 
the MHV-68 Rta promoter
IRF7 and IRF3 putative binding sites were previously identified following promoter 
analysis by the software tool Matlnspector (chapter 3). In order to assess the effect
124
of each IRF factor binding site on basal promoter activity and in different cellular
environments, four 300 bp sequences derived from the MHV-68 Rta promoter 
region were cloned into a pGL3-basic luciferase reporter plasmid. The 300bp 
sequence between genomic positions 65741 and 65441 contains a putative binding 
site for each of IRF3 and IRF7 (fig 6.1 A). Using bioinformatics tools, substitution 
mutations were introduced in the Rta 300 bp promoter region which would render 
viral IRF3 and IRF7 binding sites non-functional, without affecting neighbouring 
transcription factor finding sites (fig 6.1 B). These constructs included a wild type 
like sequence with no substitutions; two sequences with either IRF7 or IRF3 
abrogated binding sites and double mutant sequence with no IRF7/3 functional site 
(fig 6.1 C). Each construct was transiently transfected into wild type murine 
fibroblasts (NIH3T3), in type I IFN-a/p R'/' and murine B cells (A20). Cells were 
harvested at 24 hours post-transfection. The luciferase activity of cell lysates was 
measured and normalized against renilla activity. Transfection efficiency was 
measured using a GFP-expressing control plasmid.
6.3.2 The basal activity of Rta promoter differs in different cells types and is IFN- 
dependent
The effect IRF7 and IRF3 in Rta transactivation was studied in three different cell 
lines. As described above, transactivation of each promoter was studied in murine 
NIH3T3 fibroblasts (representing immunocompetent cellular environment), murine 
fibroblasts with an abrogated type I IFN pathway and murine B cells. Initial study of 
each promoter transactivation was observed in NIH3T3 cells. Samples were 
harvested at 6,12, 24, 36 and 48 hours post transfection and assayed for promoter
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AGCTTCACAG
65761 CTATGACT TCC1
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CCCIAG CAiTACGTGC
ATGCACG
TGCTGGCCAC
ACGACCGGTG
GTCCAGGTAC TCGAAGTGTC 
CAGGTCCATG AGCTTCACAG
65941
IRF3
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65941 CTCAGCAAAT TC' CTCCTAA TTGCGC3GG2 ATAG 
GAGTCGTTTA AG1 GAGGATT AACGCGICC 3 TATC
:CTTTG
GAAAC
AAGACTACTG
TTCTGATGAC
GGTCCTCCAC
CCAGGAGGTG
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WTpGL3 
AIRF7pGL3 
AIRF3pGL3 
AIRF7/ AIRF3pGL3
Fig 6.1 Promoter constructs utilized in the analysis of the effect of putative IRF7 
and 3 binding sites in the modulation of Rta activation. A) DNA sequence of the 
300 bp region containing the IRF7 and IRF3 putative binging sites utilized. IRF7 
binding site is shown within blue boxes, whereas IRF3 site is shown in green boxes. 
B) Each binding site was analysed for possible substitution mutations able to 
abrogated IRF7/3 binding without influencing other binding events. The 
substitutions in each binding site are shown in the red boxes. C) The four reporter 
constructs produced; a wild type like promoter construct (WT) containing both 
binding sites, an AIRF7 promoter sequence with an abrogated IRF7 binding site, the 
AIRF3 construct with an abrogated IRF3 site and a AIRF7/ AIRF3 sequence with no 
functional IRF sites.
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Fig 6.2 Activation of 300 bp-derived promoter constructs in murine NIH3T3 cells.
Activation of each promoter construct was tested by transient transfection of 
NIH3T3 cells with a reporter plasmid harbouring the 300 bp sequence upstream a 
luciferase gene. Murine NIH 3T3 cells were transfected with two micro grams of 
reporter plasmids using Lipofectamine 2000. Control samples included cells 
transfected with the empty vector (pGL3-basic). The relative promoter activity of 
each region determined as fold change against empty vector activation. Comparison 
of promoter activation against the negative control demonstrated that relative 
promoter activity of the AIRF7, AIRF3 and AIRF7/3 constructs was the higher than 
the wild type like promoter (n=6 ± SD).
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activation (fig 6.2). Analysis of this fold activation, demonstrated the promoter with
mutated IRF3 and 1RF7 binding sites exhibited higher activity than the wild type 
promoter at all time points. Additionally, with the exception of 6 and 12 hours post­
transfection, there was no significant difference promoter activation between the 
three sequences with mutated IRF7/IRF3 binding sites. Transactivation of the four 
promoter constructs was also studied in the context of a non functional type I IFN 
response, because IRF7 and IRF3 have important roles in IFN-a/p signalling. The 
four constructs were transiently transfected into these cells. Sample were harvested 
at 6, 12 and 24 hours post transfection and analyzed for luciferase activity. 
Activation of the four constructs exhibited a different pattern in this cell line 
different to the results obtained from NIH3T3 cells (fig 6.3). In the absence of type I 
IFN signalling, abolishment of IRF7 and IRF3 binding sites did not cause promoter 
activation (fig 6.3). While abolishment of IRF3 putative site did not cause a 
significant change in promoter activity (with the exception of time point 6, when 
activity is lower than the WT promoter), activation of AIRF7 and AIRF7/3 promoter 
sequences was reduced compared to the wild type sequence. Furthermore, 
activation of WT and AIRF3 promoters occurred at similar levels with no statistical 
significant difference between these promoters. Interestingly, overall promoter 
activity of these constructs was weak when compared to promoter activity in 
NIH3T3. A third study, regarding activation of these promoters in murine B 
lymphocytes, was conducted in the A20 cell line. Optimization of the protocol 
allowed the establishment of a time point (24 hours post-transfection) when 
maximum promoter activation was observed. The time point was considered 
suitable for comparison with transactivation of these sequences in other ceil lines.
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Fig 6.3 Activation of 300 bp-derived promoter constructs in IFN-a/p R 
fibroblast. A) Activation of a reporter plasmid harbouring the 300 bp sequences 
upstream a luciferase gene in IFN-a/P R 7‘ fibroblats. Fibroblasts were transfected 
with two micro grams of reporter plasmids using Lipofectamine 2000. Control 
samples included cells transfected with the empty vector (pGL3-basic). Total cell 
lysate was isolated and assayed for luciferase activity over the time course using 
Tristar LB 941 DLR reader (Berthold Technologies). B) Relative promoter activity of 
each region determined as fold change against empty vector activation. Comparison 
of promoter activation against the negative control demonstrated that relative 
promoter activity of the WT and AIRF3 constructs was the highest observed in this 
study (n=6 ± SD).
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Fig 6.4 Activation of 300 bp-derived promoter constructs in murine B cells.
Activation of a reporter plasmid harbouring the 300 bp sequences upstream 
a luciferase gene in murine B lymphocytes. Fibroblasts were electroporated 
with five micro grams of reporter plasmids. Control samples included cells 
transfected with the empty vector (pGL3-basic). Relative promoter activity 
of each region determined as fold change against empty vector activation. 
Mutation of the IRF7 binding site produces a 10 fold reduction in 
transcription activation observed for AIRF7 and AIRF7/3 promoter 
sequences. Conversely, mutation of the IRF3 does not result in a significant 
change in promoter activation (n=9 ± SD).
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Activation of the four promoter sequences in murine B lymphocytes resembled the
overall pattern observed in IFN-a/fJ FT/' murine fibroblasts (fig 6.4). An interesting 
observation was that the activation profiles of all promoters were more 
pronounced in murine B cells. The WT and AIRF3 promoter sequences were 
transactivated at higher levels than the remaining constructs (16 and 11 fold 
activation respectively). Conversely; mutation of the IRF7 binding site in AIRF7 and 
AIRF7/AIRF3 promoter constructs produced a reduction in promoter activation (10 
fold decrease in activation compared to the WT sequence). Again, the 
transactivation observed for both promoters displayed similar levels between them.
6.4 Discussion
IRF7 and IRF3 are two important cellular components of the type I IFIM response. In 
addition, IRF7 was first described in the context of EBV infection and a close link has 
been demonstrated between IRF7 (and to some extent IRF3) and y-herpesviruses. 
Previous analysis of the MHV-68 Rta promoter demonstrated putative sites within a 
domain shown to be downregulated following type I IFIM treatment. This evidence 
prompted an interest in understanding if modulation of Rta promoter by 
endogenous IRF7 and IRF3 occurred and possible outcomes of this modulation. In 
order to test this hypothesis, 300 bp promoter constructs were constructed from 
the MHV-68 Rta full length promoter either containing the putative binding sites for 
IRF7 and IRF3 or mutated IRF3 and IRF7 binding sites. Analysis of the activation of 
these promoters in NIH3T3 fibroblasts revealed that loss of IRF7 and IRF3 sites 
results in upregulation of promoter activity. This suggests that binding of cellular 
IRF7 and IRF3 to cognate binding sequences in the viral Rta promoter would
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suppress activation of the promoter. Of relevance here is the observation that IRF7 
expression is induced by IFN-a/p signalling (Honda et al., 2005b), therefore 
providing an explanation for the results observed above regarding Rta 
downregulation following type I IFN treatment. Interestingly, these are in contrast 
to data obtained from transfection of fibroblasts with an abrogated IFN-a/P 
signalling pathway and B lymphocytes (following a similar rationale). In these cell 
types, abolishment of the IRF7 binding site did not enhance promoter activation but 
rather reduced it. In addition, it was shown that abrogation of the IRF3 binding site 
caused no difference in promoter activation in these cells, it is interesting that the 
activation profiles between promoter constructs drew a parallel outcome between 
fibroblasts with no functional type I IFN and wild type B cells (A20 cell line). The 
evidence gathered here suggests modulation of Rta promoter by IRF7 and IRF3 is 
cell type and/or cell environment-dependent and occurs differently between 
fibroblasts and B cells (fig 6.5). In fibroblasts, endogenous expression of both 1RF7 
and IRF3 appears to have a suppressive effect on Rta activation in vitro. Considering 
Rta is the key lytic switch responsible for triggering the lytic gene cascade, inhibition 
of its transcription will then result in replication arrest. However, in B cells 
endogenous IRF7 produces the opposite effect enhancing Rta expression in vitro, 
whereas IRF3 has no significant effect on promoter activation. Activation of MHV-68 
Rta promoter by endogenous IRF7 confirms a previous study which demonstrated 
that TLR-mediated reactivation of KSHV is dependent on IRF7 (Gregory et al., 2009). 
A second study also produced evidence that TLR-mediated activation occurs in the 
context of MHV-68 infection, but in this case no interaction between IRF7 and the
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virus was demonstrated (Gargano et al., 2009). The study presented here suggests
that a similar mechanism might occur in this case.
/?to promoter
Fibroblasts
Replication
Rta promoter
B cells
Replication
Fig 6.5 Modulation of Rta by IRF7 and IRF3 is cell dependent and varies between 
fibroblasts and B lymphocytes. Endogenous IRF7 and IRF3 were shown to reduce 
Rta promoter transcription activation in vitro in fibroblasts. However, a similar study 
performed in B cells demonstrated that, while IRF3 has no significant effect in the 
modulation of Rta promoter, IRF7 is able to enhance Rta transcription activation.
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Characterization of the putative MHV-68 Rta IRF7 binding site
7.1 Introduction
Since its discovery, 1RF7 has elicited much interest which in turn has resulted in an 
extensive body of evidence. The protein itself has been best described, for obvious 
reasons, in both human and mouse but additional research have also produced 
work regarding other vertebrates (Huang et al., 2010). Characterization of human 
and mouse IRF7 revealed the protein to be comprised of a DNA binding domain 
(DBD), a transactivation domain, an inhibitory domain (ID) and a regulatory or signal 
response domain. Transactivation by the protein follows phosphorylation of 
particular serine residues in the regulatory domain. Phosphorylation of these 
residues allows dimerization and translocation to the nucleus, thus activating it 
(Caillaud et al., 2005; Lin et al., 2000b; Marie et al., 2000). Also of particular 
importance, the DBD (characteristic of the IRF family) contains a helix-turn-helix 
motif and binds a distinct consensus sequence NNGAAANNGAAANN, specifically 
recognizing the GAAA motif. The DBD secondary structure is shared among IRFs, 
which results in a high degree of similarity between binding sequences recognized 
by members of this family (Escalante et al., 1998; Taniguchi et al., 2001). Data 
presented in previous chapters clearly indicate a pivotal role by IRF7 in Rta 
activation. Functional binding between IRF7 and the putative site in MHV-68 Rta 
promoter were initially done in luciferase based co-transfection assays in murine 
fibroblasts and in cells with an abrogated type I IFN pathway. The 300 bp promoter 
constructs containing the IRF7 putative site derived from the Rta promoter were co-
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transfected with a murine phosphomimetic IRF7 construct and assayed for
promoter activation.
7.2 Experimental design
Functional binding between IRF7 and the putative site in MHV-68 Rta promoter 
were initially done in luciferase based co-transfection assays in murine fibroblasts 
and in ceils with an abrogated type I IFN pathway. The 300 bp promoter constructs 
containing the IRF7 putative site derived from the Rta promoter were co­
transfected with a murine phosphomimetic IRF7 construct and assayed for 
promoter activation. This study was then followed by gel autoradiography assays to 
demonstrate physical interaction between IRF7 and the Rta promoter. Therefore^ 
murine cells were transiently transfected with the plasmid expressing a 
phosphomimetic IRF7 (IRF7p). This was followed by isolation of nuclear material 
from these cells to be used as substrate in EMSA assays with a radio-labelled 
oligomer containing the IRF7 binding site.
7.3 Results
7.3.1 Construction of a functional murine phosphomimetic IRF7
Production of a murine phosphomimetic IRF7 construct was initially described by 
Caillaud et alv 2005. In this study, substitution of serine to aspartic acid residues in 
positions 429-431, 437, 438 and 450 produced a constitutively active IRF7 (fig 7.1). 
The engineered cDNA sequence was submitted to MWG biotech for gene synthesis. 
The construct was supplied within a pBluescript phagemid. However, pBluescript is
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mainly used in cloning experiments and was not primarily designed for expression 
studies in transfection assays. Due to this, the IRF7p gene was retrieved from this 
plasmid by double restriction digestion, followed by gel extraction and cloned into a 
pDRIVE-mEFl a expression vector generating the pDRIVE-IRF7p plasmid. Expression 
of the insert in pDRIVE-mEFl is driven by the murine elongation factor 1 alpha 
(mEFla) promoter, described as an ubiquitous mammalian promoter (Kim et al., 
1990). Synthesized IRF7p was isolated from pBluescript by double restriction 
digestion with Acc65l and Bsu36l, inserted upstream and downstream the gene 
sequence during synthesis, respectively (the multiple cloning sites were not 
compatible between vectors). The products of this restriction reaction were 
separated by electrophoresis in a low melting gel (fig 7.4). The IRF7p insert was 
identified due to size and recovered by gel extraction. The expression vector pDRIVE 
was then linearised, also by double restriction with Acc65l and Bsu36l, creating 
cohesive ends and allowing the insertion of the IRF7p gene. The digestion product 
was retrieved by gel extraction following electrophoresis (fig 7.4 A). Blue and white 
selection allowed further selection of six colonies. Four colonies were selected 
following restriction digestion of plasmids isolated from these colonies (fig 7.4 B) 
and sent for sequencing. Sequencing of the four clones allowed the selection of a 
clone (clone 14) whose sequence matched the cDNA sequence initially sent for 
synthesis.
7.3.2 Assessment of phosphomimetic IRF7 bioactivity
IFN-a6 gene expression has been shown to be induced by IRF7 (Marie et al., 1998). 
Therefore, the bioactivity of IRF7p was assayed through activation of murine IFN-a6
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Fig 7.1 Phosphomimetic murine IRF7 gene. Substitution of serine residues at 
positions 429-431, 436, 438 and 450 (signalled by dark arrows) produces a 
constitutively active form of IRF7.Based on the production of this phosphomimetic 
IRF7 construct, a DNA sequence derived from the cDNA sequence submitted in 
GenBank, accession number NM_016850, with the specific codon substitutions was 
generated. Translation of this sequence into the phosphomimetic IRF7 form (IRF7p) 
was predicted through analysis utilizing the NEBcutter V2.0 online tool (fig 7.2).
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A)
cDNA sequence
IRF7p - GAGAAGACCCTGATCCTGGTGAAGCTGGAGCCATGGGTATGCAAGGCATACCTGGAGGGC 1260 
IRF7 - GAGAAGACCCTGATCCTGGTGAAGCTGGAGCCATGGGTATGCAAGGCATACCTGGAGGGC 1260
IRF7p - 
IRF7 -
IRF7p - 
IRF7 -
GTGCAGCGTGAGGGTGTGTCCTCCCTGGi
GTGCAGCGTGAGGGTGTGTCCTCCCTGGi
:gacgacgac
:agcagcagt
:tcggcttgtgcttg
ITCGGCTTGTGCTT
GACGAC
CTAGCGT★★★★★★★★★★★★★★★
1320
1320
ACCAACG, iCCT :TACGAAGACATCGAACACTTCCTCATGGACCTGGGTCAGTGGCCTTGA 1380 
ACCAACAl iTCT;TACGAAGACATCGAACACTTCCTCATGGACCTGGGTCAGTGGCCTTGA 1380
IRF7p - CTCAGAATCCCAACTCCCAATAAATAGTTCATCTAGACCTAAGG 1424
IRF7 - CTCAGAATCCCAACTCCCAATAAATAGTTCA-- AAATC----- 1416
★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★ ★ ★ ★
B)
Peptide sequence
IRF7 -FSTFFRELEEFRARRRQGSPHYTIYLGFGQDLSAGRPKEKTLILVKLEPWVCKAYLEGVQ 420 
IRF7p-FSTFFRELEEFRARRRQGSPHYTIYLGFGQDLSAGRPKEKTLILVKLEPWVCKAYLEGVQ 420
IRF7 -REGVSSLdsSstGLCl[sstl|slYEDIEHFLMDLGQWP 457 
IRF7p-REGVSSLI DDDLGLCl|DEjrf|DjJYEDIEHFLMDLGQWP 457 
★★★★★★★★ ★★★★★ ★★ ★★★★★★★★★★★★★★★★
Fig 7.2 IRF7 phosphomimetic mutant cDNA and peptide partial sequences. A)
Alignment between the IRF7 wild type and phosphomimetic IRF7 cDNA sequences. 
The IRF7 cDNA sequence was retrieved from the GenBank database (accession 
number: NM_016850). The codons encoding serine residues in positions specified in 
Caillaud et al., 2005 were substituted by codons encoding for aspartic acid residues, 
shown here within the boxes. B) The peptide sequence was predicted by the online 
tool NEBcutter V2.0 and aligned with the wild type IRF7 peptide sequence. The 
alignment demonstrated the predicted codon substitutions could translate into 
aspartic acid residues in the correct positions.
139
A)
bp |
10000
8000
6000
5000
40jj|
2500
2000
1500
1200
1000
ad
500
1- Ladder
2- pBluescript-IRF7p
3- pBluescript-IRF7p
4- pBluescript-IRF7p
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Fig 7.3 Subcloning of murine IRF7p gene. A) DNA ladder employed for 
determination of the size of DNA fragments in cloning protocols (Fermentas, UK, 
Cat No. SM331. The pBluescript-IRF7p vector was submitted to a double restriction 
digestion with Acc65l and Bsu36l. B) Four different digestions were prepared with 
the products of these reactions being separated through electrophoresis. The IRF7p 
insert was recovered by gel extraction. The picture shows the products and the 
different sizes measured against the DNA marker. The bands at 3.0 Kbp represent 
the pBluescript vector (2961 bp in total), while the smaller bands with 1.5 Kbp 
correspond to the insert (1424 bp).
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7- Clone 14
Fig 7.4 Linearization of the expression plasmid pDRIVE-mEFla and ligation 
reactions. A) The pDRIVE-mEFla vector was submitted to a double restriction 
digestion with Acc65l and Bsu36l. Four different digestions were prepared with the 
products of these reactions being separated through electrophoresis. The picture 
shows the products measured against a DNA marker. The DNA fragment was shown 
to approximately 6.0 Kbp long, the predicted size of the expression plasmid (6051 
bp). B) Transformation of competent cells with the ligation reactions between 
pDRIVE-mEFla and IRF7p gene produced 14 colonies of which six were singled out 
(colonies number 7, 8, 11, 12, 13 and 14), following blue and white selection. 
Restriction digestion of the plasmids isolated from these colonies allowed further 
selection of 4 clones (clones 7, 8, 11 and 14) for confirmation by sequencing. Clone 
12 was shown to be the empty plasmid with 6.0 Kbp, whereas clone 13 appears to 
have multiple inserts (DNA marker is shown in fig 7.3 A).
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promoter in IFN-a/p R'/" murine fibroblasts (fig 7.5). Transcriptional activation of 
the IFN-a6 by IRF7p increased in a dose-dependent manner. Furthermore, increase 
of promoter activation was not observed in samples co-transfection with the IFN-a6 
reporter and empty expression plasmid. The study showed the phosphomimetic 
mutant was bioactive.
7.3.3 Characterization of activation of MHV-68 Rta promoter by exogenously 
expressed phosphomimetic IRF7
The evidence, produced in previous in vitro work, demonstrated that endogenous 
IRF7 could be involved in activation of Rta promoter in specific cell environments. In 
order to address further Rta promoter activation by IRF7, the 300 bp wild type 
constructs- derived from Rta promoter and containing putative IRF7 and IRF3 sites, 
were co-transfected with the phosphomimetic IRF7 plasmid. The co-transfection 
study was carried out in IFN-a/p R"/' murine fibroblasts and in a dose-dependent 
fashion (fig 7.6). The rationale here was that these cells will have residual IRF7 
activity. Cells were transfected with two micrograms of the reporter plasmid and 
increasing amounts of the IRF7 expression vector. The overall results showed 
transcriptional activity was inhibited by IRF7p. Co-transfection of the promoter 
construct with lRF7p resulted in lower levels of luciferase activity compared to the 
negative control (co-transfection with the empty expression plasmid), with the 
exception of a single time point at 12 hours post transfection where samples were 
co-transfected with one microgram of IRF7p (fig 7.6 A). Although it was readily 
observed that lRF7p reduced transcription of the reporter construct, inhibition of 
activity in a dose dependent fashion was not irrefutably observed.
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Fig 7.5 Transcriptional activation of the IFN-a6 promoter by phosphomimetic 
IRF7p. IFN-a/p R"/' murine fibroblasts were co-transfected with two micrograms of 
a reporter construct harbouring the IFNa6 promoter upstream a luciferase gene 
and increasing amounts of an expression plasmid harbouring IRF7p gene. Negative 
controls were prepared by co-transfection of the reporter construct with the empty 
expression plasmid. Increase in IFNa6 promoter activation was correlated with an 
increase in IRF7p amount, demonstrating the construct is constitutively active (n=9 
±SD).
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However, fold change of promoter activity, as determined against the negative 
control, showed an inhibition of promoter activity with increasing amounts of lRF7p 
at 12 hours. At 24 hours the change in transcription inhibition was not significant 
possibly due to an outlier replicate (fig 7.6 B). A second co-transfection assay was 
performed in IFN-ot/p R'f murine fibroblasts, to assess IRF7 effect on Rta promoter 
activity. The 300 bp promoter employed in the previous study, derived from the Rta 
promoter, contains 2 similar IRFs putative sites specific for IRF7and IRF3, 
respectively. Both sites are similar in sequence due to the nature of the 
characteristic DBD in the IRFs transcription factors family, particularly the GAAA 
motif which plays an important role in IRFs DNA binding. Site specificity was 
examined by assessing transcriptional activity of two other 300 bp promoter 
constructs by exogenous IRF7p, derived from the Rta promoter as described above. 
The two promoter constructs contained either IRF7 or IRFS mutated sequences 
(AIRF7 and A1RF3, respectively) allowing for differentiation between these two sites 
because of IRF7p. The promoter constructs were co-transfected with an expression 
plasmid harbouring the IRF7p in IFN-a/p R'/' murine fibroblasts, and transcriptional 
activation analysed at 24 hours post transfection (fig 7.7 A). The study showed the 
AIRF7 promoter activation was not altered in the presence of IRF7p, but AIRF3 
reporter construct in the presence of phosphomimetic IRF7 resulted in reduced 
promoter activity (7.7 B). Promoter inhibition by exogenous expression of 
phosphomimetic IRF7 was observed for the 300 bp promoter containing both IRF7 
and IRF3 binding sites.
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Fig 7.6 Transcriptional activation of Rta promoter by exogenous IRF7p. A) IFN-a/p 
R'/' murine fibroblasts were co-transfected with two micrograms of a reporter 
construct harbouring the IFNa6 promoter upstream a luciferase gene and either 
one or three micrograms of an expression plasmid harbouring IRF7p gene. Negative 
controls were prepared by co-transfection of the reporter construct with the empty 
expression plasmid. Analysis of luciferase activity was reduced in the presence of 
IRF7p, in both experiments. However, B) determination of fold change between the 
different doses did not exhibit a conclusive dose-dependent effect on promoter 
activity. Although inhibition of promoter activity by IRF7p in a dose dependent 
manner was observed at 12 hours post-transfection, samples collected at 24 hours 
pt did not exhibited a similar definite pattern (n=9 ± SD).
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Fig 7.7 Transcriptional activation of Rta promoter by IRF7p. A) IFN-ct/p R / murine 
fibroblasts were co-transfected with two micrograms of 300 bp reporter constructs 
containing either the IRF7 or the IRF3 putative binding sites and three micrograms 
of an expression plasmid harbouring IRF7p gene. Negative controls were prepared 
by co-transfection of the reporter construct with the empty expression plasmid. Co­
transfection with IRF7p did not produce a change in activation in the AIRF7 
sequence. Nevertheless, activation of AIRF3 sequence was reduced in the presence 
of IRF7p. B) Fold change of the promoter activity across the wild type, AIRF7 and 
AIRF3 promoter sequences presents a similar picture. Activation of the promoter is 
only reduced by IRF7p in sequences that contain the putative IRF7 binding site (n=9 
±SD).
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Abolishment of the IRF7, but not IRF3 binding site, resulted in similar promoter 
activities, in the presence or absence of IRF7p. Conversely abrogation of IRF3 but 
not IRF7 binding site, rescued the reduction of promoter activation by exogenous 
expression of IRF7p.
7.3.4 Can putative viral IRF7 binding site interact with IRF7 protein?
Data presented in this study clearly shows that the putative IRF7 binding site in the 
MHV-68 Rta promoter region appears to play a pivotal role in Rta activation and 
also appears to be cell-type (and type 1 IFN)-dependent.
However, functional binding of described putative sites is a crucial step in 
characterization the interaction between a particular DNA binding protein and a 
promoter sequence. Several biochemical assays are available to determine physical 
binding of a protein to DNA, including footprinting, electrophoretic mobility shift 
assay (EMSA) or CHIP on chip analysis. The functional binding of IRF7 and Rta 
promoter was investigated using the EMSA assay, through interaction with 
radiolabelled probes in a polyacrylamide gel. If the protein binds the DNA sequence, 
a shift in probe migration is observed (Heilman and Fried, 2007). Specificity of the 
binding can also be assayed by competition reactions with unlabelled (cold) probes 
and probes containing a mutant version of the putative binding site. If the binding is 
unspecific, the band representing the DNA-protein complex will become fainter 
with increasing amounts of cold probe. Two 21 bp probes containing the putative 
NHV-68 Rta IRF7 binding sequences were submitted to MWG biotech for synthesis. 
The wild type probe included the full version of the IRF7 site, whereas a mutant 
probe was comprised of the abrogated site described below (fig 7.8).
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Wild type probe 5' tgctgaaaaggaagtcatcga 3'
Mutant probe 5' tgctgcccaggaagtcatgga 3'
Fig 7.8 DNA probes developed for gel autoradiography assay. 21 bp DNA probes 
were synthesized containing different versions of the IRF7 binding site described in 
MHV-68 Rta promoter. The wild type probe includes the putative IRF7 binding site, 
while the mutant probe is comprised of a mutated IRF7binding site displayed as 
cytosine substitutions in red, predicted to render the binding site non-functional.
Nuclear extracts were obtained by transfection of IFN-a/P R'/" murine fibroblasts 
with the iRF7p expression plasmid. Competition assays included binding reactions 
with cold wild type and mutant probes (not tagged with v[32P]-dATP). The products 
of the binding reaction were separated by electrophoresis in a polyacrylamide gel 
and then exposed in film. No specific band representing functional binding between 
IRF7p and the promoter was observed, even upon trouble shooting and 
optimization of the methodology.
7.4 Discussion
Transcriptional activation of Rta promoter by a constitutively active form of IRF7 
was studied in IFN-a/fJ R'/" murine fibroblasts. Evidence provided in chapter five 
demonstrated that treatment with IFN-a/p results in repression Rta promoter. 
Thus, in vitro work in IFN-a/P R"/" murine fibroblasts allowed a suitable cellular 
environment for the analysis of Rta promoter activation by IRF7 (IRF7 has been 
shown to induce IFN signalling, which could then interfere with Rta promoter 
activation). These cells were transfected with a plasmid constitutively expressing 
the murine phosphomimetic IRF7 protein (IRF7p) and whose activation was
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independent of IFN signalling pathway. The evidence gathered in this study shows 
that exogenous expression of IRF7p downregulates a 300 bp construct derived from 
MHV-68 Rta promoter, containing the putative IRF7 and IRF3 binding sites. 
Furthermore, it was demonstrated that inhibition of promoter activation by IRF7 
only occurred when the specific putative binding site was present. Taken together, 
these results confirmed that down-regulation of the Rta promoter fragment which 
includes IRF3 and 1RF7 binding sites was IRF7-dependent. These observations are 
the first indications that a portion of MHV-68 Rta activity is modulated by IRF7.
IRF7 is primarily a transcription factor, involved in upregulation of gene expression 
of a responsive gene. Mechanisms by which IRF7 represses transcription of a given 
promoter are still poorly understood, although previous studies have demonstrated 
such mechanisms do exist. Dimerization of IRF7 with IRF5 leads to repression of IFN 
promoter transcription, while downregulation of KSHV ORF57 by competition with 
Rta for the same response element has been shown. IRF7 also downregulates EBV 
Qp promoter, supposedly by competition with IRF1 for the same binding site, but 
none of these lines of evidence present a suitable explain for the results observed. 
Although indirect evidence presented in this study clearly shows a role for IRF7 in 
modulating the MHV-68 Rta activity, our repeated attempts using the EMSA to 
show a physical interaction between the MHV-68 Rta-encoded IRF7 binding site and 
IRF7 expressed from a plasmid vector proved unsuccessful. There are a number of 
possible explanations for this outcome, one of which is the hindrance of the protein 
complexes migrating into the gel. Therefore, further optimisation of this technique. 
However, other strategies may prove more successful. These alternative avenues
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include the production of a recombinant IRF7p protein for use in footprinting and or 
electrophoretic mobility shift assays.
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Gammaherpesviruses are double-stranded DNA viruses of medical and veterinary 
importance and have been biologically characterized by their ability to infect cells of 
the immune lineage and by association with tumours. Examples include human 
gammaherpesviruses (Epstein-Barr virus, EBV, and Kaposi's sarcoma herpesvirus, 
KSHV) as etiological agents for several malignancies correlated with a compromised 
immune system (Virgin et al., 1997). EBV is associated with lymphomas and 
nasopharyngeal carcinoma (David M. Knipe, 2007; Gulley et al., 1993; Weiss et al., 
1987; zur Hausen et al., 1970) and KSHV is associated with Kaposi's sarcoma, body 
cavity-based lymphomas and multicentric Castleman's disease (Cesarman et al., 
1995; David M. Knipe, 2007; Soulier et al., 1995). A notable feature of infection with 
these viruses is their very narrow host range limiting the study of human 
gammaherpesviruses in their natural host. Therefore, animal models have been 
develop in which pathogenesis of gammaherpesviruses maybe be better studied. 
The murine gammaherpesvtrus-68 (MHV-68) is a gammaherpesvirus of murid 
rodents which readily infects laboratory mice providing a tractable system for 
analysis of acute and chronic pathogenesis (Nash et al., 2001). Like all 
herpesviruses, gammaherpesviruses are able to establish latency in specific cell type 
(mainly B lymphocytes) with lifelong viral persistence, while retaining the ability to 
undergo reactivation and replication in response to specific cellular and viral 
signalling events (David M. Knipe, 2007). A key viral transcription factor, Rta, 
encoded by ORF50, is responsible for the viral lytic replication and it is the
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molecular switch which can singularly reactivate the virus from latency (Chen et al., 
2000; Lukac et a!., 1999; Lukac et al., 1998; Song et al., 2003; Song et al., 2002; 
Zhang et al., 1998). As such, the promoter driving the ORF50 expression is a main 
target for cellular and viral factors that determine the establishment of latency and 
virus reactivation. Therefore, defining stimuli involved in reactivation from latency 
remain a fundamental question in herpesviruses biology to-date.
The purpose of this study was to characterize how Rta may be modulated which 
may explain the pivotal role played by Rta in virus lytic infection and reactivation 
from latency. Initial sequence analysis of the Rta promoter identified several 
putative binding sites for cellular factors most commonly associated with type I 
interferons which are important components of the innate immune system. 
Detailed analysis of a IVIHV-68 1.2 Kbp genomic sequence upstream of ORF50, 
previously described as its promoter (Rickabaugh et al., 2005), was carried out by 
Matlnspector software tool. This detailed analysis identified an array of potential 
interactions between cellular factors and the Rta promoter. Some of these binding 
sites have been previously documented (Yu et al., 2007) demonstrating a multitude 
of signalling pathways which could modulate the Rta promoter and therefore play a 
role in virus lytic cycle as well as reactivation from latency. Furthermore, analysis of 
these promoter binding sites revealed functional regulatory sites that have been 
shown to modulate transcription activation of Rta promoter not only in IVIHV-68 but 
also in EBV and KSHV. Interestingly, several binding sites associated with innate 
immunity antiviral response were identified in the promoter analysis (fig 8.1). MHV- 
68 Rta transcription is downregulated by both STAT1 response elements, albeit in 
the context of type II IFN signalling, and NF-kB is involved in the establishment of
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latency in B cells by repression of Rta gene expression (Brown et al., 2003; Goodwin 
et al., 2010). API is responsible for activation of Rta expression following induction 
of cellular signalling pathways by TPA (Wang et al., 2004), while in vitro work 
demonstrated that IRF7 may mediate activation or repression of Rta promoter in 
different infection stages (Gregory et al., 2009; Wang et al., 2005a).
-1230 bp -i_ I
STATl
Fig 8.1 Diagram representing the presence of putative binding sites in Rta 
promoter and associated with innate immunity. API, NF-kB, IRF7 and IRF3 and 
Ikaros 1 are all cellular factors that, upon stimulation of toll-like receptor 
transduction pathway participate in the activation of type I IFN gene expression. 
STATl, IRF1 and 1RF7 have been shown to be either induced or activated in the 
context of the type I IFN transduction pathway.
To assess the likelihood of how these putative binding sites may impact on MHV-68 
Rta promoter activity, murine cells were transfected with Rta promoter and its 
truncated versions(-1.2 Kbp, -1019 bp, -391 bp and -211 bp). As shown in chapter 
four, examination of Rta transcription activation, allowed characterization of 
regulatory domains in response to endogenous cellular activation within this 
promoter (fig 8.2 A). Two negative regulatory domains were identified between 
genomic positions 65530-65740 and 66360-66549. Transcription inhibition in both 
regions has already been characterized by a previous study which demonstrated 
STAT 1, following type II IFN signalling, was responsible for the observed 
downregulation (Goodwin et al., 2010). The remaining regions, between positions 
65740-66360 and 66540-66760, were characterized as positive regulatory domains
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due to their high promoter activation property and on deletion of the negative 
regulatory domain immediately upstream of the Rta start site. Several putative 
binding sites predicted within these two regions could be responsible for this 
activation, including CBP, RBP-Jk, API or MEF2. Interestingly, activation of these 
four truncated promoters by Rta protein exhibited the same pattern. Furthermore, 
it showed the positive regulatory domains were highly upregulated by Rta, even in 
the absence of Rta specific response elements. These results suggested activation of 
MHV-68 Rta promoter can be mediated by cellular proteins and in the absence of 
Rta. Previous analysis of the promoter sequence revealed several candidate sites, 
shown to be responsive to activation complexes involving Rta and cellular factors 
(fig 8.2 B). These included a CBP site within positions 66032-66046, a RBP-Jk 
response element (66249-66261) containing a sequence similar to previously 
described response elements involved in activation of viral promoters by Rta-RBP-Jx 
protein complex (Liang et al., 2002) and several OCT1 sites, demonstrated to play an 
important role in Rta auto-activation in KSHV (Sakakibara et al., 2001). However, 
putative OCT1 sites and a sequence bearing a degree of homology to a RRE have 
also been described within the domains exhibiting no transcription activation. 
Repression of activation by STAT factors in both regions could have detrimental 
effect on Rta auto-activation and impair transcription activity. However, further 
work is necessary to understand fully both the interaction between Rta protein and 
cellular transcription factors in Rta promoter auto-activation and the functionality 
of these binding sites. It is generally accepted that cells grown in vitro are not 
subject to tight signalling regulation observed in vivo. It is also known that cells 
grown in vitro have basal IFN activity. This is well demonstrated in cases where
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virus infection in vitro may be significantly enhanced by the use of neutralising
antibodies to type I interferons (IFNs).
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Fig 8.2 Regulatory domains within Rta promoter in response to cellular basal and 
Rta activation. A) Basal activation of four truncated promoter constructs allowed 
the characterization of four regulatory domains. Transcription activation of 
promoter regions between 65530-65740 and 66360-66549 was inhibited, 
presumably by STAT transcription factors, while regions between 65741-66369 and 
66549-66760 shown upregulation of their promoter activity. B) The 65741-66369 
and 66549-66760 promoter regions were demonstrated to be activated by Rta. 
Candidate responsive sites for complexes between Rta and cellular transcription 
factors are shown.
This is relevant since Rta promoter contains an array of putative binding sites for 
cellular transcription factors most closely related to type I IFNs. A similar 
investigation into Rta promoter activity was carried out in murine fibroblasts which 
do not express the functional IFNAR2 subunit of the IFN receptor. This mutation 
abrogates the type I IFN signalling pathway. Both basal and Rta activation of the 
four promoter constructs were investigated in this cellular environment. 
Interestingly, analysis of basal activation of the four reporter constructs 
demonstrated that Rta promoter was poorly functional in these cells, when
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compared to immunocompetent N1H3T cells. These observations further support 
the notion that cells grown in vitro have residual anti-viral activity because of type I 
IFNs. All promoter sequences with the exception of the reporter construct 
comprising the 66549-66760 domain, which was in turn weakly active, exhibited no 
transcription activation compared to the negative control. These results suggested 
the transactivation observed earlier could be dependent (to some extent) on 
signalling by IFN-cx/P, which include the JAK/STAT and p38/JNK transduction 
pathways. The JAK/STAT pathway might have a possible role in modulation of Rta, 
albeit a negative one, as activation of STAT factors results in downregulation of this 
promoter. Conversely, activation of p38/JNK mitogen-activated protein kinase 
(MARK) pathway by TPA has been shown to induce reactivation of KSHV in vitro, 
through API-mediated upregulation of Rta (Xie et al., 2008). Analysis of activation 
of these pathways by IFN, and the consequent interaction with Rta promoter could 
explain, at least in part, the transactivation pattern observed in this study. These 
results clearly suggest that modulation of Rta promoter by type I IFN signalling is a 
complex one, the mechanisms of which warrant further investigation.
In order to gain insight into modulation of Rta promoter by type I IFNs, basal 
transactivation of the four promoter constructs, following treatment with IFN-a/P, 
was examined (chapter five). Comparison of fold-activation of these constructs with 
respective promoter activity observed in previous experiments (chapter four) 
demonstrated that the region between positions 65740-66360 was downregulated 
following IFN-a/P treatment. Whereas fold-activation of the remaining promoter 
remained similar between experiments, the -1019 bp sequence exhibited a ~ 4 fold 
decrease in relative promoter activity. This sequence contains a previously
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confirmed STAT functional site involved in inhibition of Rta promoter in the context
of IFN-y, which could explain the phenotype observed in the current study. 
However, analysis of this region for putative binding sites associated with the type I 
IFN transduction pathway also revealed 1RF7 IRF3 putative binding sites (fig 8.1). 
Both IRF7 and IRF3 play an important role in the stimulation of IFN-ct/pJ gene 
expression and IRF7 expression is further upregulated by type I IFN signalling 
pathway in a positive feedback loop. Furthermore, IRF7 appears to be involved in 
modulation of reactivation of KSHV, with different outcomes dependent on the 
context of studies reported (Gregory et al., 2009; Wang et al., 2005a). These lines of 
evidence, together with the results observed following IFN-a/3 treatment 
suggested IRF3 and IRF7 putative binding sites (say which chapter) could also play a 
role in modulation of Rta promoter.
In order to assess the potential role of IRF3 and IRF7 sites identified within the 
MHV-68 Rta promoter, a series of 300 bp promoter sequences were constructed 
from the full length MHV-68 Rta promoter sequence. The constructs, comprised of 
Rta promoter sequences between positions 65741-66041 contained either 
functional or site-directed mutation versions of IRF7 and IRF3 binding sites. Initial 
studies shown in chapter six examined the presence or absence of IRF3 and IRF7 
sites in Rta promoter activity in wild type murine fibroblasts (NIH3T3 cells), in 
murine fibroblasts without type I IFN signalling and in murine B cells (A20). The 
results demonstrated IRF7 and IRF3 sites played a role in modulation of Rta 
promoter activity. These lRF3/IRF7-mediated promoter activities were also cell 
type-dependent. Lack of IRF7 and IRF3 binding sites resulted in activation of 
promoter activity in NIH3T3 cells, suggesting these binding sites were involved in
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inhibition of the promoter transcription in this ceil type. A different outcome was 
observed in B cells and IFN-a/p FT/' fibroblasts. In these cell lines; IRF3 did not play a 
role in Rta promoter activity when this binding site was mutated. Flowever, 
abrogation of the IRF7 putative site caused a reduction in Rta promoter activity, 
suggesting that, at least in these cells, the IRF7 binding site is implicated in the 
upregulation of Rta promoter. Interestingly, the activation profile between 
promoter constructs was similar between fibroblasts with no functional type I IFN 
and wild type B cells. This is partly explained by the fact that in B cells efficient 
internalization of TLR is dependent on binding of the B cell receptor (BCR) or the 
immunoglobulin G Fc receptor (FcyR) 1IA (Lanzavecchia and Sallusto, 2007). 
Otherwise, B cells have a low level of fluid endocytosis and are poorly phagocytic 
suggesting stimulation of DNA - and RNA-recognizing TLRs is tightly regulated. 
Consequently, induction of type I IFN gene expression following activation of TLRs in 
B cells resembles fibroblasts with no functional type I IFN and induction of IRF7 by 
basal type I IFN is minimal. Such results warranted further biochemical 
characterisation to show a bona fide viral IRF7 binding site which can interact with 
murine IRF7 protein. For this reason, the functionality and specificity of the IRF7 
binding site were studied, first by analysis of the effect on promoter activation of 
exogenous expression of a constitutively active IRF7 protein (IRF7p) in IFN-ot/p R'/' 
fibroblasts. Absence of type I IFN pathways in these cells guarantees that Rta 
promoter activation is independent of type I IFN-signalling. Interestingly, 
examination of promoter activity in this study demonstrated that expression of 
IRF7p resulted in repression of promoter activity in these cells. This study also 
showed the reduction in promoter activation was site specific, because abrogation
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of IRF7 by site-directed mutagenesis, but not the IRF3 binding site, rescued Rta 
promoter activation to levels observed in cells not expressing the exogenous IRF7. 
Therefore, the evidence produced indicated that the promoter sequence containing 
the putative IRF7 site was indeed functional and imposed a phenotype on Rta 
promoter activity. Physical interaction between MHV-68 Rta promoter and IRF7 was 
additionally assessed by EMSA assays, but repeated attempts did not reveal the 
expected DNA-protein complex. Further optimization of EMSA or, alternatively, 
investigation of this subject with different methodology will be required to show 
conclusively that the putative IRF7 binding site identified in this study can physically 
interact with IRF7 protein.
In summary, data presented in this thesis provide a detailed molecular 
characterisation of the MHV-68 Rta promoter and how different cellular 
environments may impact on the activity this vital vial promoter. The work 
produced here clearly implicates IRF7 in modulation of MHV-68 Rta promoter. As 
mentioned above, IRF7 plays a critical role in the type IIFIM innate immune response 
to viral infections, as recent work has demonstrated IRF7 (but not IRF3) is a non- 
redundant critical factor in induction of both IFN-a and IFN-|3 expression in vitro and 
in vivo. The same study has also suggested that IRF7 expression is ubiquitous but at 
very low levels, possibly induced by basal IFN-a/(3 activity (Honda et al., 2005b; 
Honda et al., 2005c; Randall and Goodbourn, 2008). Therefore, IRF7 provides a 
bottleneck and as such is of obvious interest as a target for several viruses 
(including gammaherpesviruses, rotavirus, hepatitis virus C, thogoto virus and Ebola 
Zaire virus) which have developed strategies to inhibit IRF7 induction by type I IFN. 
These include inhibition of IRF7 activation, inhibition of IRF7 transactivation
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functions and promotion of IRF7 degradation (Barro and Patton, 2007; Bentz et al., 
2010; Buettner et al., 2010; Chang et al., 2009; Joo et al., 2007; Li et al., 2005; Yu et 
al., 2005; Zhu et al., 2002). Contrasting with these studies, evidence of direct 
modulation of viral infection by IRF7 is scant. The bulk of the work investigating IRF7 
direct interaction with viruses relates to studies done in gammaherpesviruses, 
although it has been demonstrated that IRF7 activates the non coding region (NCR) 
of human papillomavirus type 8, a region which controls viral DNA replication and 
transcription (Oldak et al., 2011). In gammaherpesviruses, IRF7 participates in the 
establishment of EBV latency type III (Zhang and Pagano, 1997), and it has been 
shown that IRF7 is able to modulate the balance between latency and lytic 
replication in KSHV in vitro. Investigation into modulation of KSHV replication by 
IRF7 demonstrated its endogenous and exogenous expression downregulated 
activation of ORF57 promoter (through competition with the Rta protein) and 
abrogated viral reactivation. Considering IFN-a has been shown to inhibit KSHV 
reactivation (Monini et al., 1999), albeit through an unclear mechanism, and 1RF7 
expression is induced by type I IFN signalling, the authors suggested that IRF7 
downregulation of ORF57 expression could play a role in this inhibition (Wang et al., 
2005a). However, a recent study also demonstrated IRF7 played a critical role in the 
mediation of TLR induced KSHV reactivation, possibly by formation of IRF7 
complexes with viral proteins and indirect transactivation of Rta promoter (Gregory 
et al., 2009). The study further implies KSHV reactivation from latent infected cells 
following co infection with HIV-1 and HCMV (Merat et al., 2002; Varthakavi et al., 
2002) is associated with TLR signalling and, consequently, IRF7 activation of Rta 
promoter.
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This study further extends evidence of interaction between gammaherpesviruses 
and IRF7 to MHV-68. Additionally, the results produced from the work carried out 
demonstrate a pattern in Rta transactivation in vitro which might be translated in 
vivo to a similar trend observed in 1RF7 modulation of KSFiV reactivation. We 
observed that in the absence of type I IFN signalling or in cell lines where induction 
of type I IFN is potentially tightly regulated such as B cells, the presence of the 
putative viral IRF7 binding site can activate the Rta promoter and could, 
consequently, promote virus reactivation. This cellular scenario might be correlated 
with IRF7-mediated reactivation of KSFIV, prior to initiation of type I IFN signalling 
and further stimulation of IRF7 gene expression to higher levels. Conversely, both 
exogenous expression of IRF7 and assessment of promoter activation by 
endogenous IRF7 in a cell line where type I IFN signalling occurs at a basal level 
(inducing further IRF7 gene expression) were associated with a reduction in 
transactivation of Rta transcription. These results are analogous (to some extent) to 
inhibition of KSFIV reactivation by IRF7, and further confirms this dual modulation of 
gammaherpesviruses reactivation by IRF7. It also corroborates an interesting viral 
strategy involving innate immune responses and gammaherpesviruses. It has been 
shown that TLR signalling mediated, by secondary infection of latently infected cells 
with viruses, induces virus replication and allows the virus to propagate and escape 
a cell fated to die. However, in the absence of viral infection, factors associated with 
IFN pathways are usurped by the virus of inhibit viral replication, maintain latency 
and evade the host immune responses. In both cases IRF7 mediates both outcomes. 
Not only IRF7 plays a similar role in the context of MHV-68 infection but it also 
suggests this strategy could be conserved across gammaherpesviruses and the dual
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role might be tied to different levels of IRF7 expression (Gregory et al., 2009; Wang 
et al., 2005a). Additional work is necessary to effectively associate these results 
with stimulation/inhibition of MHV-68 reactivation. Demonstration of physical 
interaction between IVIHV-68 Rta promoter and IRF7 protein is a key experiment. 
Another crucial study relates to the construction of a mutant MHV-68 strain with an 
abrogated IRF7 binding site within Rta promoter. Such strain could give further 
insight into the interaction between IRF7 and MHV-68 reactivation in the context of 
in vitro and in vivo infection.
It has been demonstrated that stimulation TLR9 leads to reactivation of MHV-68 in 
latently infected cells (Gargano et al., 2009). Stimulation of TLR9 in SHE B cells, 
latently infected with MHV-68 (Heilman and Fried, 2007), following transfection 
with a plasmid expression a dominant IRF7 negative mutant or a IRF7 RNAi plasmid 
inhibiting IRF7 transactivation functions or expression, respectively, could assert 
IRF7-mediated reactivation induced by TLR signalling. Studies employing IRF7 knock 
out cell lines could also give some insight into Rta promoter transactivation 
following type I IFN treatment, and demonstrate if IRF7 indeed plays a role in IFN- 
mediated inhibition of reactivation in gammaherpesviruses. Parallel to this work, 
determination of IRF7 transcript and protein levels in cells in the presence and 
absence of type I IFN signalling would provide further evidence if different levels of 
IRF7 expression can be correlated to activation or repression of Rta. Additionally, 
IRF7 repression mechanisms have been poorly understood. The mechanisms 
studied so far involved competition with other transcription activating proteins or 
dimerization with IRF5, masking the IRF7 DBD. A further and more detailed analysis
163
of interactions with IRF7 with other cellular factors and the Rta promoter, possibly
through co-immunoprecipitation assays could provided some context.
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Appendix
Synthetic poly(A)
signal / transcriptional 
pause site 
(for background 
reduction)
Kpnl
Sac I
Mlul
Nhel
Smal
Xhol
Bglll
Hindlll
pGL3-Basic
Vector
(4818bp)
Ncol 86
Sail
BamHI Narl 121
SV40 late 
poly(A) signal 
(for luc+ reporter) 
Hpal 1902 Xbal 1742
Fig 1 pGLB-basic vector circle map
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poly(A)
2005 Xba I n
pRL-CMV
Vector
(4079bp)
CMV Immediate Early 
Enhancer/Promoter17
Promoter
^EcolCRI 725 
■Hind III 754
NhQI 1058
Fig 2 pRL-CMV vector circle map
180
Ase\
SnaB IApal\
MCS
(591-671)
HSVTK 
poly A pEGFP-N1
BsrQ I4.7 kb
SV40 ori
>4//II (1640)
Fig 3 pEGFP-Nl vector circle map
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Sdal (<S)
mEFla prom
^BspHI (1333) 
-Mxl 0371) 
-ACC65I (1427) 
-Bsu36I (1432)
Swal (4789)-
pDRTVE-mEFl
(6058 bp)
Khel (4524). 
EcoRI (4518)
Fig 4 pDRIVE-mEFla vector circle map
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pFLAG-CMV-2 (4.7 kb)
MET = FLAG MCS
hGH polyACMV promoter
5V40 origin
N-Terminal
pFLAG-CMVfl origin
pBR322 origin
Fig 5 pFLAG-CMV-2 vector circle map
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fl (+) ori
ampicillin
pBluescript II SK (+)
3.0 kb
-Sac I
pUC ori
Fig 6 pBluesscript II SK (+) vector circle map
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